Heteroaryl compounds for the treatment of pain

Abstract

Compounds, and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and methods of using the compounds, pharmaceutically acceptable salts, and pharmaceutical compositions in the treatment of various disorders, including pain.

Description

HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of U.S. Provisional Application No.63 / 592,362, filed October 23, 2023, U.S. Provisional Application No.63 / 592,698, filed October 24, 2023, and U.S. Provisional Application No.63 / 644,192, filed May 8, 2024, each of which is incorporated by reference herein in its entirety. BACKGROUND

[0002] Pain is a protective mechanism to avoid tissue damage and to prevent further damage to injured tissue. Nonetheless, there are many conditions where pain persists beyond its usefulness, or where patients would benefit from inhibition of pain. Acute and chronic pain are two common pain states and can be distinguished by the duration of the pain. Acute pain can arise for many reasons (e.g., a hospital procedure) and treatment options are generally limited by poor efficacy and / or adverse events. Like acute pain, chronic pain can arise for many reasons and treatment options are limited by poor efficacy and / or adverse events.

[0003] Neuropathic pain is a form of chronic pain caused by an injury to the sensory nerves (Dieleman, J.P., et al., Incidence rates and treatment of neuropathic pain conditions in the general population. Pain, 2008.137(3): p.681-8). Neuropathic pain can be divided into two categories, pain caused by generalized metabolic damage to the nerve and pain caused by a discrete nerve injury. The metabolic neuropathies include post-herpetic neuropathy, diabetic neuropathy, and drug-induced neuropathy. Discrete nerve injury indications include post-amputation pain, post-surgical nerve injury pain, and nerve entrapment injuries like neuropathic back pain.

[0004] Voltage-gated sodium channels (NaVs) are involved in pain signaling. NaVs are biological mediators of electrical signaling as they mediate the rapid upstroke of the action potential of many excitable cell types, for example, neurons, skeletal myocytes, cardiac myocytes (Hille, Bertil, Ion Channels of Excitable Membranes, Third ed. (Sinauer Associates, Inc., Sunderland, MA, 2001)). The evidence for the role of these channels in normal physiology, the pathological states arising from mutations in sodium channel genes, preclinical work in animal models, and the clinical pharmacology of known sodium channel modulating agents all point to the central role of NaVs in pain sensation (Rush, A.M. and T.R. Cummins, Painful Research: Identification of a Small-Molecule Inhibitor that Selectively Targets NaV1.8 Sodium Channels. Mol. Interv., 2007.7(4): p.192-5); England, S., Voltage-gated sodium channels: the search for subtype-selective analgesics. Expert Opin. Investig. Drugs 17 (12), p.1849-64 (2008); Krafte, D. S. and Bannon, A. W., Sodium channels and nociception: recent concepts and therapeutic opportunities. Curr. Opin. Pharmacol.8 (1), p.50-56 (2008)). Because of the role NaVs play in the initiation and propagation of neuronal signals,antagonists that reduce NaVcurrents can prevent or reduce neural signaling and NaVchannels have been considered likely targets to reduce pain in conditions where hyper-excitability is observed (Chahine, M., Chatelier, A., Babich, O., and Krupp, J. J., Voltage-gated sodium channels in neurological disorders. CNS Neurol. Disord. Drug Targets 7 (2), p.144-58 (2008)). Several clinically useful analgesics have been identified as inhibitors of NaVchannels. The local anesthetic drugs such as lidocaine block pain by inhibiting NaVchannels, and other compounds, such as carbamazepine, lamotrigine, and tricyclic antidepressants that have proven effective at reducing pain have also been suggested to act by sodium channel inhibition (Soderpalm, B., Anticonvulsants: aspects of their mechanisms of action. Eur. J. Pain 6 Suppl. A, p.3-9 (2002); Wang, G. K., Mitchell, J., and Wang, S. Y., Block of persistent late Na+currents by antidepressant sertraline and paroxetine. J. Membr. Biol.222 (2), p.79-90 (2008)).

[0005] The NaVs form a subfamily of the voltage-gated ion channel super-family and comprises 9 isoforms, designated NaV1.1 – NaV1.9. The tissue localizations of the nine isoforms vary. NaV1.4 is the primary sodium channel of skeletal muscle, and NaV1.5 is primary sodium channel of cardiac myocytes. NaVs 1.7, 1.8 and 1.9 are primarily localized to the peripheral nervous system, while NaVs 1.1, 1.2, 1.3, and 1.6 are neuronal channels found in both the central and peripheral nervous systems. The functional behaviors of the nine isoforms are similar but distinct in the specifics of their voltage- dependent and kinetic behavior (Catterall, W. A., Goldin, A. L., and Waxman, S. G., International Union of Pharmacology. XLVII. Nomenclature and structure-function relationships of voltage-gated sodium channels. Pharmacol. Rev.57 (4), p.397 (2005)).

[0006] Upon their discovery, NaV1.8 channels were identified as likely targets for analgesia (Akopian, A.N., L. Sivilotti, and J.N. Wood, A tetrodotoxin-resistant voltage-gated sodium channel expressed by sensory neurons. Nature, 1996.379(6562): p.257-62). Since then, NaV1.8 has been shown to be a carrier of the sodium current that maintains action potential firing in small dorsal root ganglia (DRG) neurons (Blair, N.T. and B.P. Bean, Roles of tetrodotoxin (TTX)-sensitive Na+current, TTX-resistant Na+current, and Ca2+current in the action potentials of nociceptive sensory neurons. J. Neurosci., 2002.22(23): p.10277-90). NaV1.8 is involved in spontaneous firing in damaged neurons, like those that drive neuropathic pain (Roza, C., et al., The tetrodotoxin-resistant Na+channel NaV1.8 is essential for the expression of spontaneous activity in damaged sensory axons of mice. J. Physiol., 2003.550(Pt 3): p.921-6; Jarvis, M.F., et al., A-803467, a potent and selective NaV1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat. Proc. Natl. Acad. Sci. U S A, 2007.104(20): p.8520-5; Joshi, S.K., et al., Involvement of the TTX-resistant sodium channel NaV1.8 in inflammatory and neuropathic, but not post-operative, pain states. Pain, 2006.123(1-2): pp.75-82; Lai, J., et al., Inhibition of neuropathic pain by decreased expression of the tetrodotoxin-resistant sodium channel, NaV1.8. Pain, 2002.95(1-2): p.143-52; Dong, X.W., et al., Small interfering RNA-mediated selective knockdown of NaV1.8 tetrodotoxin-resistant sodium channel reverses mechanical allodynia in neuropathic rats. Neuroscience, 2007.146(2): p.812-21;Huang, H.L., et al., Proteomic profiling of neuromas reveals alterations in protein composition and local protein synthesis in hyper-excitable nerves. Mol. Pain, 2008.4: p.33; Black, J.A., et al., Multiple sodium channel isoforms and mitogen-activated protein kinases are present in painful human neuromas. Ann. Neurol., 2008.64(6): p.644-53; Coward, K., et al., Immunolocalization of SNS / PN3 and NaN / SNS2 sodium channels in human pain states. Pain, 2000.85(1-2): p.41-50; Yiangou, Y., et al., SNS / PN3 and SNS2 / NaN sodium channel-like immunoreactivity in human adult and neonate injured sensory nerves. FEBS Lett., 2000.467(2-3): p.249-52; Ruangsri, S., et al., Relationship of axonal voltage-gated sodium channel 1.8 (NaV1.8) mRNA accumulation to sciatic nerve injury- induced painful neuropathy in rats. J. Biol. Chem.286(46): p.39836-47). The small DRG neurons where NaV1.8 is expressed include the nociceptors involved in pain signaling, where NaV1.8 mediates large amplitude action potentials (Blair, N.T. and B.P. Bean, Roles of tetrodotoxin (TTX)-sensitive Na+current, TTX-resistant Na+current, and Ca2+current in the action potentials of nociceptive sensory neurons. J. Neurosci., 2002.22(23): p.10277-90). NaV1.8 is necessary for rapid repetitive action potentials in nociceptors, and for spontaneous activity of damaged neurons. (Choi, J.S. and S.G. Waxman, Physiological interactions between NaV1.7 and NaV1.8 sodium channels: a computer simulation study. J. Neurophysiol.106(6): p.3173-84; Renganathan, M., T.R. Cummins, and S.G. Waxman, Contribution of Na(V)1.8 sodium channels to action potential electrogenesis in DRG neurons. J. Neurophysiol., 2001.86(2): p.629-40; Roza, C., et al., The tetrodotoxin-resistant Na+channel NaV1.8 is essential for the expression of spontaneous activity in damaged sensory axons of mice. J. Physiol., 2003.550(Pt 3): p.921-6). In depolarized or damaged DRG neurons, NaV1.8 appears to be a driver of hyper-excitablility (Rush, A.M., et al., A single sodium channel mutation produces hyper- or hypoexcitability in different types of neurons. Proc. Natl. Acad. Sci. USA, 2006. 103(21): p.8245-50). In some animal pain models, NaV1.8 mRNA expression levels have been shown to increase in the DRG (Sun, W., et al., Reduced conduction failure of the main axon of polymodal nociceptive C-fibers contributes to painful diabetic neuropathy in rats. Brain, 135(Pt 2): p. 359-75; Strickland, I.T., et al., Changes in the expression of NaV1.7, NaV1.8 and NaV1.9 in a distinct population of dorsal root ganglia innervating the rat knee joint in a model of chronic inflammatory joint pain. Eur. J. Pain, 2008.12(5): p.564-72; Qiu, F., et al., Increased expression of tetrodotoxin- resistant sodium channels NaV1.8 and NaV1.9 within dorsal root ganglia in a rat model of bone cancer pain. Neurosci. Lett., 512(2): p.61-6).

[0007] The inventors have discovered that some voltage-gated sodium channel inhibitors have limitations as therapeutic agents due to, for example, a poor therapeutic window (e.g., due to a lack of NaVisoform selectivity, low potency, and / or other reasons). Accordingly, there remains a need to develop selective voltage-gated sodium channel inhibitors, such as selective NaV1.8 inhibitors.SUMMARY

[0008] In one aspect, the invention relates to a compound described herein, or a pharmaceutically acceptable salt thereof.

[0009] In another aspect, the invention relates to a pharmaceutical composition comprising the compound, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers or vehicles.

[0010] In still another aspect, the invention relates to a method of inhibiting a voltage gated sodium channel in a subject by administering the compound, pharmaceutically acceptable salt, or pharmaceutical composition to the subject.

[0011] In yet another aspect, the invention relates to a method of treating or lessening the severity in a subject of a variety of diseases, disorders, or conditions, including, but not limited to, chronic pain, gut pain, neuropathic pain, musculoskeletal pain, acute pain, inflammatory pain, cancer pain, idiopathic pain, postsurgical pain (e.g., bunionectomy pain, herniorrhaphy pain or abdominoplasty pain), visceral pain, multiple sclerosis, Charcot-Marie-Tooth syndrome, incontinence, pathological cough, and cardiac arrhythmia, by administering the compound, pharmaceutically acceptable salt, or pharmaceutical composition to the subject. DETAILED DESCRIPTION

[0012] In one aspect, the invention relates to a compound of formula (I-A):; or a pharmaceutically acceptable salt thereof, wherein: X1is C-R1or N; X2is C-R2, N, or N+-O-; X3is C-R3, N, or N+-O-; X5is C-R5, N, or N+-O-; p, Xa, and Xbare defined as follows: (i) p is 1, Xais C-R11R12, and Xbis O; (ii) p is 1, Xais O, and Xbis C-R13R14; or (iii) p is 0 and Xbis O;Xsis C-Rsor N; Xtis C-Rtor N; R1is H, OH, halo, CN, C1-C6alkyl, C1-C6haloalkyl, C1-C6alkoxy, C1-C6haloalkoxy, –(CH2)mOn(CH2)oOCH3, –(CH2)mRa, –C(O)(CH2)mRa, –C(O)ORb, –C(O)Rb, –C(O)NRbRc, –NRbRc, –CRdReRf, –CRbRcNRgC(O)CRhRiRj, –NRbC(O)CRcRgRj, C3-C6cycloalkyl, 5-6 membered heteroaryl, or 4-10 membered heterocyclyl, wherein said C3-C6cycloalkyl, 5-6 membered heteroaryl, or 4-10 membered heterocyclyl may be unsubstituted or may be substituted with 1-4 substituents independently selected from halo, C1-C6alkyl, C1-C6haloalkyl, C1-C6alkoxy, and C1-C6haloalkoxy; R2, R3, R4, and R5are each independently H, OH, CN, halo, C1-C6alkyl, C1-C6alkoxy, C1-C6haloalkyl, –NHS(O)2(C1-C6alkyl), –C(O)ORb, –C(O)NRbRc, –(CH2)mO(CH2)oCH3, 5-6 membered heteroaryl, or 5-6 membered heterocyclyl, wherein said 5-6 membered heteroaryl or 5-6 membered heterocyclyl may be unsubstituted or may be substituted with 1-4 substituents independently selected from C1-C6alkyl and –C(O)NRbRc; R6, R7, R8, and R9are defined as follows: (i) R6and R7are each independently H, OH, C1-C6alkyl, C1-C6haloalkyl, C3-C6cycloalkyl, or C1-C6alkoxy; and R8and R9are each independently H, OH, C1-C6alkyl, C1-C6haloalkyl, C3-C6cycloalkyl, or C1-C6alkoxy; or (ii) R6and R7are each independently H, OH, C1-C6alkyl, C1-C6haloalkyl, C3-C6cycloalkyl, or C1-C6alkoxy; and R8and R9, together with the carbon atom to which they are attached, form a C3-C6cycloalkyl; or (iii) R6, R7, R8, and R9, together with the carbon atom to which they are attached, form a fused C6-C10aryl optionally substituted with 1-3 Ry; R10is H or CH3; R11and R12are each independently H, OH, C1-C6alkyl, C1-C6haloalkyl, C3-C6cycloalkyl, or C1-C6alkoxy; R13and R14are each independently H, OH, C1-C6alkyl, C1-C6haloalkyl, C3-C6cycloalkyl, or C1-C6alkoxy; Rsand Rtare each independently H, OH, halo, C1-C6alkyl, C1-C6alkoxy, C1-C6haloalkyl, C1-C6haloalkoxy, C3-C6cycloalkyl, –O-C3-C6cycloalkyl, –NRbRc, –NO2, –SO3H, –(CH2)mORb, or –O(CH2)mOCH3, or Rsand Rt, together with the carbon atoms to which they are attached, form a ring of formula:Y is O or CH2; Ru, Rv, and Rware each independently H, OH, halo, C1-C6alkyl, C1-C6alkoxy, C1-C6haloalkyl, C1-C6haloalkoxy, –NRbRc, –NO2, –SO3H, –(CH2)mORb, or –O(CH2)mOCH3; each Rxis independently H, halo, C1-C6alkyl, or C1-C6haloalkyl; each Ryis independently H, OH, C1-C6alkyl, C1-C6haloalkyl, C3-C6cycloalkyl, or C1-C6alkoxy; Rais OH, halo, C1-C6alkoxy, or –NRbRc; Rb, Rc, Rg, Rh, and Riare each independently H or C1-C6alkyl, or Rband Rc, together with the nitrogen atom to which they are attached, form a 3-6 membered heterocyclyl; Rd, Re, and Rfare each independently H, OH, halo, C1-C6alkyl, or C1-C6alkoxy; Rjis H, C1-C6alkyl, –NRbRc, or –N(CH3)3+; m and o are each independently 0, 1, 2, or 3; and n is 0 or 1.

[0013] For purposes of this invention, the chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75thEd. Additionally, general principles of organic chemistry are described in “Organic Chemistry,” Thomas Sorrell, University Science Books, Sausalito: 1999, and “March’s Advanced Organic Chemistry,” 5thEd., Ed.: Smith, M.B. and March, J., John Wiley & Sons, New York: 2001, the entire contents of which are hereby incorporated by reference.

[0014] As used herein, the term “compounds of the invention” refers to the compounds of formula (I-A) and all of the embodiments thereof (e.g., formulas (I-A-1), (I-A-2), (I-B-1), (I-B-2), (I- C-1), (I-C-2), (I-D-1), (I-D-2), etc.), as described herein, and to the compounds identified in Table A, Table B, Table C, Table D, and Table E.

[0015] As described herein, the compounds of the invention comprise multiple variable groups (e.g., X1, R1, R6, Ru, etc.). As one of ordinary skill in the art will recognize, combinations of groups envisioned by this invention are those combinations that result in the formation of stable or chemically feasible compounds. The term “stable,” in this context, refers to compounds that are not substantially altered when subjected to conditions to allow for their production, detection, and preferably their recovery, purification, and use for one or more of the purposes disclosed herein. In some embodiments, a stable compound or chemically feasible compound is one that is not substantially altered when kept at a temperature of 40°C or less, in the absence of moisture or other chemically reactive conditions, for at least a week.

[0016] As used herein, the term “halo” means F, Cl, Br or I.

[0017] As used herein, the term “alkyl” refers to a straight or branched hydrocarbon chain radical group consisting solely of carbon and hydrogen atoms, containing no unsaturation, and having the specified number of carbon atoms, which is attached to the rest of the molecule by a single bond. For example, a “C1-C6alkyl” group is an alkyl group having between one and six carbon atoms.

[0018] As used herein, the term “cycloalkyl” refers to a stable, non-aromatic, mono- or bicyclic (fused, bridged, or spiro) saturated hydrocarbon radical consisting solely of carbon and hydrogen atoms, having the specified number of carbon ring atoms, and which is attached to the rest of the molecule by a single bond. For example, a “C3-C8cycloalkyl” group is a cycloalkyl group having between three and eight carbon atoms.

[0019] As used herein, the term “alkoxy” refers to a radical of the formula -ORawhere Rais an alkyl group having the specified number of carbon atoms. For example, a “C1-C6alkoxy” group is a radical of the formula -ORawhere Rais an alkyl group having the between one and six carbon atoms.

[0020] As used herein, the term “haloalkyl” refers to an alkyl group having the specified number of carbon atoms, wherein one or more of the hydrogen atoms of the alkyl group are replaced by halo groups. For example, a “C1-C6haloalkyl” group is an alkyl group having between one and six carbon atoms, wherein one or more of the hydrogen atoms of the alkyl group are replaced by halo groups.

[0021] As used herein, the term “haloalkoxy” refers to an alkoxy group having the specified number of carbon atoms, wherein one or more of the hydrogen atoms of the of the alkyl group are replaced by halo groups.

[0022] As used herein, the term “heterocyclyl” refers to a stable, non-aromatic, mono-, bi-, or tricyclic (fused, bridged, or spiro) radical in which one or more ring atoms is a heteroatom (e.g., a heteroatom independently selected from N, O, P, and S), which has the specified number of ring atoms, and which is attached to the rest of the molecule by a single bond. Heterocyclic rings can be saturated, or can contain one or more double or triple bonds. In some embodiments, the “heterocyclyl” group has the indicated number of ring members, in which one or more ring members is a heteroatom independently selected from oxygen, sulfur, nitrogen, and phosphorus, and each ring in the ring system contains 3 to 7 ring members. For example, a 6-membered heterocyclyl includes a total of 6 ring members, at least one of which is a heteroatom (e.g., a heteroatom independently selected from N, O, P, and S).

[0023] As used herein, the term “heteroaryl” refers to a stable mono-, bi-, or tricyclic ring radical having the specified number of ring atoms, wherein at least one ring in the system is aromatic, at least one aromatic ring in the system contains one or more heteroatoms (e.g., one or more heteroatoms independently selected from N, O, P, and S). In some embodiments, each ring in the system contains 3 to 7 ring members. For example, a 6-membered heteroaryl includes a total of 6 ring members, at least one of which is a heteroatom selected from N, S, O, and P. The term “heteroaryl” may be used interchangeably with the term “heteroaryl ring” or the term “heteroaromatic”.

[0024] As used herein, labels such as “*s” and “*t”, such as those shown in the following structures, designate the carbon atoms to which the corresponding R groups (in this case, the Rsand Rtgroups, respectively) are attached:

[0025] Unless otherwise specified, the compounds of the invention, whether identified by chemical name or chemical structure, include all stereoisomers (e.g., enantiomers and diastereomers), double bond isomers (e.g., (Z) and (E)), conformational isomers, and tautomers of the compounds identified by the chemical names and chemical structures provided herein. In addition, single stereoisomers, double bond isomers, conformational isomers, and tautomers as well as mixtures of stereoisomers, double bond isomers, conformational isomers, and tautomers are within the scope of the invention.

[0026] As used herein, in any chemical structure or formula, a non-bold, straight bond attached to a stereocenter of a compound, such as in, denotes that the configuration of the stereocenter is unspecified. The compound may have any configuration, or a mixture of configurations, at the stereocenter.

[0027] As used herein, in any chemical structure or formula, a bold or hashed straight bond attached to a stereocenter of a compound, such as in, denotes the relative stereochemistry of the stereocenter, relative to other stereocenter(s) to which bold or hashed straight bonds are attached.

[0028] As used herein, in any chemical structure or formula, a bold or hashed wedge bond attached to a stereocenter of a compound, such as in, denotes the absolute stereochemistry of the stereocenter, as well as the relative stereochemistry of the stereocenter, relative to other stereocenter(s) to which bold or hashed wedge bonds are attached.

[0029] As used herein, the prefix “rac-,” when used in connection with a chiral compound, refers to a racemic mixture of the compound. In a compound bearing the “rac-” prefix, the (R)- and (S)- designators in the chemical name reflect the relative stereochemistry of the compound.

[0030] As used herein, the prefix “dia-,” when used in connection with a chiral compound, refers to a mixture of two or more diastereomers of the compound. In a compound bearing the “dia-“ prefix, the (R)- and (S)- designators are assigned arbitrarily and do not necessarily reflect the absolute or relative configuration of the corresponding stereocenters in any component of the mixture. In some instances, all of the diastereomers in a mixture have a single absolute configuration at one or more stereocenters. In these instances, the stereochemical designators associated with the stereocenters having a single absolute configuration are marked with an asterisk (*), e.g., (R*)- and (S*)-. In some instances, all of the diastereomers in a mixture have the same relative stereochemistry at two or more stereocenters. In these instances, the stereochemical designators associated with such stereocenters are marked with a superscript number (n), e.g., (Rn)- and (Sn)-. The stereochemical designators marked with a superscript number reflect the relative stereochemistry of the corresponding stereocenters with respect to other stereocenters associated with stereochemical designators having the same superscript number, e.g., (R1)- and (S1)-, but they do not necessarily reflect the absolute configuration of such stereocenters. The stereochemical designators marked with an asterisk (*) do not necessarily reflect the relative stereochemistry of the corresponding stereocenters with respect to stereocenters associated with stereochemical designators marked with a superscript number (n) (and vice versa) or with respect to stereocenters associated with unmarked stereochemical designators. Likewise, the stereochemical designators marked with a superscript number (n) do not necessarily reflect the relative stereochemistry of the corresponding stereocenters with respect to stereocenters associated with stereochemical designators marked with a different superscript number (n) or with respect to stereocenters associated with unmarked stereochemical designators.

[0031] As used herein, the prefix “rel-,” when used in connection with a chiral compound, refers to a single enantiomer of unknown absolute configuration. In a compound bearing the “rel-” prefix, the (R)- and (S)- designators in the chemical name reflect the relative stereochemistry of the compound, but do not necessarily reflect the absolute stereochemistry of the compound. In some instances, the absolute configuration of some stereocenters is known, while only the relativeconfiguration of the other stereocenters is known. In these instances, the stereochemical designators associated with the stereocenters of known absolute configuration are marked with an asterisk (*), e.g., (R*)- and (S*)-, while the stereochemical designators associated with stereocenters of unknown absolute configuration are not so marked. The unmarked stereochemical designators associated with the stereocenters of unknown absolute configuration reflect the relative stereochemistry of those stereocenters with respect to other stereocenters of unknown absolute configuration, but do not necessarily reflect the relative stereochemistry with respect to the stereocenters of known absolute configuration. Where a compound contains two or more stereocenters of unknown absolute configuration, and the relative stereochemistry of such stereocenters with respect to each other is unknown, no stereochemical designator is provided for such stereocenters.

[0032] As used herein, the term “compound,” when referring to the compounds of the invention, refers to a collection of molecules having identical chemical structures, except that there may be isotopic variation among the constituent atoms of the molecules. The term “compound” includes such a collection of molecules without regard to the purity of a given sample containing the collection of molecules. Thus, the term “compound” includes such a collection of molecules in pure form, in a mixture (e.g., solution, suspension, colloid, or pharmaceutical composition, or dosage form) with one or more other substances, or in the form of a hydrate, solvate, or co-crystal.

[0033] In the specification and claims, unless otherwise specified, any atom not specifically designated as a particular isotope in any compound of the invention is meant to represent any stable isotope of the specified element. In the Examples, where an atom is not specifically designated as a particular isotope in any compound of the invention, no effort was made to enrich that atom in a particular isotope, and therefore a person of ordinary skill in the art would understand that such atom likely was present at approximately the natural abundance isotopic composition of the specified element.

[0034] As used herein, the term “stable,” when referring to an isotope, means that the isotope is not known to undergo spontaneous radioactive decay. Stable isotopes include, but are not limited to, the isotopes for which no decay mode is identified in V.S. Shirley & C.M. Lederer, Isotopes Project, Nuclear Science Division, Lawrence Berkeley Laboratory, Table of Nuclides (January 1980).

[0035] As used herein in the specification and claims, “H” refers to hydrogen and includes any stable isotope of hydrogen, namely1H and D. In the Examples, where an atom is designated as “H,” no effort was made to enrich that atom in a particular isotope of hydrogen, and therefore a person of ordinary skill in the art would understand that such hydrogen atom likely was present at approximately the natural abundance isotopic composition of hydrogen.

[0036] As used herein, “1H” refers to protium. Where an atom in a compound of the invention, or a pharmaceutically acceptable salt thereof, is designated as protium, protium is present at the specified position with at least the natural abundance concentration of protium.

[0037] As used herein, “D,” “d,” and “2H” refer to deuterium.

[0038] In some embodiments, the compounds of the invention, and pharmaceutically acceptable salts thereof, include each constituent atom at approximately the natural abundance isotopic composition of the specified element.

[0039] In some embodiments, the compounds of the invention, and pharmaceutically acceptable salts thereof, include one or more atoms having an atomic mass or mass number which differs from the atomic mass or mass number of the most abundant isotope of the specified element (“isotope- labeled” compounds and salts). Examples of stable isotopes which are commercially available and suitable for the invention include without limitation isotopes of hydrogen, carbon, nitrogen, oxygen, and phosphorus, for example2H,13C,15N,18O,17O, and31P, respectively.

[0040] The isotope-labeled compounds and salts can be used in a number of beneficial ways, including as medicaments. In some embodiments, the isotope-labeled compounds and salts are deuterium (2H)-labeled. Deuterium (2H)-labeled compounds and salts are therapeutically useful with potential therapeutic advantages over the non-2H-labeled compounds. In general, deuterium (2H)- labeled compounds and salts can have higher metabolic stability as compared to those that are not isotope-labeled owing to the kinetic isotope effect described below. Higher metabolic stability translates directly into an increased in vivo half-life or lower dosages, which under most circumstances would represent a preferred embodiment of the present invention. The isotope-labeled compounds and salts can usually be prepared by carrying out the procedures disclosed in the synthesis schemes, the Examples and the related description, replacing a non-isotope-labeled reactant by a readily available isotope-labeled reactant.

[0041] The deuterium (2H)-labeled compounds and salts can manipulate the rate of oxidative metabolism of the compound by way of the primary kinetic isotope effect. The primary kinetic isotope effect is a change of the rate for a chemical reaction that results from exchange of isotopic nuclei, which in turn is caused by the change in ground state energies of the covalent bonds involved in the reaction. Exchange of a heavier isotope usually results in a lowering of the ground state energy for a chemical bond and thus causes a reduction in the rate-limiting bond breakage. If the bond breakage occurs in or in the vicinity of a saddle-point region along the coordinate of a multi-product reaction, the product distribution ratios can be altered substantially. For example, if deuterium is bonded to a carbon atom at a non-exchangeable position, rate differences of kH / kD= 2-7 are typical. For a further discussion, see S. L. Harbeson and R. D. Tung, Deuterium In Drug Discovery and Development, Ann. Rep. Med. Chem.2011, 46, 403-417, incorporated in its entirety herein by reference.

[0042] The concentration of an isotope (e.g., deuterium) incorporated at a given position of an isotope-labeled compound of the invention, or a pharmaceutically acceptable salt thereof, may be defined by the isotopic enrichment factor. The term “isotopic enrichment factor,” as used herein, means the ratio between the abundance of an isotope at a given position in an isotope-labeled compound (or salt) and the natural abundance of the isotope.

[0043] Where an atom in a compound of the invention, or a pharmaceutically acceptable salt thereof, is designated as deuterium, such compound (or salt) has an isotopic enrichment factor for such atom of at least 3000 (~45% deuterium incorporation). In some embodiments, the isotopic enrichment factor is at least 3500 (~52.5% deuterium incorporation), at least 4000 (~60% deuterium incorporation), at least 4500 (~67.5% deuterium incorporation), at least 5000 (~75% deuterium incorporation), at least 5500 (~82.5% deuterium incorporation), at least 6000 (~90% deuterium incorporation), at least 6333.3 (~95% deuterium incorporation), at least 6466.7 (~97% deuterium incorporation), at least 6600 (~99% deuterium incorporation), or at least 6633.3 (~99.5% deuterium incorporation).

[0044] In some embodiments, the invention relates to a compound of formula (I-A), or a pharmaceutically acceptable salt thereof, wherein: Xais CH2; Xbis O; R6and R7are each independently H, OH, C1-C6alkyl, C1-C6haloalkyl, C3-C6cycloalkyl, or C1-C6alkoxy; R8and R9are each independently H, OH, C1-C6alkyl, C1-C6haloalkyl, C3-C6cycloalkyl, or C1-C6alkoxy; or R8and R9, together with the carbon atom to which they are attached, form a C3-C6cycloalkyl; Rsand Rtare each independently H, OH, halo, C1-C6alkyl, C1-C6alkoxy, C1-C6haloalkyl, C1-C6haloalkoxy, –NRbRc, –NO2, –SO3H, –(CH2)mORb, or –O(CH2)mOCH3, or Rsand Rt, together with the carbon atoms to which they are attached, form a ring of formula:p is 0 or 1.

[0045] In some embodiments, the invention relates to a compound of formula (I-A), or a pharmaceutically acceptable salt thereof, wherein: R1is H, OH, halo, CN, C1-C6alkyl, C1-C6alkoxy, C1-C6haloalkoxy, or –C(O)ORb; R10is H; and Rsand Rtare each independently H, OH, halo, C1-C6alkyl, C1-C6alkoxy, C1-C6haloalkyl, C1- C6haloalkoxy, –NRbRc, –NO2, –SO3H, –(CH2)mORa, or –O(CH2)mOCH3, or Rsand Rt, together with the carbon atoms to which they are attached, form a ring of formula:

[0046] In some embodiments, the invention relates to a compound of formula (I-A), or a pharmaceutically acceptable salt thereof, wherein p is 1, Xais CR11R12, and Xbis O.

[0047] In some embodiments, the invention relates to a compound of formula (I-A), or a pharmaceutically acceptable salt thereof, wherein R11is H.

[0048] In some embodiments, the invention relates to a compound of formula (I-A), or a pharmaceutically acceptable salt thereof, wherein R12is H.

[0049] In some embodiments, the invention relates to a compound of formula (I-A), or a pharmaceutically acceptable salt thereof, wherein p is 1, Xais O, and Xbis CR13R14.

[0050] In some embodiments, the invention relates to a compound of formula (I-A), or a pharmaceutically acceptable salt thereof, wherein R13is C1-C6alkyl or C1-C6haloalkyl. In other embodiments, R13is C1-C6alkyl. In other embodiments, R13is C1-C6haloalkyl. In some embodiments, the invention relates to a compound of formula (I-A), or a pharmaceutically acceptable salt thereof, wherein R13is –CH3or –CF3. In other embodiments, R13is –CH3. In other embodiments, R13is –CF3.

[0051] In some embodiments, the invention relates to a compound of formula (I-A), or a pharmaceutically acceptable salt thereof, wherein R14is C1-C6alkyl or C1-C6haloalkyl. In other embodiments, R14is C1-C6alkyl. In other embodiments, R14is C1-C6haloalkyl. In some embodiments, the invention relates to a compound of formula (I-A), or a pharmaceutically acceptable salt thereof, wherein R14is –CH3or –CF3. In other embodiments, R14is –CH3. In other embodiments, R14is –CF3.

[0052] In some embodiments, the invention relates to a compound of formula (I-A), or a pharmaceutically acceptable salt thereof, wherein R6, R7, R8, and R9, together with the carbon atom to which they are attached, form a fused C6-C10aryl optionally substituted with 1-3 Ry. In some embodiments, the invention relates to a compound of formula (I-A), or a pharmaceutically acceptable salt thereof, wherein R6, R7, R8, and R9, together with the carbon atom to which they are attached, form a fused phenyl.

[0053] In some embodiments, the invention relates to a compound of formula (I-A), or a pharmaceutically acceptable salt thereof, wherein R10is H. In some embodiments, the invention relates to a compound of formula (I-A), or a pharmaceutically acceptable salt thereof, wherein R10is CH3.

[0054] In some embodiments, the invention relates to a compound of formula (I-A), or a pharmaceutically acceptable salt thereof, wherein Rwis H.

[0055] In some embodiments, the invention relates to a compound of formula (I-A-1):; or a pharmaceutically acceptable salt thereof, wherein all variable groups are defined as they are defined for the compound of formula (I-A).

[0056] In some embodiments, the invention relates to a compound of formula (I-B-1):; or a pharmaceutically acceptable salt thereof, wherein all variable groups are defined as they are defined for the compound of formula (I-A).

[0057] In some embodiments, the invention relates to a compound of formula (I-C-1):; or a pharmaceutically acceptable salt thereof, wherein all variable groups are defined as they are defined for the compound of formula (I-A).

[0058] In some embodiments, the invention relates to a compound of formula (I-D-1):; or a pharmaceutically acceptable salt thereof, wherein all variable groups are defined as they are defined for the compound of formula (I-A).

[0059] In some embodiments, the invention relates to a compound of formula (I-A), (I-A-1), or (I-B-1), or a pharmaceutically acceptable salt thereof, wherein p is 0.

[0060] In some embodiments, the invention relates to a compound of formula (I-A), (I-A-1), or (I-B-1), or a pharmaceutically acceptable salt thereof, wherein p is 1.

[0061] In some embodiments, the invention relates to a compound of formula (I-A), (I-A-1), (I- B-1), (I-C-1), or (I-D-1), or a pharmaceutically acceptable salt thereof, wherein X1is N. In some embodiments, the invention relates to a compound of formula (I-A), (I-A-1), (I-B-1), (I-C-1), or (I-D- 1), or a pharmaceutically acceptable salt thereof, wherein X1is C-R1, and R1is H, CN, C1-C6alkyl, C1-C6alkoxy, or –C(O)ORb. In other embodiments, X1is C-R1, and R1is H. In other embodiments, X1is C-R1, and R1is CN. In other embodiments, X1is C-R1, and R1is C1-C6alkyl. In other embodiments, X1is C-R1, and R1is C1-C6alkoxy. In other embodiments, X1is C-R1, and R1is –C(O)ORb. In some embodiments, the invention relates to a compound of formula (I- A), (I-A-1), (I-B-1), (I-C-1), or (I-D-1), or a pharmaceutically acceptable salt thereof, wherein X1is C-R1, and R1is H, CN, –CH3, –OCH3, –C(O)OCH3, or –C(O)OCH2CH3. In other embodiments, X1is C-R1, and R1is CN. In other embodiments, X1is C-R1, and R1is –CH3. In other embodiments, X1is C-R1, and R1is –OCH3. In other embodiments, X1is C-R1, and R1is –C(O)OCH3. In other embodiments, X1is C-R1, and R1is –C(O)OCH2CH3.

[0062] In some embodiments, the invention relates to a compound of formula (I-A), (I-A-1), (I- B-1), (I-C-1), or (I-D-1), or a pharmaceutically acceptable salt thereof, wherein X2is N. In some embodiments, the invention relates to a compound of formula (I-A) or (I-A-1), or a pharmaceutically acceptable salt thereof, wherein X2is C-R2, and R2is H, OH, CN, halo, C1-C6alkyl, C1-C6alkoxy, – NHS(O)2(C1-C6alkyl), –C(O)ORb, –C(O)NRbRc, 5-6 membered heteroaryl, or 5-6 membered heterocyclyl, wherein said 5-6 membered heteroaryl or 5-6 membered heterocyclyl may be unsubstituted or may be substituted with 1-4 substituents independently selected from C1-C6alkyl and –C(O)NRbRc. In other embodiments, X2is C-R2, and R2is H. In other embodiments, X2is C-R2, andR2is OH. In other embodiments, X2is C-R2, and R2is CN. In other embodiments, X2is C-R2, and R2is halo. In other embodiments, X2is C-R2, and R2is C1-C6alkyl. In other embodiments, X2is C-R2, and R2is C1-C6alkoxy. In other embodiments, X2is C-R2, and R2is –NHS(O)2(C1-C6alkyl). In other embodiments, X2is C-R2, and R2is –C(O)ORb. In other embodiments, X2is C-R2, and R2is –C(O)NRbRc. In other embodiments, X2is C-R2, and R2is 5-6 membered heteroaryl, wherein said 5- 6 membered heteroaryl may be unsubstituted or may be substituted with 1-4 substituents independently selected from C1-C6alkyl and –C(O)NRbRc.. In other embodiments, X2is C-R2, and R2is 5-6 membered heterocyclyl, wherein said 5-6 membered heterocyclyl may be unsubstituted or may be substituted with 1-4 substituents independently selected from C1-C6alkyl and –C(O)NRbRc. In some embodiments, the invention relates to a compound of formula (I-A), (I-A-1), (I-B-1), (I-C-1), or (I-D-1), or a pharmaceutically acceptable salt thereof, wherein X2is C-R2, and R2is H, Cl, F, OH, CN, –CH3, –OCH3, –C(O)OH, –C(O)NH2, –C(O)N(H)CH3, –N(H)S(O)2(CH3),. In some embodiments, the invention relates to a compound of formula (I-A), (I-A-1), (I-B-1), (I-C-1), or (I-D-1), or a pharmaceutically acceptable salt thereof, wherein X2is C-R2, and R2is H, Cl, F, OH, CN, –CH3, –OCH3, –C(O)OH, –C(O)NH2, –C(O)N(H)CH3, –N(H)S(O)2(CH3),In other embodiments, X2is C-R2, and R2is Cl. In other embodiments, X2is C-R2, and R2is F. In other embodiments, X2is C-R2, and R2is OH. In other embodiments, X2is C-R2, and R2is CN. In other embodiments, X2is C-R2, and R2is –CH3. In other embodiments, X2is C-R2, and R2is –OCH3. In other embodiments, X2is C-R2, and R2is –C(O)OH. In other embodiments, X2is C-R2, and R2is –C(O)NH2. In other embodiments, X2is C-R2, and R2is –C(O)N(H)CH3. In other embodiments, X2is C-R2, and R2is –N(H)S(O)2(CH3). In other embodiments, X2is C-R2, and R2is

[0063] In some embodiments, the invention relates to a compound of formula (I-A), (I-A-1), (I- B-1), (I-C-1), or (I-D-1), or a pharmaceutically acceptable salt thereof, wherein X3is N. In some embodiments, the invention relates to a compound of formula (I-A), (I-A-1), (I-B-1), (I-C-1), or (I-D- 1), or a pharmaceutically acceptable salt thereof, wherein X3is C-R3, and R3is H, CN, halo, C1-C6alkoxy, –C(O)ORb, or –C(O)NRbRc. In other embodiments, X3is C-R3, and R3is H. In other embodiments, X3is C-R3, and R3CN. In other embodiments, X3is C-R3, and R3halo. In other embodiments, X3is C-R3, and R3C1-C6alkoxy. In other embodiments, X3is C-R3, and R3–C(O)ORb. In other embodiments, X3is C-R3, and R3–C(O)NRbRc. In some embodiments, the invention relates to a compound of formula (I-A), (I-A-1), (I-B-1), (I-C-1), or (I-D-1), or a pharmaceutically acceptable salt thereof, wherein X3is C-R3, and R3is H, Cl, F, CN, –OCH3, –C(O)OCH3or –C(O)N(CH3)2. In other embodiments, X3is C-R3, and R3is Cl. In other embodiments, X3is C-R3, and R3is F. In other embodiments, X3is C-R3, and R3is CN. In other embodiments, X3is C-R3, and R3is –OCH3. In other embodiments, X3is C-R3, and R3is –C(O)OCH3. In other embodiments, X3is C-R3, and R3is – C(O)N(CH3)2.

[0064] In some embodiments, the invention relates to a compound of formula (I-A), (I-A-1), (I- B-1), (I-C-1), or (I-D-1), or a pharmaceutically acceptable salt thereof, wherein R4is H, halo, C1-C6alkyl, –C(O)ORb, or –C(O)NRbRc. In other embodiments, R4is H. In other embodiments, R4is halo. In other embodiments, R4is C1-C6alkyl. In other embodiments, R4is –C(O)ORb. In other embodiments, R4is –C(O)NRbRc. In some embodiments, the invention relates to a compound of formula (I-A), (I-A-1), (I-B-1), (I-C-1), or (I-D-1), or a pharmaceutically acceptable salt thereof, wherein R4is H, Cl, F, –CH3, –C(O)OCH2CH3or –C(O)NH2. In other embodiments, R4is Cl. Inother embodiments, R4is F. In other embodiments, R4is –CH3. In other embodiments, R4is – C(O)OCH2CH3. In other embodiments, R4is –C(O)NH2.

[0065] In some embodiments, the invention relates to a compound of formula (I-A), (I-A-1), (I- B-1), (I-C-1), or (I-D-1), or a pharmaceutically acceptable salt thereof, wherein X5is N. In some embodiments, the invention relates to a compound of formula (I-A), (I-A-1), (I-B-1), (I-C-1), or (I-D- 1), or a pharmaceutically acceptable salt thereof, wherein X5is CR5, and R5is H, halo, or – C(O)NRbRc. In other embodiments, X5is CR5, and R5is H. In other embodiments, X5is CR5, and R5is halo. In other embodiments, X5is CR5, and R5is –C(O)NRbRc. In some embodiments, the invention relates to a compound of formula (I-A), (I-A-1), (I-B-1), (I-C-1), or (I-D-1), or a pharmaceutically acceptable salt thereof, wherein X5is CR5, and R5is H, F, or –C(O)NH2. In other embodiments, X5is CR5, and R5is F. In other embodiments, X5is CR5, and R5is –C(O)NH2.

[0066] In some embodiments, the invention relates to a compound of formula (I-A), or a pharmaceutically acceptable salt thereof, wherein R6is H.

[0067] In some embodiments, the invention relates to a compound of formula (I-A), (I-A-1), (I- B-1), (I-C-1), or (I-D-1), or a pharmaceutically acceptable salt thereof, wherein R7is H, OH, C1-C6alkyl, C3-C6cycloalkyl, or C1-C6alkoxy. In other embodiments, R7is H. In other embodiments, R7is OH. In other embodiments, R7is C1-C6alkyl. In other embodiments, R7is C3-C6cycloalkyl. In other embodiments, R7is C1-C6alkoxy. In some embodiments, the invention relates to a compound of formula (I-A), (I-A-1), (I-B-1), (I-C-1), or (I-D-1), or a pharmaceutically acceptable salt thereof, wherein R7is H, OH, –OCH3, –CH3, or cyclopropyl. In other embodiments, R7is –OCH3. In other embodiments, R7is –CH3. In other embodiments, R7is cyclopropyl.

[0068] In some embodiments, the invention relates to a compound of formula (I-A), (I-A-1), (I- B-1), (I-C-1), or (I-D-1), or a pharmaceutically acceptable salt thereof, wherein R8and R9are each independently H, C1-C6alkyl, C1-C6haloalkyl, or C3-C6cycloalkyl, or R8and R9, together with the carbon atom to which they are attached, form a C3-C6cycloalkyl. In other embodiments, at least one of R8and R9is H. In other embodiments, at least one of R8and R9is C1-C6alkyl. In other embodiments, at least one of R8and R9is C1-C6haloalkyl. In other embodiments, at least one of R8and R9is C3-C6cycloalkyl In some embodiments, the invention relates to a compound of formula (I- A), (I-A-1), (I-B-1), (I-C-1), or (I-D-1), or a pharmaceutically acceptable salt thereof, wherein R8is H or C1-C6alkyl. In other embodiments, R8is H. In other embodiments, R8is C1-C6alkyl. In some embodiments, the invention relates to a compound of formula (I-A), (I-A-1), (I-B-1), (I-C-1), or (I-D- 1), or a pharmaceutically acceptable salt thereof, wherein R8is H, –CH3, or –CH2CH3. In other embodiments, R8is –CH3. In other embodiments, R8is –CH2CH3. In some embodiments, the invention relates to a compound of formula (I-A), (I-A-1), (I-B-1), (I-C-1), or (I-D-1), or a pharmaceutically acceptable salt thereof, wherein R9is H, C1-C6alkyl, or C1-C6haloalkyl. In other embodiments, R9is H. In other embodiments, R9is C1-C6alkyl. In other embodiments, R9is C1-C6haloalkyl. In some embodiments, the invention relates to a compound of formula (I-A), (I-A-1), (I-B-1), (I-C-1), or (I-D-1), or a pharmaceutically acceptable salt thereof, wherein R9is H, –CH3, or –CF3. In other embodiments, R9is –CH3. In other embodiments, R9is –CF3. In some embodiments, the invention relates to a compound of formula (I-A), (I-A-1), (I-B-1), (I-C-1), or (I-D-1), or a pharmaceutically acceptable salt thereof, wherein R8and R9, together with the carbon atom to which they are attached, form a C3-C6cycloalkyl. In some embodiments, the invention relates to a compound of formula (I-A), (I-A-1), (I-B-1), (I-C-1), or (I-D-1), or a pharmaceutically acceptable salt thereof, wherein R8and R9, together with the carbon atom to which they are attached, form a cyclobutane.

[0069] In some embodiments, the invention relates to a compound of formula (I-C-1) or (I-D-1), or a pharmaceutically acceptable salt thereof, wherein R11is H, and R12is H.

[0070] In some embodiments, the invention relates to a compound of formula (I-A), (I-A-1), (I- B-1), (I-C-1), or (I-D-1), or a pharmaceutically acceptable salt thereof, wherein Xsis N. In some embodiments, the invention relates to a compound of formula (I-A), (I-A-1), (I-B-1), (I-C-1), or (I-D- 1), or a pharmaceutically acceptable salt thereof, wherein Xsis C-Rs, and Rsis H, OH, halo, C1-C6alkyl, C1-C6alkoxy, C3-C6cycloalkyl, –O-C3-C6cycloalkyl, –(CH2)mORb, or –O(CH2)mOCH3. In some embodiments, the invention relates to a compound of formula (I-A), (I-A-1), (I-B-1), (I-C-1), or (I-D-1), or a pharmaceutically acceptable salt thereof, wherein Xsis C-Rs, and Rsis H, OH, halo, C1- C6alkyl, C1-C6alkoxy, –(CH2)mORb, or –O(CH2)mOCH3. In other embodiments, Xsis C-Rs, and Rsis H. In other embodiments, Xsis C-Rs, and Rsis OH. In other embodiments, Xsis C-Rs, and Rsis halo. In other embodiments, Xsis C-Rs, and Rsis C1-C6alkyl. In other embodiments, Xsis C-Rs, and Rsis C1-C6alkoxy. In other embodiments, Xsis C-Rs, and Rsis C3-C6cycloalkyl. In other embodiments, Xsis C-Rs, and Rsis –O-C3-C6cycloalkyl. In other embodiments, Xsis C-Rs, and Rsis –(CH2)mORb. In other embodiments, Xsis C-Rs, and Rsis –O(CH2)mOCH3. In some embodiments, the invention relates to a compound of formula (I-A), (I-A-1), (I-B-1), (I-C-1), or (I-D-1), or a pharmaceutically acceptable salt thereof, wherein Xsis C-Rs, and Rsis H, F, Cl, OH, –CH3, –CH2OH, –CH2OCH3, – OCH3, cyclopropyl, –O-cyclopropyl, –OCH(CH3)2, or –OCH2CH2OCH3. In some embodiments, the invention relates to a compound of formula (I-A), (I-A-1), (I-B-1), (I-C-1), or (I-D-1), or a pharmaceutically acceptable salt thereof, wherein Xsis C-Rs, and Rsis H, F, Cl, OH, –CH3, –CH2OH, –CH2OCH3, –OCH3, cyclopropyl, –OCH(CH3)2, or –OCH2CH2OCH3. In some embodiments, the invention relates to a compound of formula (I-A), (I-A-1), (I-B-1), (I-C-1), or (I-D-1), or a pharmaceutically acceptable salt thereof, wherein Xsis C-Rs, and Rsis H, F, OH, –CH3, –CH2OH, – OCH3, –OCH(CH3)2, or –OCH2CH2OCH3. In some embodiments, the invention relates to a compound of formula (I-A), (I-A-1), (I-B-1), (I-C-1), or (I-D-1), or a pharmaceutically acceptable salt thereof, wherein Xsis C-Rs, and Rsis H, Cl, F, OH, –CH3, –CH2OH, –OCH3, –OCH2CH3, – OCH(CH3)2, or –OCH2CH2OCH3. In other embodiments, Xsis C-Rs, and Rsis F. In other embodiments, Xsis C-Rs, and Rsis Cl. In other embodiments, Xsis C-Rs, and Rsis –CH3. In other embodiments, Xsis C-Rs, and Rsis –CH2OH. In other embodiments, Xsis C-Rs, and Rsis –CH2OCH3. In other embodiments, Xsis C-Rs, and Rsis –OCH3. In other embodiments, Xsis C-Rs, and Rsis cyclopropyl. In other embodiments, Xsis C-Rs, and Rsis –O-cyclopropyl. In other embodiments, Xsis C-Rs, and Rsis –OCH(CH3)2. In other embodiments, Xsis C-Rs, and Rsis – OCH2CH2OCH3.

[0071] In some embodiments, the invention relates to a compound of formula (I-A), (I-A-1), (I- B-1), (I-C-1), or (I-D-1), or a pharmaceutically acceptable salt thereof, wherein Xtis N. In some embodiments, the invention relates to a compound of formula (I-A), (I-A-1), (I-B-1), (I-C-1), or (I-D- 1), or a pharmaceutically acceptable salt thereof, wherein Xtis C-Rt, and Rtis H, halo, C1-C6alkyl, C1-C6alkoxy, or C3-C6cycloalkyl. In some embodiments, the invention relates to a compound of formula (I-A), (I-A-1), (I-B-1), (I-C-1), or (I-D-1), or a pharmaceutically acceptable salt thereof, wherein Xtis C-Rt, and Rtis H, halo, C1-C6alkyl, or C1-C6alkoxy. In other embodiments, Xtis C-Rt, and Rtis H. In other embodiments, Xtis C-Rt, and Rtis halo. In other embodiments, Xtis C-Rt, and Rtis C1-C6alkyl. In other embodiments, Xtis C-Rt, and Rtis C1-C6alkoxy. In other embodiments, Xtis C-Rt, and Rtis C3-C6cycloalkyl. In some embodiments, the invention relates to a compound of formula (I-A), (I-A-1), (I-B-1), (I-C-1), or (I-D-1), or a pharmaceutically acceptable salt thereof, wherein Xtis C-Rt, and Rtis H, Cl, F, –CH3, –OCH3, or cyclopropyl. In some embodiments, the invention relates to a compound of formula (I-A), (I-A-1), (I-B-1), (I-C-1), or (I-D-1), or a pharmaceutically acceptable salt thereof, wherein Xtis C-Rt, and Rtis H, Cl, F, –CH3, or –OCH3. In other embodiments, Xtis C-Rt, and Rtis Cl. In other embodiments, Xtis C-Rt, and Rtis F. In other embodiments, Xtis C-Rt, and Rtis –CH3. In other embodiments, Xtis C-Rt, and Rtis –OCH3. In other embodiments, Xtis C-Rt, and Rtis cyclopropyl.

[0072] In some embodiments, the invention relates to a compound of formula (I-A), (I-A-1), (I- B-1), (I-C-1), or (I-D-1), or a pharmaceutically acceptable salt thereof, wherein Xsis C-Rs, Xtis C-Rt, and Rsand Rt, together with the carbon atoms to which they are attached, form a ring of formula:In other embodiments, Xsis C-Rs, Xtis C-Rt, and Rsand Rt, together with the carbon atoms to which they are attached, form a ring of formula. In other embodiments, Xsis C-Rs, Xtis C-Rt, and Rsand Rt, together with the carbon atoms to which they are attached, form a ring of formula. In some embodiments, the invention relates to a compound of formula (I-A), (I-A-1), (I- B-1), (I-C-1), or (I-D-1), or a pharmaceutically acceptable salt thereof, wherein Xsis C-Rs, Xtis C-Rt, and Rsand Rt, together with the carbon atoms to which they are attached, form a ring of formula:. In other embodiments, Xsis C-Rs, Xtis C-Rt, and Rsand Rt, together with the carbon atoms to which they are attached, form a ring of formula. In other embodiments, Xsis C-Rs, Xtis C-Rt, and Rsand Rt, together with the carbon atoms to which they are attached, form a ring of formula. In other embodiments, Xsis C-Rs, Xtis C-Rt, and Rsand Rt, together with the carbon atoms to which they are attached, form a ring of formula.

[0073] In some embodiments, the invention relates to a compound of formula (I-A), (I-A-1), (I- B-1), (I-C-1), or (I-D-1), or a pharmaceutically acceptable salt thereof, wherein wherein Ruis H, halo, C1-C6alkyl, C1-C6alkoxy, C1-C6haloalkyl. In other embodiments, Ruis H. In other embodiments, Ruis halo. In other embodiments, Ruis C1-C6alkyl. In other embodiments, Ruis C1-C6alkoxy. In other embodiments, Ruis C1-C6haloalkyl. In some embodiments, the invention relates to a compound of formula (I-A), (I-A-1), (I-B-1), (I-C-1), or (I-D-1), or a pharmaceutically acceptable salt thereof, wherein Ruis H, F, or –CH3. In some embodiments, the invention relates to a compound of formula (I-A), (I-A-1), (I-B-1), (I-C-1), or (I-D-1), or a pharmaceutically acceptable salt thereof, wherein Ruis H, Cl, F, –CH3, or –OCH3. In other embodiments, Ruis Cl. In other embodiments, Ruis F. In other embodiments, Ruis –CH3. In other embodiments, Ruis –OCH3.

[0074] In some embodiments, the invention relates to a compound of formula (I-A), (I-A-1), (I- B-1), (I-C-1), or (I-D-1), or a pharmaceutically acceptable salt thereof, wherein Rvis H, halo, or C1-C6alkyl. In some embodiments, the invention relates to a compound of formula (I-A), (I-A-1), (I-B-1), (I-C-1), or (I-D-1), or a pharmaceutically acceptable salt thereof, wherein Rvis H or C1-C6alkyl. In other embodiments, Rvis H. In other embodiments, Rvis halo. In other embodiments, Rvis C1-C6alkyl. In some embodiments, the invention relates to a compound of formula (I-A), (I-A-1), (I-B-1), (I-C-1), or (I-D-1), or a pharmaceutically acceptable salt thereof, wherein Rvis H, F, or –CH3. In some embodiments, the invention relates to a compound of formula (I-A), (I-A-1), (I-B-1), (I-C-1), or (I-D-1), or a pharmaceutically acceptable salt thereof, wherein Rvis H or –CH3. In other embodiments, Rvis F. In other embodiments, Rvis or –CH3.

[0075] In some embodiments, the invention relates to a compound of formula (I-A-2):; or a pharmaceutically acceptable salt thereof, wherein all variable groups are defined as they are defined for the compound of formula (I-A).

[0076] In some embodiments, the invention relates to a compound of formula (I-B-2):or a pharmaceutically acceptable salt thereof, wherein all variable groups are defined as they are defined for the compound of formula (I-A).

[0077] In some embodiments, the invention relates to a compound of formula (I-C-2):; or a pharmaceutically acceptable salt thereof, wherein all variable groups are defined as they are defined for the compound of formula (I-A).

[0078] In some embodiments, the invention relates to a compound of formula (I-D-2):; or a pharmaceutically acceptable salt thereof, wherein all variable groups are defined as they are defined for the compound of formula (I-A).

[0079] In some embodiments, the invention relates to a compound of formula (I-A), (I-A-1), (I- B-1), (I-A-2), or (I-B-2), or a pharmaceutically acceptable salt thereof, wherein p is 0.

[0080] In some embodiments, the invention relates to a compound of formula (I-A), (I-A-1), (I- B-1), (I-A-2), or (I-B-2), or a pharmaceutically acceptable salt thereof, wherein p is 1.

[0081] In some embodiments, the invention relates to a compound of formula (I-A), (I-A-1), (I- A-2), (I-B-1), (I-B-2), (I-C-1), (I-C-2), (I-D-1), or (I-D-2), or a pharmaceutically acceptable salt thereof, wherein R7is H, C1-C6alkyl, or C1-C6alkoxy. In some embodiments, the invention relates to a compound of formula (I-A), (I-A-1), (I-A-2), (I-B-1), (I-B-2), (I-C-1), (I-C-2), (I-D-1), or (I-D-2), or a pharmaceutically acceptable salt thereof, wherein R7is H or C1-C6alkoxy. In other embodiments, R7is H. In other embodiments, R7is C1-C6alkyl. In other embodiments, R7is C1-C6alkoxy. In some embodiments, the invention relates to a compound of formula (I-A), (I-A-1), (I-A-2), (I-B-1), (I-B-2), (I-C-1), (I-C-2), (I-D-1), or (I-D-2), or a pharmaceutically acceptable salt thereof, wherein R7is H, – CH3, or –OCH3. In some embodiments, the invention relates to a compound of formula (I-A), (I-A- 1), or (I-A-2), or a pharmaceutically acceptable salt thereof, wherein R7is H or –OCH3. In other embodiments, R7is –CH3. In other embodiments, R7is –OCH3.

[0082] In some embodiments, the invention relates to a compound of formula (I-A), (I-A-1), (I- A-2), (I-B-1), (I-B-2), (I-C-1), (I-C-2), (I-D-1), or (I-D-2), or a pharmaceutically acceptable salt thereof, wherein Rsis H, OH, halo, C1-C6alkyl, C1-C6alkoxy, C3-C6cycloalkyl, –O-C3-C6cycloalkyl, –(CH2)mORb, or –O(CH2)mOCH3. In some embodiments, the invention relates to a compound of formula (I-A), (I-A-1), (I-A-2), (I-B-1), (I-B-2), (I-C-1), (I-C-2), (I-D-1), or (I-D-2), or a pharmaceutically acceptable salt thereof, wherein Rsis H, halo, C1-C6alkyl, C1-C6alkoxy, C3-C6cycloalkyl, or –(CH2)mORb. In some embodiments, the invention relates to a compound of formula (I- A), (I-A-1), (I-A-2), (I-B-1), (I-B-2), (I-C-1), (I-C-2), (I-D-1), or (I-D-2), or a pharmaceutically acceptable salt thereof, wherein Rsis C1-C6alkyl or C1-C6alkoxy. In other embodiments, Rsis H. In other embodiments, Rsis halo. In other embodiments, Rsis C1-C6alkyl. In other embodiments, RsisC1-C6alkoxy. In other embodiments, Rsis C3-C6cycloalkyl. In other embodiments, Rsis –O-C3-C6cycloalkyl. In other embodiments, Rsis –(CH2)mORb. In some embodiments, the invention relates to a compound of formula (I-A), (I-A-1), (I-A-2), (I-B-1), (I-B-2), (I-C-1), (I-C-2), (I-D-1), or (I-D-2), or a pharmaceutically acceptable salt thereof, wherein Rsis H, F, Cl, OH, –CH3, –CH2OH, –CH2OCH3, – OCH3, cyclopropyl, –O-cyclopropyl, –OCH(CH3)2, or –OCH2CH2OCH3.. In some embodiments, the invention relates to a compound of formula (I-A), (I-A-1), (I-A-2), (I-B-1), (I-B-2), (I-C-1), (I-C-2), (I-D-1), or (I-D-2), or a pharmaceutically acceptable salt thereof, wherein Rsis H, F, Cl, –CH3, – OCH3, cyclopropyl, or –CH2OCH3. In some embodiments, the invention relates to a compound of formula (I-A), (I-A-1), (I-A-2), (I-B-1), (I-B-2), (I-C-1), (I-C-2), (I-D-1), or (I-D-2), or a pharmaceutically acceptable salt thereof, wherein Rsis –CH3or –OCH3. In other embodiments, Rsis F. In other embodiments, Rsis Cl. In other embodiments, Rsis –CH3. In other embodiments, Rsis – OCH3. In other embodiments, Rsis cyclopropyl. In other embodiments, Rsis –OCH3. In other embodiments, Rsis –O-cyclopropyl. In other embodiments, Rsis –CH2OCH3.

[0083] In some embodiments, the invention relates to a compound of formula (I-A), (I-A-1), (I- A-2), (I-B-1), (I-B-2), (I-C-1), (I-C-2), (I-D-1), or (I-D-2), or a pharmaceutically acceptable salt thereof, wherein Rtis H, halo, C1-C6alkyl, or C3-C6cycloalkyl. In some embodiments, the invention relates to a compound of formula (I-A), (I-A-1), (I-A-2), (I-B-1), (I-B-2), (I-C-1), (I-C-2), (I-D-1), or (I-D-2), or a pharmaceutically acceptable salt thereof, wherein Rtis H or halo. In other embodiments, Rtis H. In other embodiments, Rtis halo. In other embodiments, Rtis C1-C6alkyl. In other embodiments, Rtis C3-C6cycloalkyl. In some embodiments, the invention relates to a compound of formula (I-A), (I-A-1), (I-A-2), (I-B-1), (I-B-2), (I-C-1), (I-C-2), (I-D-1), or (I-D-2), or a pharmaceutically acceptable salt thereof, wherein Rtis H, F, Cl, –CH3, or cyclopropyl. In some embodiments, the invention relates to a compound of formula (I-A), (I-A-1), (I-A-2), (I-B-1), (I-B-2), (I-C-1), (I-C-2), (I-D-1), or (I-D-2), or a pharmaceutically acceptable salt thereof, wherein Rtis H or F. In other embodiments, Rtis F. In other embodiments, Rtis Cl. In other embodiments, Rtis –CH3. In other embodiments, Rtis cyclopropyl.

[0084] In some embodiments, the invention relates to a compound selected from Table A, or a pharmaceutically acceptable salt thereof. In other embodiments, the invention relates to a compound selected from Table A, i.e., the compound in non-salt form.

[0085] Table A. Compound Structures and Names.

[0086] In some embodiments, the invention relates to a compound selected from Table B, or a pharmaceutically acceptable salt thereof. In other embodiments, the invention relates to a compound selected from Table B, i.e., the compound in non-salt form.

[0087] Table B. Compound Structures and Names.

[0088] In some embodiments, the invention relates to a compound selected from Table C, or a pharmaceutically acceptable salt thereof. In other embodiments, the invention relates to a compound selected from Table C, i.e., the compound in non-salt form.

[0089] Table C. Compound Structures and Names.

[0090] In some embodiments, the invention relates to a compound selected from Table D, or a pharmaceutically acceptable salt thereof. In other embodiments, the invention relates to a compound selected from Table D, i.e., the compound in non-salt form.

[0091] Table D. Compound Structures and Names.

[0092] In some embodiments, the invention relates to a compound selected from Table D, or a pharmaceutically acceptable salt thereof. In other embodiments, the invention relates to a compound selected from Table E, i.e., the compound in non-salt form.

[0093] Table E. Compound Structures and Names.Salts. Compositions, Uses, Formulation. Administration and Additional AgentsPharmaceutically acceptable salts and compositions

[0094] As discussed herein, the invention provides compounds, and pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, and thus the present compounds, and pharmaceutically acceptable salts thereof, are useful for the treatment of diseases, disorders, and conditions including, but not limited to chronic pain, gut pain, neuropathic pain, musculoskeletal pain, acute pain, inflammatory pain, cancer pain, idiopathic pain, postsurgical pain (e.g., bunionectomypain, herniorrhaphy pain or abdominoplasty pain), visceral pain, multiple sclerosis, Charcot-Marie- Tooth syndrome, incontinence, pathological cough, or cardiac arrhythmia. Accordingly, in another aspect of the invention, pharmaceutical compositions are provided, wherein these compositions comprise a compound as described herein, or a pharmaceutically acceptable salt thereof, and optionally comprise a pharmaceutically acceptable carrier, adjuvant or vehicle. In certain embodiments, these compositions optionally further comprise one or more additional therapeutic agents. In some embodiments, the additional therapeutic agent is a sodium channel inhibitor.

[0095] As used herein, the term “pharmaceutically acceptable salt” refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit / risk ratio. A “pharmaceutically acceptable salt” of a compound of this invention includes any non-toxic salt that, upon administration to a recipient, is capable of providing, either directly or indirectly, a compound of this invention or an inhibitorily active metabolite or residue thereof. The salt may be in pure form, in a mixture (e.g., solution, suspension, or colloid) with one or more other substances, or in the form of a hydrate, solvate, or co- crystal. As used herein, the term “inhibitorily active metabolite or residue thereof” means that a metabolite or residue thereof is also an inhibitor of a voltage-gated sodium channel.

[0096] Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge, et al. describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66, 1-19, incorporated herein by reference. Pharmaceutically acceptable salts of the compound of this invention include those derived from suitable inorganic and organic acids and bases. Examples of pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange. Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2- hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate salts, and the like. Salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium and N+(C1-4alkyl)4salts. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed usingcounterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, lower alkyl sulfonate and aryl sulfonate.

[0097] As described herein, the pharmaceutically acceptable compositions of the invention additionally comprise a pharmaceutically acceptable carrier, adjuvant, or vehicle, which, as used herein, includes any and all solvents, diluents, or other liquid vehicle, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like, as suited to the particular dosage form desired. Remington’s Pharmaceutical Sciences, Sixteenth Edition, E. W. Martin (Mack Publishing Co., Easton, Pa., 1980) discloses various carriers used in formulating pharmaceutically acceptable compositions and known teclmiques for the preparation thereof. Except insofar as any conventional carrier medium is incompatible with the compounds of the invention, such as by producing any undesirable biological effect or otherwise interacting in a deleterious manner with any other component(s) of the pharmaceutically acceptable composition, its use is contemplated to be within the scope of this invention. Some examples of materials which can serve as pharmaceutically acceptable carriers include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, or potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, polyacrylates, waxes, polyethylene- polyoxypropylene-block polymers, wool fat, sugars such as lactose, glucose and sucrose; starches such as com starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil; safflower oil; sesame oil; olive oil; com oil and soybean oil; glycols; such a propylene glycol or polyethylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffering agents such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer’s solution; ethyl alcohol, and phosphate buffer solutions, as well as other non-toxic compatible lubricants such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, releasing agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in tlie composition, according to the judgment of the fonnulator.

[0098] In another aspect, tlie invention features a pharmaceutical composition comprising a compound of the invention, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

[0099] In another aspect, the invention features a pharmaceutical composition comprising a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers or vehicles.Uses of Compounds and Pharmaceutically Acceptable Salts and Compositions

[0100] In another aspect, the invention features a method of inhibiting a voltage-gated sodium channel in a subject comprising administering to the subject a compound of the invention or a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof. In another aspect, the voltage-gated sodium channel is NaV1.8.

[0101] In yet another aspect, the invention features a method of treating or lessening the severity in a subject of chronic pain, gut pain, neuropathic pain, musculoskeletal pain, acute pain, inflammatory pain, cancer pain, idiopathic pain, postsurgical pain (e.g., bunionectomy pain, herniorrhaphy pain or abdominoplasty pain), visceral pain, multiple sclerosis, Charcot-Marie-Tooth syndrome, incontinence, pathological cough, or cardiac arrhythmia comprising administering an effective amount of a compound of the invention, a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof.

[0102] In yet another aspect, the invention features a method of treating or lessening the severity in a subject of chronic pain, gut pain, neuropathic pain, musculoskeletal pain, acute pain, inflammatory pain, cancer pain, idiopathic pain, postsurgical pain, herniorrhaphy pain, bunionectomy pain, multiple sclerosis, Charcot-Marie-Tooth syndrome, incontinence, or cardiac arrhythmia comprising administering an effective amount of a compound of the invention, a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof.

[0103] In yet another aspect, the invention features a method of treating or lessening the severity in a subject of gut pain, wherein gut pain comprises inflammatory bowel disease pain, Crohn’s disease pain, irritable bowel syndrome, endometriosis, polycystic ovarian disease, salpingitis, cervicitis or interstitial cystitis pain wherein said method comprises administering an effective amount of a compound of the invention, a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof.

[0104] In yet another aspect, the invention features a method of treating or lessening the severity in a subject of neuropathic pain comprising administering an effective amount of a compound of the invention, a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof. In some aspects, the neuropathic pain comprises post-herpetic neuralgia, small fiber neuropathy, diabetic neuropathy, or idiopathic small-fiber neuropathy. In some aspects, the neuropathic pain comprises diabetic neuropathy (e.g., diabetic peripheral neuropathy). As used herein, the phrase “idiopathic small-fiber neuropathy” shall be understood to include any small fiber neuropathy.

[0105] In yet another aspect, the invention features a method of treating or lessening the severity in a subject of neuropathic pain, wherein neuropathic pain comprises post-herpetic neuralgia, diabetic neuralgia, painful HIV-associated sensory neuropathy, trigeminal neuralgia, burning mouth syndrome, post-amputation pain, phantom pain, painful neuroma; traumatic neuroma; Morton’s neuroma; nerve entrapment injury, spinal stenosis, carpal tunnel syndrome, radicular pain, sciatica pain; nerveavulsion injury, brachial plexus avulsion injury; complex regional pain syndrome, drug therapy induced neuralgia, cancer chemotherapy induced neuralgia, anti-retroviral therapy induced neuralgia, HIV-induced neuropathy; post spinal cord injury pain, spinal stenosis pain, small fiber neuropathy, idiopathic small-fiber neuropathy, idiopathic sensory neuropathy or trigeminal autonomic cephalalgia wherein said method comprises administering an effective amount of a compound of tire invention, a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof.

[0106] In yet another aspect, the invention features a method of treating or lessening the severity in a subject of musculoskeletal pain comprising administering an effective amount of a compound of the invention, a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof. In some aspects, the musculoskeletal pain comprises osteoarthritis pain.

[0107] In yet another aspect, the invention features a method of treating or lessening the severity in a subject of musculoskeletal pain, wherein musculoskeletal pain comprises osteoarthritis pain, back pain, cold pain, bum pain or dental pain wherein said method comprises administering an effective amount of a compound of the invention, a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof.

[0108] In yet another aspect, the invention features a method of treating or lessening the severity in a subject of inflammatory pain, wherein inflammatory pain comprises rheumatoid arthritis pain, ankylosing spondylitis or vulvodynia wherein said method comprises administering an effective amount of a compound of the invention, a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof.

[0109] In yet another aspect, tire invention features a method of treating or lessening the severity in a subject of inflammatory pain, wherein inflammatory pain comprises rheumatoid arthritis pain wherein said method comprises administering an effective amount of a compound of the invention, a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof.

[0110] In yet another aspect, tire invention features a method of treating or lessening the severity in a subject of idiopathic pain, wherein idiopathic pain comprises fibromyalgia pain wherein said method comprises administering an effective amount of a compound of tire invention, a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof.

[0111] In yet another aspect, the invention features a method of treating or lessening tire severity in a subject of idiopathic pain, wherein idiopathic pain comprises reflex sympathetic dystrophy pain, wherein said method comprises administering an effective amount of a compound of tire invention, a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof.

[0112] In yet another aspect, the invention features a method of treating or lessening the severity in a subject of pathological cough wherein said method comprises administering an effective amount of a compound of the invention, a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof.

[0113] In yet another aspect, the invention features a method of treating or lessening the severity in a subject of acute pain comprising administering an effective amount of a compound of the invention, a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof. In some aspects, the acute pain comprises acute post-operative pain.

[0114] In yet another aspect, the invention features a method of treating or lessening the severity in a subject of postsurgical pain (e.g., joint replacement pain, soft tissue surgery pain, post- thoracotomy pain, post-mastectomy pain, hemorrhoidectomy pain, herniorrhaphy pain, bunionectomy pain or abdominoplasty pain) comprising administering an effective amount of a compound of the invention, a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof.

[0115] In yet another aspect, the invention features a method of treating or lessening the severity in a subject of bunionectomy pain comprising administering an effective amount of a compound of the invention, a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof.

[0116] In yet another aspect, the invention features a method of treating or lessening the severity in a subject of shoulder arthroplasty pain or shoulder arthroscopy pain comprising administering an effective amount of a compound of the invention, a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof.

[0117] In yet another aspect, the invention features a method of treating or lessening the severity in a subject of herniorrhaphy pain comprising administering an effective amount of a compound of the invention, a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof.

[0118] In yet another aspect, the invention features a method of treating or lessening the severity in a subject of abdominoplasty pain comprising administering an effective amount of a compound of the invention, a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof.

[0119] In yet another aspect, the invention features a method of treating or lessening the severity in a subject of visceral pain comprising administering an effective amount of a compound of the invention, a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof. In some aspects, the visceral pain comprises visceral pain from abdominoplasty.

[0120] In yet another aspect, the invention features a method of treating or lessening the severity in a subject of a neurodegenerative disease comprising administering an effective amount of a compound of the invention, a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof. In some aspects, the neurodegenerative disease comprises multiple sclerosis. In some aspects, the neurodegenerative disease comprises Pitt Hopkins Syndrome (PTHS).

[0121] In yet another aspect, the invention features a method wherein the subject is treated with one or more additional therapeutic agents administered concurrently with, prior to, or subsequent to treatment with an effective amount of the compound, pharmaceutically acceptable salt or pharmaceutical composition. In some embodiments, the additional therapeutic agent is a sodium channel inhibitor.

[0122] In another aspect, the invention features a method of inhibiting a voltage-gated sodium channel in a biological sample comprising contacting the biological sample with an effective amount of a compound of the invention, a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof. In another aspect, the voltage-gated sodium channel is NaV1.8.

[0123] In another aspect, the invention features a method of treating or lessening the severity in a subject of acute pain, sub-acute and chronic pain, nociceptive pain, neuropathic pain, inflammatory pain, nociplastic pain, arthritis, migraine, cluster headaches, tension headaches, and all other forms of headaches, trigeminal neuralgia, herpetic neuralgia, general neuralgias, epilepsy, epilepsy conditions, neurodegenerative disorders, psychiatric disorders, anxiety, depression, bipolar disorder, myotonia, arrhythmia, movement disorders, neuroendocrine disorders, ataxia, central neuropathic pain of multiple sclerosis and irritable bowel syndrome, incontinence, pathological cough, visceral pain, osteoarthritis pain, postherpetic neuralgia, diabetic neuropathy, radicular pain, sciatica, back pain, unspecific chronic back pain, head pain, neck pain, moderate pain, severe pain, intractable pain, nociceptive pain, breakthrough pain, postsurgical pain (e.g., joint replacement pain, soft tissue surgery pain, post-thoracotomy pain, post-mastectomy pain, herniorrhaphy pain, bunionectomy pain or abdominoplasty pain), cancer pain including chronic cancer pain and breakthrough cancer pain, stroke (e.g., post stroke central neuropathic pain), whiplash associated disorders, fragility fractures, spinal fractures, ankylosing spondylitis, pemphigus, Raynaud’s Disease, scleroderma, systemic lupus erythematosus, Epidermolysis bullosa, gout, juvenile idiopathic arthritis, melorheostosis, polymyalgia reumatica, pyoderma gangrenosum, chronic widespread pain, diffuse idiopathic skeletal hyperostosis, disc degeneration / herniation pain, radiculopathy, facet joint syndrome, failed back surgery syndrome, burns, carpal tunnel syndrome, Paget’s disease pain, spinal canal stenosis, spondylodyscitis, transverse myelitis, Ehlers-Danlos syndrome, Fabry’s disease, mastocytocytosis, neurofibromatosis, ocular neuropathic pain, sarcoidosis, spondylolysis, spondylolisthesis, chemotherapy induced oral mucositis, Charcot neuropathic osteoarhropathy, temporo-mandibular joint disorder, painful joint arthroplasties, non-cardiac chest pain, pudendal neuralgia, renal colic, biliary tract diseases, vascular leg ulcers, pain in Parkinson’s disease, pain in Alzheimer’s disease, cerebral ischemia, traumatic brain injury, amyotrophic lateral sclerosis, stress induced angina, exercise induced angina, palpitations, hypertension, or abnormal gastro-intestinal motility, comprising administering an effective amount of a compound of the invention, a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof.

[0124] In another aspect, the invention features a method of treating or lessening the severity in a subject of femur cancer pain; non-malignant chronic bone pain; rheumatoid arthritis; osteoarthritis; spinal stenosis; neuropathic low back pain; myofascial pain syndrome; fibromyalgia; temporomandibular joint pain; chronic visceral pain, abdominal pain; pancreatic pain; IBS pain; chronic and acute headache pain; migraine; tension headache; cluster headaches; chronic and acute neuropathic pain, post-herpetic neuralgia; diabetic neuropathy; HIV-associated neuropathy; trigeminalneuralgia; Charcot-Marie-Tooth neuropathy; hereditary sensory neuropathy; peripheral nerve injury; painful neuromas; ectopic proximal and distal discharges; radiculopathy; chemotherapy induced neuropathic pain; radiotherapy-induced neuropathic pain; persistent / chronic post-surgical pain (e.g., post amputation, post-thoracotomy, post-cardiac surgery), post-mastectomy pain; central pain; spinal cord injury pain; post-stroke pain; thalamic pain; phantom pain (e.g., following removal of lower extremity, upper extremity, breast); intractable pain; acute pain, acute post-operative pain; acute musculoskeletal pain; joint pain; mechanical low back pain; neck pain; tendonitis; injury pain; exercise pain; acute visceral pain; pyelonephritis; appendicitis; cholecystitis; intestinal obstruction; hernias; chest pain, cardiac pain; pelvic pain, renal colic pain, acute obstetric pain, labor pain; cesarean section pain; acute inflammatory pain, burn pain, trauma pain; acute intermittent pain, endometriosis; acute herpes zoster pain; sickle cell anemia; acute pancreatitis; breakthrough pain; orofacial pain; sinusitis pain; dental pain; multiple sclerosis (MS) pain; pain in depression; leprosy pain; Behcet's disease pain; adiposis dolorosa; phlebitic pain; Guillain-Barre pain; painful legs and moving toes; Haglund syndrome; erythromelalgia pain; Fabry's disease pain; bladder and urogenital disease; urinary incontinence, pathological cough; hyperactive bladder; painful bladder syndrome; interstitial cystitis (IC); prostatitis; complex regional pain syndrome (CRPS), type I, complex regional pain syndrome (CRPS) type II; widespread pain, paroxysmal extreme pain, pruritus, tinnitus, or angina-induced pain, comprising administering an effective amount of a compound of the invention, a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof.

[0125] In another aspect, the invention features a method of treating or lessening the severity in a subject of trigeminal neuralgia, migraines treated with botox, cervical radiculopathy, occipital neuralgia, axillary neuropathy, radial neuropathy, ulnar neuropathy, brachial plexopathy, thoracic radiculopathy, intercostal neuralgia, lumbosacral radiculopathy, iliolingual neuralgia, pudendal neuralgia, femoral neuropathy, meralgia paresthetica, saphenous neuropathy, sciatic neuropathy, peroneal neuropathy, tibial neuropathy, lumbosacral plexopathy, traumatic neuroma stump pain or postamputation pain, comprising administering an effective amount of a compound of the invention, a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof. Compounds, Pharmaceutically Acceptable Salts, and Compositions for Use

[0126] In another aspect, the invention features a compound of the invention, or a pharmaceutically acceptable salt or pharmaceutical composition thereof, for use as a medicament.

[0127] In another aspect, the invention features a compound of the invention, or a pharmaceutically acceptable salt or pharmaceutical composition thereof, for use in a method of inhibiting a voltage-gated sodium channel in a subject. In another aspect, the voltage-gated sodium channel is NaV1.8.

[0128] In another aspect, the invention features a compound of the invention, or a pharmaceutically acceptable salt or pharmaceutical composition thereof, for use in a method oftreating or lessening the severity in a subject of chronic pain, gut pain, neuropathic pain, musculoskeletal pain, acute pain, inflammatory pain, cancer pain, idiopathic pain, postsurgical pain (e.g., herniorrhaphy pain, bunionectomy pain or abdominoplasty pain), visceral pain, multiple sclerosis, Charcot-Marie-Tooth syndrome, incontinence, pathological cough, or cardiac arrhythmia.

[0129] In another aspect, the invention features a compound of the invention, or a pharmaceutically acceptable salt or pharmaceutical composition thereof, for use in a method of treating or lessening the severity in a subject of chronic pain, gut pain, neuropathic pain, musculoskeletal pain, acute pain, inflammatory pain, cancer pain, idiopathic pain, postsurgical pain, herniorrhaphy pain, bunionectomy pain, multiple sclerosis, Charcot-Marie-Tooth syndrome, incontinence, or cardiac arrhythmia.

[0130] In another aspect, the invention features a compound of the invention, or a pharmaceutically acceptable salt or pharmaceutical composition thereof, for use in a method of treating or lessening the severity in a subject of gut pain, wherein gut pain comprises inflammatory bowel disease pain, Crohn’s disease pain, irritable bowel syndrome, endometriosis, polycystic ovarian disease, salpingitis, cervicitis or interstitial cystitis pain.

[0131] In another aspect, the invention features a compound of the invention, or a pharmaceutically acceptable salt or pharmaceutical composition thereof, for use in a method of treating or lessening the severity in a subject of neuropathic pain. In some aspects, the neuropathic pain comprises post-herpetic neuralgia, small fiber neuropathy, diabetic neuropathy, or idiopathic small-fiber neuropathy. In some aspects, the neuropathic pain comprises diabetic neuropathy (e.g., diabetic peripheral neuropathy). As used herein, the phrase “idiopathic small-fiber neuropathy” shall be understood to include any small fiber neuropathy.

[0132] In another aspect, the invention features a compound of the invention, or a pharmaceutically acceptable salt or pharmaceutical composition thereof, for use in a method of treating or lessening the severity in a subject of neuropathic pain, wherein neuropathic pain comprises post-herpetic neuralgia, diabetic neuralgia, painful HIV-associated sensory neuropathy, trigeminal neuralgia, burning mouth syndrome, post-amputation pain, phantom pain, painful neuroma; traumatic neuroma; Morton’s neuroma; nerve entrapment injury, spinal stenosis, carpal tunnel syndrome, radicular pain, sciatica pain; nerve avulsion injury, brachial plexus avulsion injury; complex regional pain syndrome, drug therapy induced neuralgia, cancer chemotherapy induced neuralgia, anti- retroviral therapy induced neuralgia, HIV-induced neuropathy; post spinal cord injury pain, spinal stenosis pain, small fiber neuropathy, idiopathic small-fiber neuropathy, idiopathic sensory neuropathy or trigeminal autonomic cephalalgia.

[0133] In another aspect, the invention features a compound of the invention, or a pharmaceutically acceptable salt or pharmaceutical composition thereof, for use in a method of treating or lessening the severity in a subject of musculoskeletal pain. In some aspects, the musculoskeletal pain comprises osteoarthritis pain.

[0134] In another aspect, the invention features a compound of the invention, or a pharmaceutically acceptable salt or pharmaceutical composition thereof, for use in a method of treating or lessening the severity in a subject of musculoskeletal pain, wherein musculoskeletal pain comprises osteoarthritis pain, back pain, cold pain, burn pain or dental pain.

[0135] In another aspect, the invention features a compound of the invention, or a pharmaceutically acceptable salt or pharmaceutical composition thereof, for use in a method of treating or lessening the severity in a subject of inflammatory pain, wherein inflammatory pain comprises rheumatoid arthritis pain, ankylosing spondylitis or vulvodynia.

[0136] In another aspect, the invention features a compound of the invention, or a pharmaceutically acceptable salt or pharmaceutical composition thereof, for use in a method of treating or lessening the severity in a subject of inflammatory pain, wherein inflammatory pain comprises rheumatoid arthritis pain.

[0137] In another aspect, the invention features a compound of the invention, or a pharmaceutically acceptable salt or pharmaceutical composition thereof, for use in a method of treating or lessening the severity in a subject of idiopathic pain, wherein idiopathic pain comprises fibromyalgia pain.

[0138] In another aspect, the invention features a compound of the invention, or a pharmaceutically acceptable salt or pharmaceutical composition thereof, for use in a method of treating or lessening the severity in a subject of idiopathic pain, wherein idiopathic pain comprises reflex sympathetic dystrophy pain.

[0139] In another aspect, the invention features a compound of the invention, or a pharmaceutically acceptable salt or pharmaceutical composition thereof, for use in a method of treating or lessening the severity in a subject of pathological cough.

[0140] In another aspect, the invention features a compound of the invention, or a pharmaceutically acceptable salt or pharmaceutical composition thereof, for use in a method of treating or lessening the severity in a subject of acute pain. In some aspects, the acute pain comprises acute post-operative pain.

[0141] In another aspect, the invention features a compound of the invention, or a pharmaceutically acceptable salt or pharmaceutical composition thereof, for use in a method of treating or lessening the severity in a subject of postsurgical pain (e.g., joint replacement pain, soft tissue surgery pain, post-thoracotomy pain, post-mastectomy pain, hemorrhoidectomy pain, herniorrhaphy pain, bunionectomy pain or abdominoplasty pain).

[0142] In another aspect, the invention features a compound of the invention, or a pharmaceutically acceptable salt or pharmaceutical composition thereof, for use in a method of treating or lessening the severity in a subject of bunionectomy pain.

[0143] In another aspect, the invention features a compound of the invention, or a pharmaceutically acceptable salt or pharmaceutical composition thereof, for use in a method oftreating or lessening the severity in a subject of shoulder arthroplasty pain or shoulder arthroscopy pain.

[0144] In another aspect, the invention features a compound of the invention, or a pharmaceutically acceptable salt or pharmaceutical composition thereof, for use in a method of treating or lessening the severity in a subject of herniorrhaphy pain.

[0145] In another aspect, the invention features a compound of the invention, or a pharmaceutically acceptable salt or pharmaceutical composition thereof, for use in a method of treating or lessening the severity in a subject of abdominoplasty pain.

[0146] In another aspect, the invention features a compound of the invention, or a pharmaceutically acceptable salt or pharmaceutical composition thereof, for use in a method of treating or lessening the severity in a subject of visceral pain. In some aspects, the visceral pain comprises visceral pain from abdominoplasty.

[0147] In another aspect, the invention features a compound of the invention, or a pharmaceutically acceptable salt or pharmaceutical composition thereof, for use in a method of treating or lessening the severity in a subject of a neurodegenerative disease. In some aspects, the neurodegenerative disease comprises multiple sclerosis. In some aspects, the neurodegenerative disease comprises Pitt Hopkins Syndrome (PTHS).

[0148] In another aspect, the invention features a compound of the invention, or a pharmaceutically acceptable salt or pharmaceutical composition thereof, for use in a method wherein the subject is treated with one or more additional therapeutic agents administered concurrently with, prior to, or subsequent to treatment with an effective amount of the compound, pharmaceutically acceptable salt or pharmaceutical composition. In some embodiments, the additional therapeutic agent is a sodium channel inhibitor.

[0149] In another aspect, the invention features a compound of the invention, or a pharmaceutically acceptable salt or pharmaceutical composition thereof, for use in a method of inhibiting a voltage-gated sodium channel in a biological sample comprising contacting the biological sample with an effective amount of a compound of the invention, a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof. In another aspect, the voltage-gated sodium channel is NaV1.8.

[0150] In another aspect, the invention features a compound of the invention, or a pharmaceutically acceptable salt or pharmaceutical composition thereof, for use in a method of treating or lessening the severity in a subject of acute pain, sub-acute and chronic pain, nociceptive pain, neuropathic pain, inflammatory pain, nociplastic pain, arthritis, migraine, cluster headaches, tension headaches, and all other forms of headaches, trigeminal neuralgia, herpetic neuralgia, general neuralgias, epilepsy, epilepsy conditions, neurodegenerative disorders, psychiatric disorders, anxiety, depression, bipolar disorder, myotonia, arrhythmia, movement disorders, neuroendocrine disorders, ataxia, central neuropathic pain of multiple sclerosis and irritable bowel syndrome, incontinence,pathological cough, visceral pain, osteoarthritis pain, postherpetic neuralgia, diabetic neuropathy, radicular pain, sciatica, back pain, unspecific chronic back pain, head pain, neck pain, moderate pain, severe pain, intractable pain, nociceptive pain, breakthrough pain, postsurgical pain (e.g., joint replacement pain, soft tissue surgery pain, post-thoracotomy pain, post-mastectomy pain, herniorrhaphy pain, bunionectomy pain or abdominoplasty pain), cancer pain including chronic cancer pain and breakthrough cancer pain, stroke (e.g., post stroke central neuropathic pain), whiplash associated disorders, fragility fractures, spinal fractures, ankylosing spondylitis, pemphigus, Raynaud’s Disease, scleroderma, systemic lupus erythematosus, Epidermolysis bullosa, gout,juvenile idiopathic arthritis, melorheostosis, polymyalgia reumatica, pyodenna gangrenosum, chronic widespread pain, diffuse idiopathic skeletal hyperostosis, disc degeneration / herniation pain, radiculopathy, facet joint syndrome, failed back surgery syndrome, bums, carpal tunnel syndrome, Paget’s disease pain, spinal canal stenosis, spondylodyscitis, transverse myelitis, Ehlers-Danlos syndrome, Fabry ’ s disease, mastocytocytosis, neurofibromatosis, ocular neuropathic pain, sarcoidosis, spondylolysis, spondylolisthesis, chemotherapy induced oral mucositis, Charcot neuropathic osteoarhropathy, temporo-mandibular joint disorder, painful joint arthroplasties, non-cardiac chest pain, pudendal neuralgia, renal colic, biliary tract diseases, vascular leg ulcers, pain in Parkinson’s disease, pain in Alzheimer’s disease, cerebral ischemia, traumatic brain injury, amyotrophic lateral sclerosis, stress induced angina, exercise induced angina, palpitations, hypertension, or abnormal gastro-intestinal motility.

[0151] In another aspect, the invention features a compound of the invention, or a pharmaceutically acceptable salt or pharmaceutical composition thereof, for use in a method of treating or lessening the severity in a subject of femur cancer pain; non-malignant clironic bone pain; rheumatoid arthritis; osteoarthritis; spinal stenosis; neuropathic low back pain; my ofascial pain syndrome; fibromyalgia; temporomandibular joint pain; clironic visceral pain, abdominal pain; pancreatic pain; IBS pain; chronic and acute headache pain; migraine; tension headache; cluster headaches; chronic and acute neuropathic pain, post-herpetic neuralgia; diabetic neuropathy; HIV- associated neuropathy; trigeminal neuralgia; Charcot-Marie -Tooth neuropathy; hereditary sensory neuropathy; peripheral nerve injury; painful neuromas; ectopic proximal and distal discharges; radiculopathy; chemotherapy induced neuropathic pain; radiotherapy -induced neuropathic pain; persistent / chronic post-surgical pain (e.g., post amputation, post-thoracotomy, post-cardiac surgery), post-mastectomy pain; central pain; spinal cord injury pain; post-stroke pain; thalamic pain; phantom pain (e.g., following removal of lower extremity, upper extremity , breast); intractable pain; acute pain, acute post-operative pain; acute musculoskeletal pain; joint pain; mechanical low back pain; neck pain; tendonitis; injury pain; exercise pain; acute visceral pain; pyelonephritis; appendicitis; cholecystitis; intestinal obstruction; hernias; chest pain, cardiac pain; pelvic pain, renal colic pain, acute obstetric pain, labor pain: cesarean section pain: acute inflammatory pain, bum pain, trauma pain; acute intermittent pain, endometriosis; acute herpes zoster pain; sickle cell anemia; acutepancreatitis; breakthrough pain; orofacial pain; sinusitis pain; dental pain; multiple sclerosis (MS) pain; pain in depression; leprosy pain; Behcet's disease pain; adiposis dolorosa; phlebitic pain; Guillain-Barre pain; painful legs and moving toes; Haglund syndrome; erythromelalgia pain; Fabry's disease pain; bladder and urogenital disease; urinary incontinence, pathological cough; hyperactive bladder; painful bladder syndrome; interstitial cystitis (IC); prostatitis; complex regional pain syndrome (CRPS), type I, complex regional pain syndrome (CRPS) type II; widespread pain, paroxysmal extreme pain, pruritus, tinnitus, or angina-induced pain.

[0152] In another aspect, the invention features a compound of the invention, or a pharmaceutically acceptable salt or pharmaceutical composition thereof, for use in a method of treating or lessening the severity in a subject of trigeminal neuralgia, migraines treated with botox, cervical radiculopathy, occipital neuralgia, axillary neuropathy, radial neuropathy, ulnar neuropathy, brachial plexopathy, thoracic radiculopathy, intercostal neuralgia, lumbosacral radiculopathy, iliolingual neuralgia, pudendal neuralgia, femoral neuropathy, meralgia paresthetica, saphenous neuropathy, sciatic neuropathy, peroneal neuropathy, tibial neuropathy, lumbosacral plexopathy, traumatic neuroma stump pain or postamputation pain. Manufacture of Medicaments

[0153] In another aspect, the invention provides the use of a compound of the invention, or a pharmaceutically acceptable salt or pharmaceutical composition thereof, for the manufacture of a medicament.

[0154] In another aspect, the invention provides the use of a compound of the invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof for the manufacture of a medicament for use in inhibiting a voltage-gated sodium channel. In another aspect, the voltage- gated sodium channel is NaV1.8.

[0155] In yet another aspect, the invention provides the use of a compound of the invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof for the manufacture of a medicament for use in treating or lessening the severity in a subject of chronic pain, gut pain, neuropathic pain, musculoskeletal pain, acute pain, inflammatory pain, cancer pain, idiopathic pain, postsurgical pain (e.g., herniorrhaphy pain, bunionectomy pain or abdominoplasty pain), visceral pain, multiple sclerosis, Charcot-Marie-Tooth syndrome, incontinence, pathological cough, or cardiac arrhythmia.

[0156] In yet another aspect, the invention provides the use of a compound of the invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof for the manufacture of a medicament for use in treating or lessening the severity in a subject of chronic pain, gut pain, neuropathic pain, musculoskeletal pain, acute pain, inflammatory pain, cancer pain, idiopathic pain, postsurgical pain, herniorrhaphy pain, bunionectomy pain, multiple sclerosis, Charcot-Marie-Tooth syndrome, incontinence, or cardiac arrhythmia.

[0157] In yet another aspect, the invention provides tire use of the compound, pharmaceutically acceptable salt, or pharmaceutical composition described herein for the manufacture of a medicament for use in treating or lessening the severity in a subject of gut pain, wherein gut pain comprises inflammatory bowel disease pain, Crohn’s disease pain, irritable bowel syndrome, endometriosis, polycystic ovarian disease, salpingitis, cervicitis or interstitial cystitis pain.

[0158] In yet another aspect, the invention provides a compound of the invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition tiiereof for the manufacture of a medicament for use in treating or lessening the severity in a subject of neuropathic pain. In some aspects, the neuropathic pain comprises post-herpetic neuralgia, small fiber neuropathy, diabetic neuropathy, or idiopathic small-fiber neuropathy. In some aspects, the neuropathic pain comprises diabetic neuropathy (e.g., diabetic peripheral neuropatiiy).

[0159] In yet another aspect, the invention provides the use of a compound of the invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof for the manufacture of a medicament for use in a treating or lessening the severity in a subject of neuropathic pain, wherein neuropathic pain comprises post-herpetic neuralgia, diabetic neuralgia, painful HIV- associated sensory neuropathy, trigeminal neuralgia, burning mouth syndrome, post-amputation pain, phantom pain, painful neuroma; traumatic neuroma; Morton’s neuroma; nerve entrapment injury, spinal stenosis, carpal tunnel syndrome, radicular pain, sciatica pain; nerve avulsion injury, brachial plexus avulsion injury; complex regional pain syndrome, drug therapy induced neuralgia, cancer chemotherapy induced neuralgia, anti-retroviral therapy induced neuralgia, HIV-induced neuropatiiy; post spinal cord injury pain, spinal stenosis pain, small fiber neuropathy, idiopathic small-fiber neuropathy, idiopathic sensory neuropathy or trigeminal autonomic neuropathy.

[0160] In yet another aspect, the invention provides the use of a compound of the invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof for the manufacture of a medicament for use in treating or lessening the severity in a subject of musculoskeletal pain. In some aspects, the musculoskeletal pain comprises osteoarthritis pain.

[0161] In yet another aspect, the invention provides the use of a compound of the invention, a pharmaceutically acceptable salt tiiereof, or a pharmaceutical composition tiiereof for the manufacture of a medicament for use in treating or lessening the severity in a subject of musculoskeletal pain, wherein musculoskeletal pain comprises osteoarthritis pain, back pain, cold pain, bum pain or dental pain.

[0162] In yet another aspect, the invention provides the use of a compound of the invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition tiiereof for the manufacture of a medicament for use in treating or lessening the severity in a subject of inflammatory pain, wherein inflammatory pain comprises rheumatoid arthritis pain, ankylosing spondylitis or vulvodynia.

[0163] In yet another aspect, the invention provides the use of a compound of the invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof for the manufactureof a medicament for use in treating or lessening the severity in a subject of inflammatory pain, wherein inflammatory pain comprises rheumatoid arthritis pain.

[0164] In yet another aspect, the invention provides tire use of a compound of the invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof for the manufacture of a medicament for use in treating or lessening the severity in a subject of idiopathic pain, wherein idiopathic pain comprises fibromyalgia pain.

[0165] In yet another aspect, the invention provides the use of a compound of the invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof for the manufacture of a medicament for use in treating or lessening the severity in a subject of idiopathic pain, wherein idiopathic pain comprises reflex sympathetic dystrophy pain.

[0166] In yet another aspect, the invention provides the use of a compound of the invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof for the manufacture of a medicament for use in treating or lessening the severity in a subject of pathological cough.

[0167] In yet another aspect, the invention provides the use of a compound of the invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof for the manufacture of a medicament for use in treating or lessening the severity in a subject of acute pain. In some aspects, the acute pain comprises acute post-operative pain.

[0168] In yet another aspect, tire invention provides the use of a compound of the invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof for the manufacture of a medicament for use in treating or lessening the severity in a subject of postsurgical pain (e.g., joint replacement pain, soft tissue surgery pain, post-thoracotomy pain, post-mastectomy pain, hemorrhoidectomy pain, herniorrhaphy pain, bunionectomy pain or abdominoplasty pain).

[0169] In yet another aspect, tire invention provides tire use of a compound of the invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof for the manufacture of a medicament for use in treating or lessening the severity in a subject of herniorrhaphy pain.

[0170] In yet another aspect, the invention provides tire use of a compound of the invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof for the manufacture of a medicament for use in treating or lessening the severity in a subject of bunionectomy pain.

[0171] In yet another aspect, the invention provides the use of a compound of the invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof for the manufacture of a medicament for use in treating or lessening the severity in a subject of shoulder arthroplasty pain or shoulder arthroscopy pain.

[0172] In yet another aspect, the invention provides the use of a compound of the invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof for the manufacture of a medicament for use in treating or lessening the severity in a subject of abdominoplasty pain.

[0173] In yet another aspect, the invention provides the use of a compound of the invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof for the manufactureof a medicament for use in treating or lessening the severity in a subject of visceral pain. In some aspects, the visceral pain comprises visceral pain from abdominoplasty.

[0174] In another aspect, the invention features a compound of the invention, or a pharmaceutically acceptable salt or pharmaceutical composition thereof, for the manufacture of a medicament for use in treating or lessening the severity in a subject of a neurodegenerative disease. In some aspects, the neurodegenerative disease comprises multiple sclerosis. In some aspects, the neurodegenerative disease comprises Pitt Hopkins Syndrome (PTHS).

[0175] In yet another aspect, the invention provides the use of a compound of the invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof for the manufacture of a medicament for use in combination with one or more additional therapeutic agents administered concurrently with, prior to, or subsequent to treatment with the compound or pharmaceutical composition. In some embodiments, the additional therapeutic agent is a sodium channel inhibitor.

[0176] In another aspect, the invention provides the use of a compound of the invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof for the manufacture of a medicament for use in treating or lessening the severity of acute pain, sub-acute and chronic pain, nociceptive pain, neuropathic pain, inflammatory pain, nociplastic pain, arthritis, migraine, cluster headaches, tension headaches, and all other forms of headaches, trigeminal neuralgia, herpetic neuralgia, general neuralgias, epilepsy, epilepsy conditions, neurodegenerative disorders, psychiatric disorders, anxiety, depression, bipolar disorder, myotonia, arrhythmia, movement disorders, neuroendocrine disorders, ataxia, central neuropathic pain of multiple sclerosis and irritable bowel syndrome, incontinence, pathological cough, visceral pain, osteoarthritis pain, postherpetic neuralgia, diabetic neuropathy, radicular pain, sciatica, back pain, unspecific chronic back pain, head pain, neck pain, moderate pain, severe pain, intractable pain, nociceptive pain, breakthrough pain, postsurgical pain (e.g., joint replacement pain, soft tissue surgery pain, post-thoracotomy pain, post-mastectomy pain, herniorrhaphy pain, bunionectomy pain or abdominoplasty pain), cancer pain including chronic cancer pain and breakthrough cancer pain, stroke (e.g., post stroke central neuropathic pain), whiplash associated disorders, fragility fractures, spinal fractures, ankylosing spondylitis, pemphigus, Raynaud’s Disease, scleroderma, systemic lupus erythematosus, Epidermolysis bullosa, gout, juvenile idiopathic arthritis, melorheostosis, polymyalgia reumatica, pyoderma gangrenosum, chronic widespread pain, diffuse idiopathic skeletal hyperostosis, disc degeneration / herniation pain, radiculopathy, facet joint syndrome, failed back surgery syndrome, burns, carpal tunnel syndrome, Paget’s disease pain, spinal canal stenosis, spondylodyscitis, transverse myelitis, Ehlers-Danlos syndrome, Fabry’s disease, mastocytocytosis, neurofibromatosis, ocular neuropathic pain, sarcoidosis, spondylolysis, spondylolisthesis, chemotherapy induced oral mucositis, Charcot neuropathic osteoarhropathy, temporo-mandibular joint disorder, painful joint arthroplasties, non-cardiac chest pain, pudendal neuralgia, renal colic, biliary tract diseases, vascular leg ulcers, pain in Parkinson’s disease, pain in Alzheimer’s disease, cerebral ischemia, traumatic brain injury, amyotrophic lateralsclerosis, stress induced angina, exercise induced angina, palpitations, hypertension, or abnormal gastro-intestinal motility.

[0177] In another aspect, the invention provides the use of a compound of the invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof for the manufacture of a medicament for use in treating or lessening the severity of femur cancer pain; non-malignant chronic bone pain; rheumatoid arthritis; osteoarthritis; spinal stenosis; neuropathic low back pain; myofascial pain syndrome; fibromyalgia; temporomandibular joint pain; chronic visceral pain, abdominal pain; pancreatic pain; IBS pain; chronic and acute headache pain; migraine; tension headache; cluster headaches; chronic and acute neuropathic pain, post-herpetic neuralgia; diabetic neuropathy; HIV-associated neuropathy; trigeminal neuralgia; Charcot-Marie-Tooth neuropathy; hereditary sensory neuropathy; peripheral nerve injury; painful neuromas; ectopic proximal and distal discharges; radiculopathy; chemotherapy induced neuropathic pain; radiotherapy -induced neuropathic pain; persistent / chronic post-surgical pain (e.g., post amputation, post-thoracotomy, post-cardiac surgery), post-mastectomy pain; central pain; spinal cord injury pain; post-stroke pain; thalamic pain; phantom pain (e.g., following removal of lower extremity, upper extremity, breast); intractable pain; acute pain, acute post-operative pain; acute musculoskeletal pain; joint pain; mechanical low back pain; neck pain; tendonitis; injury pain; exercise pain; acute visceral pain; pyelonephritis; appendicitis; cholecystitis; intestinal obstruction; hernias; chest pain, cardiac pain; pelvic pain, renal colic pain, acute obstetric pain, labor pain; cesarean section pain; acute inflammatory pain, bum pain, trauma pain; acute intermittent pain, endometriosis; acute herpes zoster pain; sickle cell anemia; acute pancreatitis; breakthrough pain; orofacial pain; sinusitis pain; dental pain; multiple sclerosis (MS) pain; pain in depression; leprosy pain; Behcet's disease pain; adiposis dolorosa; phlebitic pain;Guillain-Barre pain; painful legs and moving toes; Haglund syndrome; erythromelalgia pain; Fabry's disease pain; bladder and urogenital disease; urinary incontinence, pathological cough; hyperactive bladder; painful bladder syndrome; interstitial cystitis (IC); prostatitis; complex regional pain syndrome (CRPS), type I, complex regional pain syndrome (CRPS) type II; widespread pain, paroxysmal extreme pain, pruritus, tinnitus, or angina-induced pain.

[0178] In another aspect, the invention provides the use of a compound of the invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof for the manufacture of a medicament for use in treating or lessening the severity of trigeminal neuralgia, migraines treated with botox, cervical radiculopathy, occipital neuralgia, axillary neuropathy, radial neuropathy, ulnar neuropathy, brachial plexopathy, thoracic radiculopathy, intercostal neuralgia, lumbosacral radiculopathy, iliolingual neuralgia, pudendal neuralgia, femoral neuropathy, meralgia paresthetica, saphenous neuropathy, sciatic neuropatiiy, peroneal neuropathy, tibial neuropathy, lumbosacral plexopathy, traumatic neuroma stump pain or postamputation pain.Administration of Compounds, Pharmaceutically Acceptable Salts, and Compositions

[0179] In certain embodiments of the invention, an “effective amount” of a compound of the invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof is that amount effective for treating or lessening the severity of one or more of the conditions recited above.

[0180] The compounds, salts, and compositions, according to the method of the invention, may be administered using any amount and any route of administration effective for treating or lessening the severity of one or more of the pain or non-pain diseases recited herein. The exact amount required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the condition, the particular agent, its mode of administration, and the like. The compounds, salts, and compositions of the invention are preferably formulated in dosage unit form for ease of administration and uniformity of dosage. The expression “dosage unit form” as used herein refers to a physically discrete unit of agent appropriate for the subject to be treated. It will be understood, however, that the total daily usage of the compounds, salts, and compositions of the invention will be decided by the attending physician within the scope of sound medical judgment. The specific effective dose level for any particular subject or organism will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the specific compound or salt employed; the specific composition employed; the age, body weight, general health, sex and diet of the subject; the time of administration, route of administration, and rate of excretion of the specific compound or salt employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound or salt employed, and like factors well known in the medical arts. The term “subject” or “patient,” as used herein, means an animal, preferably a mammal, and most preferably a human.

[0181] The pharmaceutically acceptable compositions of this invention can be administered to humans and other animals orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, or drops), bucally, as an oral or nasal spray, or the like, depending on the severity of the condition being treated. In certain embodiments, the compound, salts, and compositions of the invention may be administered orally or parenterally at dosage levels of about 0.001 mg / kg to about 1000 mg / kg, one or more times a day, effective to obtain the desired therapeutic effect.

[0182] Liquid dosage forms for oral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active compound or salt, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfurylalcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.

[0183] Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution, suspension or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer’s solution, U.S.P. and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil can be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid are used in the preparation of injectables.

[0184] The injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions that can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.

[0185] In order to prolong the effect of the compounds of the invention, it is often desirable to slow the absorption of the compounds from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the compound then depends upon its rate of dissolution that, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered compound form is accomplished by dissolving or suspending the compound in an oil vehicle. Injectable depot forms are made by forming microencapsule matrices of the compound in biodegradable polymers such as polylactide-polyglycolide. Depending upon the ratio of compound to polymer and the nature of the particular polymer employed, the rate of compound release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the compound in liposomes or microemulsions that are compatible with body tissues.

[0186] Compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compound or salt of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.

[0187] Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound or salt is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and / or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binderssuch as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and glycerol monostearate, h) absorbents such as kaolin and bentonite clay, and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also comprise buffering agents.

[0188] Solid compositions of a similar type may also be employed as fillers in soft and hard- filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.

[0189] The active compound or salt can also be in microencapsulated form with one or more excipients as noted above. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings, release-controlling coatings and other coatings well known in the pharmaceutical formulating art. In such solid dosage forms, the active compound or salt may be admixed with at least one inert diluent such as sucrose, lactose or starch. Such dosage forms may also comprise, as is normal practice, additional substances other than inert diluents, e.g., tableting lubricants and other tableting aids such a magnesium stearate and microcrystalline cellulose. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes.

[0190] Dosage forms for topical or transdermal administration of a compound or salt of this invention include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches. The active component is admixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives or buffers as may be required. Ophthalmic formulation, eardrops, and eye drops are also contemplated as being within the scope of this invention. Additionally, the invention contemplates the use of transdermal patches, which have the added advantage of providing controlled delivery of a compound to the body. Such dosage forms areprepared by dissolving or dispensing the compound in the proper medium. Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate can be controlled by either providing a rate controlling membrane or by dispersing the compound in a polymer matrix or gel.

[0191] As described generally above, the compounds of the invention are useful as inhibitors of voltage-gated sodium channels. In one embodiment, the compounds are inhibitors of NaV1.8 and thus, without wishing to be bound by any particular theory, the compounds, salts, and compositions are particularly useful for treating or lessening the severity of a disease, condition, or disorder where activation or hyperactivity of NaV1.8 is implicated in the disease, condition, or disorder. When activation or hyperactivity of NaV1.8 is implicated in a particular disease, condition, or disorder, the disease, condition, or disorder may also be referred to as a “NaV1.8-mediated disease, condition or disorder.” Accordingly, in another aspect, the invention provides a method for treating or lessening the severity of a disease, condition, or disorder where activation or hyperactivity of NaV1.8 is implicated in the disease state.

[0192] The activity of a compound utilized in this invention as an inhibitor of NaV1.8 may be assayed according to methods described generally in International Publication No. WO 2014 / 120808 A9 and U.S. Publication No.2014 / 0213616 A1, both of which are incorporated by reference in their entirety, methods described herein, and other methods known and available to one of ordinary skill in the art. Additional Therapeutic Agents

[0193] It will also be appreciated that the compounds, salts, and pharmaceutically acceptable compositions of the invention can be employed in combination therapies, that is, the compounds, salts, and pharmaceutically acceptable compositions can be administered concurrently with, prior to, or subsequent to, one or more other desired therapeutics or medical procedures. The particular combination of therapies (therapeutics or procedures) to employ in a combination regimen will take into account compatibility of the desired therapeutics and / or procedures and the desired therapeutic effect to be achieved. It will also be appreciated that the therapies employed may achieve a desired effect for the same disorder (for example, an inventive compound may be administered concurrently with another agent used to treat the same disorder), or they may achieve different effects (e.g., control of any adverse effects). As used herein, additional therapeutic agents that are normally administered to treat or prevent a particular disease, or condition, are known as “appropriate for the disease, or condition, being treated.” For example, exemplary additional therapeutic agents include, but are not limited to: non-opioid analgesics (indoles such as Etodolac, Indomethacin, Sulindac, Tolmetin; naphthylalkanones such as Nabumetone; oxicams such as Piroxicam; para-aminophenol derivatives, such as Acetaminophen; propionic acids such as Fenoprofen, Flurbiprofen, Ibuprofen, Ketoprofen, Naproxen, Naproxen sodium, Oxaprozin; salicylates such as Aspirin, Choline magnesium trisalicylate, Diflunisal; fenamates such as meclofenamic acid, Mefenamic acid; and pyrazoles such asPhenylbutazone); or opioid (narcotic) agonists (such as Codeine, Fentanyl, Hydromorphone, Levorphanol, Meperidine, Methadone, Morphine, Oxycodone, Oxymorphone, Propoxyphene, Buprenorphine, Butorphanol, Dezocine, Nalbuphine, and Pentazocine). Additionally, nondrug analgesic approaches may be utilized in conjunction with administration of one or more compounds of the invention. For example, anesthesiologic (intraspinal infusion, neural blockade), neurosurgical (neurolysis of CNS pathways), neurostimulatory (transcutaneous electrical nerve stimulation, dorsal column stimulation), physiatric (physical therapy, orthotic devices, diathermy), or psychologic (cognitive methods-hypnosis, biofeedback, or behavioral methods) approaches may also be utilized. Additional appropriate therapeutic agents or approaches are described generally in The Merck Manual, Nineteenth Edition, Ed. Robert S. Porter and Justin L. Kaplan, Merck Sharp &Dohme Corp., a subsidiary of Merck & Co., Inc., 2011, and the Food and Drug Administration website, www.fda.gov, the entire contents of which are hereby incorporated by reference.

[0194] In another embodiment, additional appropriate therapeutic agents are selected from the following:

[0195] (1) an opioid analgesic, e.g. morphine, heroin, hydromorphone, oxymorphone, levorphanol, levallorphan, methadone, meperidine, fentanyl, cocaine, codeine, dihydrocodeine, oxycodone, hydrocodone, propoxyphene, nalmefene, nalorphine, naloxone, naltrexone, buprenorphine, butorphanol, nalbuphine, pentazocine, or difelikefalin;

[0196] (2) a nonsteroidal antiinflammatory drug (NSAID), e.g. aspirin, diclofenac, diflunisal, etodolac, fenbufen, fenoprofen, flufenisal, flurbiprofen, ibuprofen (including without limitation intravenous ibuprofen (e.g., Caldolor®)), indomethacin, ketoprofen, ketorolac (including without limitation ketorolac tromethamine (e.g., Toradol®)), meclofenamic acid, mefenamic acid, meloxicam, IV meloxicam (e.g., Anjeso®), nabumetone, naproxen, nimesulide, nitroflurbiprofen, olsalazine, oxaprozin, phenylbutazone, piroxicam, sulfasalazine, sulindac, tolmetin or zomepirac;

[0197] (3) a barbiturate sedative, e.g. amobarbital, aprobarbital, butabarbital, butalbital, mephobarbital, metharbital, methohexital, pentobarbital, phenobarbital, secobarbital, talbutal, thiamylal or thiopental;

[0198] (4) a benzodiazepine having a sedative action, e.g. chlordiazepoxide, clorazepate, diazepam, flurazepam, lorazepam, oxazepam, temazepam or triazolam;

[0199] (5) a histamine (H1) antagonist having a sedative action, e.g. diphenhydramine, pyrilamine, promethazine, chlorpheniramine or chlorcyclizine;

[0200] (6) a sedative such as glutethimide, meprobamate, methaqualone or dichloralphenazone;

[0201] (7) a skeletal muscle relaxant, e.g. baclofen, carisoprodol, chlorzoxazone, cyclobenzaprine, methocarbamol or orphenadrine;

[0202] (8) an NMDA receptor antagonist, e.g. dextromethorphan ((+)-3-hydroxy-N- methylmorphinan) or its metabolite dextrorphan ((+)-3-hydroxy-N-methylmorphinan), ketamine, memantine, pyrroloquinoline quinine, cis-4-(phosphonomethyl)-2- piperidinecarboxylic acid,budipine, EN-3231 (MorphiDex®), a combination formulation of morphine and dextromethorphan), topiramate, neramexane or perzinfotel including an NR2B antagonist, e.g. ifenprodil, traxoprodil or (- )-(R)-6-{2-[4-(3-fluorophenyl)-4-hydroxy-l- piperidinyl]-l-hydroxyethyl-3,4-dihydro-2(lH)- quinolinone;

[0203] (9) an alpha-adrenergic, e.g. doxazosin, tamsulosin, clonidine, guanfacine, dexmedetomidine, modafinil, or 4-amino-6,7-dimethoxy-2-(5-methane-sulfonamido-l, 2,3,4- tetrahydroisoquinolin-2-yl)-5-(2-pyridyl) quinazoline;

[0204] (10) a tricyclic antidepressant, e.g. desipramine, imipramine, amitriptyline or nortriptyline;

[0205] (11) an anticonvulsant, e.g. carbamazepine (Tegretol®), lamotrigine, topiramate, lacosamide (Vimpat®) or valproate;

[0206] (12) a tachykinin (NK) antagonist, particularly an NK-3, NK-2 or NK-1 antagonist, e.g. (alphaR,9R)-7-[3,5-bis(trifluoromethyl)benzyl]-8,9,10,11 -tetrahydro-9-methyl-5-(4- methylphenyl)- 7H-[l,4]diazocino[2,l-g][l,7]-naphthyridine-6-13-dione (TAK-637), 5- [[(2R,3S)-2-[(lR)-l-[3,5- bis(trifluoromethyl)phenyl]ethoxy-3-(4-fluorophenyl)-4-morpholinyl]-methyl]-l,2-dihydro-3H-l,2,4- triazol-3-one (MK-869), aprepitant, lanepitant, dapitant or 3-[[2-methoxy-5- (trifluoromethoxy)phenyl]-methylamino]-2-phenylpiperidine (2S,3S);

[0207] (13) a muscarinic antagonist, e.g oxybutynin, tolterodine, propiverine, tropsium chloride, darifenacin, solifenacin, temiverine and ipratropium;

[0208] (14) a COX-2 selective inhibitor, e.g. celecoxib, rofecoxib, parecoxib, valdecoxib, deracoxib, etoricoxib, or lumiracoxib;

[0209] (15) a coal-tar analgesic, in particular paracetamol;

[0210] (16) a neuroleptic such as droperidol, chlorpromazine, haloperidol, perphenazine, thioridazine, mesoridazine, trifluoperazine, fluphenazine, clozapine, olanzapine, risperidone, ziprasidone, quetiapine, sertindole, aripiprazole, sonepiprazole, blonanserin, iloperidone, perospirone, raclopride, zotepine, bifeprunox, asenapine, lurasidone, amisulpride, balaperidone, palindore, eplivanserin, osanetant, rimonabant, meclinertant, Miraxion® or sarizotan;

[0211] (17) a vanilloid receptor agonist (e.g. resinferatoxin or civamide) or antagonist (e.g. capsazepine, GRC-15300);

[0212] (18) a beta-adrenergic such as propranolol;

[0213] (19) a local anesthetic such as mexiletine;

[0214] (20) a corticosteroid such as dexamethasone;

[0215] (21) a 5-HT receptor agonist or antagonist, particularly a 5-HT1B / 1Dagonist such as eletriptan, sumatriptan, naratriptan, zolmitriptan or rizatriptan;

[0216] (22) a 5-HT2Areceptor antagonist such as R(+)-alpha-(2,3-dimethoxy-phenyl)-l-[2-(4- fluorophenylethyl)]-4-piperidinemethanol (MDL-100907);

[0217] (23) a cholinergic (nicotinic) analgesic, such as ispronicline (TC-1734), (E)-N-methyl-4- (3-pyridinyl)-3-buten-l-amine (RJR-2403), (R)-5-(2-azetidinylmethoxy)-2-chloropyridine (ABT-594) or nicotine;

[0218] (24) Tramadol®, Tramadol ER (Ultram ER®), IV Tramadol, Tapentadol ER (Nucynta®);

[0219] (25) a PDE5 inhibitor, such as 5-[2-ethoxy-5-(4-methyl-l-piperazinyl-sulphonyl)phenyl]- l-methyl-3-n-propyl-l,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (sildenafil), (6R,12aR)- 2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)-pyrazino[2',l':6,l]-pyrido[3,4- b]indole-l,4-dione (IC-351 or tadalafil), 2-[2-ethoxy-5-(4-ethyl-piperazin-l-yl-l-sulphonyl)-phenyl]-5- methyl-7-propyl-3H-imidazo[5,l-f][l,2,4]triazin-4-one (vardenafil), 5-(5-acetyl-2-butoxy-3-pyridinyl)- 3-ethyl-2-(l-ethyl-3-azetidinyl)-2,6-dihydro-7H- pyrazolo[4,3-d]pyrimidin-7-one, 5-(5-acetyl-2- propoxy-3-pyridinyl)-3-ethyl-2-(l-isopropyl-3-azetidinyl)-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin- 7-one, 5-[2-ethoxy-5-(4-ethylpiperazin-l-ylsulphonyl)pyridin-3-yl]-3-ethyl-2-[2-methoxyethyl]-2,6- dihydro-7H- pyrazolo[4,3-d]pyrimidin-7-one, 4-[(3-chloro-4-methoxybenzyl)amino]-2-[(2S)-2- (hydroxymethyl)pyrrolidin-l-yl]-N-(pyrimidin-2-ylmethyl)pyrimidine-5-carboxamide, 3-(l- methyl-7- oxo-3-propyl-6,7-dihydro-lH-pyrazolo[4,3-d]pyrimidin-5-yl)-N-[2-(l-methylpyrrolidin-2-yl)ethyl]-4- propoxybenzenesulfonamide;

[0220] (26) an alpha-2-delta ligand such as gabapentin (Neurontin®), gabapentin GR (Gralise®), gabapentin, enacarbil (Horizant®), pregabalin (Lyrica®), 3-methyl gabapentin, (l[alpha],3[alpha],5[alpha])(3-amino-methyl-bicyclo[3.2.0]hept-3-yl)-acetic acid, (3S,5R)-3- aminomethyl-5-methyl-heptanoic acid, (3S,5R)-3-amino-5-methyl-heptanoic acid, (3S,5R)-3-amino- 5-methyl-octanoic acid, (2S,4S)-4-(3-chlorophenoxy)proline, (2S,4S)-4-(3-fluorobenzyl)-proline, [(lR,5R,6S)-6-(aminomethyl)bicyclo[3.2.0]hept-6-yl]acetic acid, 3-(l-aminomethyl- cyclohexylmethyl)-4H-[1,2,4]oxadiazol-5-one, C-[1-(1H-tetrazol-5-ylmethyl)-cycloheptyl]- methylamine, (3S,4S)-(l-aminomethyl-3,4-dimethyl-cyclopentyl)-acetic acid, (3S,5R)-3- aminomethyl-5-methyl-octanoic acid, (3S,5R)-3-amino-5-methyl-nonanoic acid, (3S,5R)-3-amino-5- methyl-octanoic acid, (3R,4R,5R)-3-amino-4,5-dimethyl-heptanoic acid and (3R,4R,5R)-3-amino- 4,5-dimethyl-octanoic acid;

[0221] (27) a cannabinoid such as KHK-6188;

[0222] (28) metabotropic glutamate subtype 1 receptor (mGluRl) antagonist;

[0223] (29) a serotonin reuptake inhibitor such as sertraline, sertraline metabolite demethylsertraline, fluoxetine, norfluoxetine (fluoxetine desmethyl metabolite), fluvoxamine, paroxetine, citalopram, citalopram metabolite desmethylcitalopram, escitalopram, d,l-fenfluramine, femoxetine, ifoxetine, cyanodothiepin, litoxetine, dapoxetine, nefazodone, cericlamine and trazodone;

[0224] (30) a noradrenaline (norepinephrine) reuptake inhibitor, such as maprotiline, lofepramine, mirtazepine, oxaprotiline, fezolamine, tomoxetine, mianserin, bupropion, bupropion metabolite hydroxybupropion, nomifensine and viloxazine (Vivalan®), especially a selective noradrenaline reuptake inhibitor such as reboxetine, in particular (S,S)-reboxetine;

[0225] (31) a dual serotonin-noradrenaline reuptake inhibitor, such as venlafaxine, venlafaxine metabolite O-desmethylvenlafaxine, clomipramine, clomipramine metabolite desmethylclomipramine, duloxetine (Cymbalta®), milnacipran and imipramine;

[0226] (32) an inducible nitric oxide synthase (iNOS) inhibitor such as S-[2-[(l- iminoethyl)amino]ethyl]-L-homocysteine, S-[2-[(l-iminoethyl)-amino]ethyl]-4,4-dioxo-L-cysteine, S- [2-[(l-iminoethyl)amino]ethyl]-2-methyl-L-cysteine, (2S,5Z)-2-amino-2-methyl-7-[(l- iminoethyl)amino]-5-heptenoic acid, 2-[[(lR,3S)-3-amino-4-hydroxy-l-(5-thiazolyl)-butyl]thio]-S- chloro-S-pyridinecarbonitrile; 2-[[(lR,3S)-3-amino-4-hydroxy-l-(5- thiazolyl)butyl]thio]-4- chlorobenzonitrile, (2S,4R)-2-amino-4-[[2-chloro-5- (trifluoromethyl)phenyl]thio]-5-thiazolebutanol, 2-[[(lR,3S)-3-amino-4-hydroxy-l-(5-thiazolyl) butyl]thio]-6-(trifluoromethyl)-3-pyridinecarbonitrile, 2-[[(lR,3S)-3-amino-4-hydroxy-1-(5-thiazolyl)butyl]thio]-5-chlorobenzonitrile, N-[4-[2-(3- chlorobenzylamino)ethyl]phenyl]thiophene-2-carboxamidine, NXN-462, or guanidinoethyldisulfide;

[0227] (33) an acetylcholinesterase inhibitor such as donepezil;

[0228] (34) a prostaglandin E2 subtype 4 (EP4) antagonist such as N-[({2-[4-(2-ethyl-4,6- dimethyl-lH-imidazo[4,5-c]pyridin-l-yl)phenyl]ethyl}amino)-carbonyl]-4- methylbenzenesulfonamide or 4-[(15)-l-({[5-chloro-2-(3-fluorophenoxy)pyridin-3- yl]carbonyl}amino)ethyl]benzoic acid;

[0229] (35) a leukotriene B4 antagonist; such as l-(3-biphenyl-4-ylmethyl-4-hydroxy-chroman-7- yl)-cyclopentanecarboxylic acid (CP- 105696), 5-[2-(2-Carboxyethyl)-3-[6-(4-methoxyphenyl)-5E- hexenyl]oxyphenoxy]-valeric acid (ONO-4057) or DPC-11870;

[0230] (36) a 5-lipoxygenase inhibitor, such as zileuton, 6-[(3-fluoro-5-[4-methoxy-3,4,5,6- tetrahydro-2H-pyran-4-yl])phenoxy-methyl]-l-methyl-2-quinolone (ZD-2138), or 2,3,5- trimethyl-6- (3-pyridylmethyl)-l,4-benzoquinone (CV-6504);

[0231] (37) a sodium channel blocker, such as lidocaine, lidocaine plus tetracaine cream (ZRS- 201) or eslicarbazepine acetate;

[0232] (38) a NaV1.7 blocker, such as XEN-402, XEN403, TV-45070, PF-05089771, CNV1014802, GDC-0276, RG7893 BIIB-074 (Vixotrigine), BIIB-095, ASP-1807, DSP-3905, OLP- 1002, RQ-00432979, FX-301, DWP-1706, DWP-17061, IMB-110, IMB-111, IMB-112 and such as those disclosed in WO2011 / 140425 (US2011 / 306607); WO2012 / 106499 (US2012196869); WO2012 / 112743 (US2012245136); WO2012 / 125613 (US2012264749), WO2012 / 116440 (US2014187533), WO2011026240 (US2012220605), US8883840, US8466188, WO2013 / 109521 (US2015005304), CN111217776, WO2020 / 117626, WO2021 / 252822, WO2021 / 252818, WO2021 / 252820, WO2014 / 201173, WO2012 / 125973, WO2013 / 086229, WO2013 / 134518, WO2014 / 201206, or WO2016 / 141035 the entire contents of each application hereby incorporated by reference;

[0233] (38a) a NaV1.7 blocker such as (2-benzylspiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4'- piperidine]-1'-yl)-(4-isopropoxy-3-methyl-phenyl)methanone, 2,2,2-trifluoro-1-[1'-[3-methoxy-4-[2- (trifluoromethoxy)ethoxy]benzoyl]-2,4-dimethyl-spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4'-piperidine]-6-yl]ethanone, [8-fluoro-2-methyl-6-(trifluoromethyl)spiro[3,4-dihydropyrrolo[1,2- a]pyrazine-1,4'-piperidine]-1'-yl]-(4-isobutoxy-3-methoxy-phenyl)methanone, 1-(4- benzhydrylpiperazin-1-yl)-3-[2-(3,4-dimethylphenoxy)ethoxy]propan-2-ol, (4-butoxy-3-methoxy- phenyl)-[2-methyl-6-(trifluoromethyl)spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4'-piperidine]-1'- yl]methanone, [8-fluoro-2-methyl-6-(trifluoromethyl)spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4'- piperidine]-1'-yl]-(5-isopropoxy-6-methyl-2-pyridyl)methanone, (4-isopropoxy-3-methyl-phenyl)-[2- methyl-6-(1,1,2,2,2-pentafluoroethyl)spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4'-piperidine]-1'- yl]methanone, 5-[2-methyl-4-[2-methyl-6-(2,2,2-trifluoroacetyl)spiro[3,4-dihydropyrrolo[1,2- a]pyrazine-1,4'-piperidine]-1'-carbonyl]phenyl]pyridine-2-carbonitrile, (4-isopropoxy-3-methyl- phenyl)-[6-(trifluoromethyl)spiro[3,4-dihydro-2H-pyrrolo[1,2-a]pyrazine-1,4'-piperidine]-1'- yl]methanone, 2,2,2-trifluoro-1-[1'-[3-methoxy-4-[2-(trifluoromethoxy)ethoxy]benzoyl]-2-methyl- spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4'-piperidine]-6-yl]ethanone, 2,2,2-trifluoro-1-[1'-(5- isopropoxy-6-methyl-pyridine-2-carbonyl)-3,3-dimethyl-spiro[2,4-dihydropyrrolo[1,2-a]pyrazine- 1,4'-piperidine]-6-yl]ethanone, 2,2,2-trifluoro-1-[1'-(5-isopentyloxypyridine-2-carbonyl)-2-methyl- spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4'-piperidine]-6-yl]ethanone, (4-isopropoxy-3-methoxy- phenyl)-[2-methyl-6-(trifluoromethyl)spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4'-piperidine]-1'- yl]methanone, 2,2,2-trifluoro-1-[1'-(5-isopentyloxypyridine-2-carbonyl)-2,4-dimethyl-spiro[3,4- dihydropyrrolo[1,2-a]pyrazine-1,4'-piperidine]-6-yl]ethanone, 1-[(3S)-2,3-dimethyl-1'-[4-(3,3,3- trifluoropropoxymethyl)benzoyl]spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4'-piperidine]-6-yl]-2,2,2- trifluoro-ethanone, [8-fluoro-2-methyl-6-(trifluoromethyl)spiro[3,4-dihydropyrrolo[1,2-a]pyrazine- 1,4'-piperidine]-1'-yl]-[3-methoxy-4-[(1R)-1-methylpropoxy]phenyl]methanone, 2,2,2-trifluoro-1-[1'- (5-isopropoxy-6-methyl-pyridine-2-carbonyl)-2,4-dimethyl-spiro[3,4-dihydropyrrolo[1,2-a]pyrazine- 1,4'-piperidine]-6-yl]ethanone, 1-[1'-[4-methoxy-3-(trifluoromethyl)benzoyl]-2-methyl-spiro[3,4- dihydropyrrolo[1,2-a]pyrazine-1,4'-piperidine]-6-yl]-2,2-dimethyl-propan-1-one, (4-isopropoxy-3- methyl-phenyl)-[2-methyl-6-(trifluoromethyl)spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4'- piperidine]-1'-yl]methanone, [2-methyl-6-(1-methylcyclopropanecarbonyl)spiro[3,4- dihydropyrrolo[1,2-a]pyrazine-1,4'-piperidine]-1'-yl]-[4-(3,3,3- trifluoropropoxymethyl)phenyl]methanone, 4-bromo-N-(4-bromophenyl)-3-[(1-methyl-2-oxo-4- piperidyl)sulfamoyl]benzamide or (3-chloro-4-isopropoxy-phenyl)-[2-methyl-6-(1,1,2,2,2- pentafluoroethyl)spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4'-piperidine]-1'-yl]methanone.

[0234] (39) a NaV1.8 blocker, such as PF-04531083, PF-06372865 and such as those disclosed in WO2008 / 135826 (US2009048306), WO2006 / 011050 (US2008312235), WO2013 / 061205 (US2014296313), US20130303535, WO2013131018, US8466188, WO2013114250 (US2013274243), WO2014 / 120808 (US2014213616), WO2014 / 120815 (US2014228371) WO2014 / 120820 (US2014221435), WO2015 / 010065 (US20160152561), WO2015 / 089361 (US20150166589), WO2019 / 014352 (US20190016671), WO2018 / 213426, WO2020 / 146682, WO2020 / 146612, WO2020 / 014243, WO2020 / 014246, WO2020 / 092187, WO2020 / 092667(US2020140411), WO2020 / 144375, WO2020 / 261114, WO2020 / 140959, WO2020 / 151728, WO2021 / 032074, WO2021 / 047622 (CN112479996), WO2021 / 257490, WO2021 / 257420, WO2021 / 257418, WO2022 / 263498, WO2022 / 235558, WO2022 / 235859, WO2023 / 138599, WO2024 / 041613, WO2024 / 046253, WO2024 / 046409, CN112390745, CN111808019, CN112225695, CN112457294, CN112300051, CN112300069, CN112441969, and CN114591293, the entire contents of each application hereby incorporated by reference;

[0235] (39a) a NaV1.8 blocker such as 4,5-dichloro-2-(4-fluoro-2-methoxyphenoxy)-N-(2-oxo- 1,2-dihydropyridin-4-yl)benzamide, 2-(4-fluoro-2-methoxyphenoxy)-N-(2-oxo-1,2-dihydropyridin-4- yl)-4-(perfluoroethyl)benzamide, 4,5-dichloro-2-(4-fluorophenoxy)-N-(2-oxo-1,2-dihydropyridin-4- yl)benzamide, 4,5-dichloro-2-(3-fluoro-4-methoxyphenoxy)-N-(2-oxo-1,2-dihydropyridin-4- yl)benzamide, 2-(4-fluoro-2-methoxyphenoxy)-N-(2-oxo-1,2-dihydropyridin-4-yl)-5- (trifluoromethyl)benzamide, N-(2-oxo-1,2-dihydropyridin-4-yl)-2-(4-(trifluoromethoxy)phenoxy)-4- (trifluoromethyl)benzamide, 2-(4-fluorophenoxy)-N-(2-oxo-1,2-dihydropyridin-4-yl)-4- (perfluoroethyl)benzamide, 5-chloro-2-(4-fluoro-2-methoxyphenoxy)-N-(2-oxo-1,2-dihydropyridin-4- yl)benzamide, N-(2-oxo-1,2-dihydropyridin-4-yl)-2-(4-(trifluoromethoxy)phenoxy)-5- (trifluoromethyl)benzamide, 2-(4-fluoro-2-methylphenoxy)-N-(2-oxo-1,2-dihydropyridin-4-yl)-5- (trifluoromethyl)benzamide, 2-(2-chloro-4-fluorophenoxy)-N-(2-oxo-1,2-dihydropyridin-4-yl)-5- (trifluoromethyl)benzamide, 5-chloro-2-(4-fluoro-2-methylphenoxy)-N-(2-oxo-1,2-dihydropyridin-4- yl)benzamide, 4-chloro-2-(4-fluoro-2-methylphenoxy)-N-(2-oxo-1,2-dihydropyridin-4-yl)benzamide, 5-chloro-2-(2-chloro-4-fluorophenoxy)-N-(2-oxo-1,2-dihydropyridin-4-yl)benzamide, 2-((5-fluoro-2- hydroxybenzyl)oxy)-N-(2-oxo-1,2-dihydropyridin-4-yl)-4-(trifluoromethyl)benzamide, N-(2-oxo-1,2- dihydropyridin-4-yl)-2-(o-tolyloxy)-5-(trifluoromethyl)benzamide, 2-(2,4-difluorophenoxy)-N-(2- oxo-1,2-dihydropyridin-4-yl)-4-(trifluoromethyl)benzamide, N-(2-oxo-1,2-dihydropyridin-4-yl)-2-(2- (trifluoromethoxy)phenoxy)-5-(trifluoromethyl)benzamide, 2-(4-fluorophenoxy)-N-(2-oxo-1,2- dihydropyridin-4-yl)-5-(trifluoromethyl)benzamide, 2-(4-fluoro-2-methyl-phenoxy)-N-(2-oxo-1H- pyridin-4-yl)-4-(trifluoromethyl)benzamide, [4-[[2-(4-fluoro-2-methyl-phenoxy)-4- (trifluoromethyl)benzoyl]amino]-2-oxo-1-pyridyl]methyl dihydrogen phosphate, 2-(4-fluoro-2- (methyl-d3)phenoxy)-N-(2-oxo-1,2-dihydropyridin-4-yl)-4-(trifluoromethyl)benzamide, (4-(2-(4- fluoro-2-(methyl-d3)phenoxy)-4-(trifluoromethyl)benzamido)-2-oxopyridin-1(2H)-yl)methyl dihydrogen phosphate, 3-(4-fluoro-2-methoxyphenoxy)-N-(3-(methylsulfonyl)phenyl)quinoxaline-2- carboxamide, 3-(2-chloro-4-fluorophenoxy)-N-(3-sulfamoylphenyl)quinoxaline-2-carboxamide, 3-(2- chloro-4-methoxyphenoxy)-N-(3-sulfamoylphenyl)quinoxaline-2-carboxamide, 3-(4-chloro-2- methoxyphenoxy)-N-(3-sulfamoylphenyl)quinoxaline-2-carboxamide, 4-(3-(4- (trifluoromethoxy)phenoxy)quinoxaline-2-carboxamido)picolinic acid, 2-(2,4-difluorophenoxy)-N-(3- sulfamoylphenyl)quinoline-3-carboxamide, 2-(4-fluoro-2-methoxyphenoxy)-N-(3- sulfamoylphenyl)quinoline-3-carboxamide, 3-(2,4-difluorophenoxy)-N-(3- sulfamoylphenyl)quinoxaline-2-carboxamide, N-(3-sulfamoylphenyl)-2-(4-(trifluoromethoxy)phenoxy)quinoline-3-carboxamide, N-(3-sulfamoylphenyl)-3-(4- (trifluoromethoxy)phenoxy)quinoxaline-2-carboxamide, 3-(4-chloro-2-methylphenoxy)-N-(3- sulfamoylphenyl)quinoxaline-2-carboxamide, 5-(3-(4-(trifluoromethoxy)phenoxy)quinoxaline-2- carboxamido)picolinic acid, 3-(4-fluoro-2-methoxyphenoxy)-N-(2-oxo-2,3-dihydro-1H- benzo[d]imidazol-5-yl)quinoxaline-2-carboxamide, 3-(4-fluoro-2-methoxyphenoxy)-N-(pyridin-4- yl)quinoxaline-2-carboxamide, 3-(4-fluorophenoxy)-N-(3-sulfamoylphenyl)quinoxaline-2- carboxamide, N-(3-cyanophenyl)-3-(4-fluoro-2-methoxyphenoxy)quinoxaline-2-carboxamide, N-(4- carbamoylphenyl)-3-(4-fluoro-2-methoxyphenoxy)quinoxaline-2-carboxamide, 4-(3-(4- (trifluoromethoxy)phenoxy)quinoxaline-2-carboxamido)benzoic acid, N-(4-cyanophenyl)-3-(4-fluoro- 2-methoxyphenoxy)quinoxaline-2-carboxamide, 5-(4,5-dichloro-2-(4-fluoro-2- methoxyphenoxy)benzamido)picolinic acid, 5-(2-(2,4-dimethoxyphenoxy)-4,6- bis(trifluoromethyl)benzamido)picolinic acid, 4-(4,5-dichloro-2-(4-fluoro-2- methoxyphenoxy)benzamido)benzoic acid, 5-(2-(4-fluoro-2-methoxyphenoxy)-4,6- bis(trifluoromethyl)benzamido)picolinic acid, 4-(2-(4-fluoro-2-methoxyphenoxy)-4- (perfluoroethyl)benzamido)benzoic acid, 5-(2-(4-fluoro-2-methoxyphenoxy)-4- (perfluoroethyl)benzamido)picolinic acid, 4-(2-(4-fluoro-2-methylphenoxy)-4- (trifluoromethyl)benzamido)benzoic acid, 5-(4,5-dichloro-2-(4-fluoro-2- methoxyphenoxy)benzamido)picolinic acid, 4-(2-(2-chloro-4-fluorophenoxy)-4- (perfluoroethyl)benzamido)benzoic acid, 4-(2-(4-fluoro-2-methylphenoxy)-4- (perfluoroethyl)benzamido)benzoic acid, 4-(4,5-dichloro-2-(4- (trifluoromethoxy)phenoxy)benzamido)benzoic acid, 4-(4,5-dichloro-2-(4-chloro-2- methylphenoxy)benzamido)benzoic acid, 5-(4-(tert-butyl)-2-(4-fluoro-2- methoxyphenoxy)benzamido)picolinic acid, 5-(4,5-dichloro-2-(4- (trifluoromethoxy)phenoxy)benzamido)picolinic acid, 4-(4,5-dichloro-2-(4-fluoro-2- methylphenoxy)benzamido)benzoic acid, 5-(4,5-dichloro-2-(2,4- dimethoxyphenoxy)benzamido)picolinic acid, 5-(4,5-dichloro-2-(2-chloro-4- fluorophenoxy)benzamido)picolinic acid, 5-(4,5-dichloro-2-(4-fluoro-2- methylphenoxy)benzamido)picolinic acid, 4-(4,5-dichloro-2-(4-chloro-2- methoxyphenoxy)benzamido)benzoic acid, 5-(4,5-dichloro-2-(2,4- difluorophenoxy)benzamido)picolinic acid, 2-(4-fluorophenoxy)-N-(3-sulfamoylphenyl)-5- (trifluoromethyl)benzamide, 2-(4-fluorophenoxy)-N-(3-sulfamoylphenyl)-4- (trifluoromethyl)benzamide, 2-(2-chloro-4-fluorophenoxy)-N-(3-sulfamoylphenyl)-5- (trifluoromethyl)benzamide, 2-(4-fluorophenoxy)-N-(3-sulfamoylphenyl)-4- (trifluoromethyl)benzamide, 2-(2-chloro-4-fluorophenoxy)-N-(3-sulfamoylphenyl)-6- (trifluoromethyl)benzamide, 2-(2-chloro-4-fluorophenoxy)-5-(difluoromethyl)-N-(3- sulfamoylphenyl)benzamide, 2-(4-fluorophenoxy)-4-(perfluoroethyl)-N-(3- sulfamoylphenyl)benzamide, 2-(4-chloro-2-methoxyphenoxy)-4-(perfluoroethyl)-N-(3-sulfamoylphenyl)benzamide, 2-(4-fluoro-2-methoxyphenoxy)-N-(3-sulfamoylphenyl)-5- (trifluoromethyl)benzamide, 5-chloro-2-(4-fluoro-2-methylphenoxy)-N-(3- sulfamoylphenyl)benzamide, 4,5-dichloro-2-(4-fluoro-2-methoxyphenoxy)-N-(3- sulfamoylphenyl)benzamide, 2,4-dichloro-6-(4-chloro-2-methoxyphenoxy)-N-(3- sulfamoylphenyl)benzamide, 2,4-dichloro-6-(4-fluoro-2-methylphenoxy)-N-(3- sulfamoylphenyl)benzamide, 2-(4-fluoro-2-methoxyphenoxy)-N-(3-sulfamoylphenyl)-4,6- bis(trifluoromethyl)benzamide, 2-(4-fluoro-2-methylphenoxy)-N-(3-sulfamoylphenyl)-4,6- bis(trifluoromethyl)benzamide, 5-chloro-2-(2-chloro-4-fluorophenoxy)-N-(3- sulfamoylphenyl)benzamide, 2-(4-fluoro-2-methoxyphenoxy)-N-(3-sulfamoylphenyl)-4- (trifluoromethoxy)benzamide, 2-(4-fluoro-2-methoxyphenoxy)-N-(3-sulfamoylphenyl)-4- (trifluoromethyl)benzamide, 4,5-dichloro-2-(4-fluorophenoxy)-N-(3-sulfamoylphenyl)benzamide, 2- (4-fluoro-2-methoxyphenoxy)-4-(perfluoroethyl)-N-(3-sulfamoylphenyl)benzamide, 5-fluoro-2-(4- fluoro-2-methylphenoxy)-N-(3-sulfamoylphenyl)benzamide, 2-(2-chloro-4-fluorophenoxy)-4-cyano- N-(3-sulfamoylphenyl)benzamide, N-(3-sulfamoylphenyl)-2-(4-(trifluoromethoxy)phenoxy)-4- (trifluoromethyl)benzamide, N-(3-carbamoyl-4-fluoro-phenyl)-2-fluoro-6-[2-(trideuteriomethoxy)-4- (trifluoromethoxy)phenoxy]-3-(trifluoromethyl)benzamide, N-(3-carbamoyl-4-fluoro-phenyl)-2- fluoro-6-[2-methoxy-4-(trifluoromethoxy)phenoxy]-3-(trifluoromethyl)benzamide, N-(3-carbamoyl- 4-fluoro-phenyl)-2-fluoro-6-[2-(trideuteriomethoxy)-4-(trifluoromethoxy)phenoxy]-3- (trifluoromethoxy)benzamide, 4-[[2-fluoro-6-[2-methoxy-4-(trifluoromethoxy)phenoxy]-3- (trifluoromethyl)benzoyl]amino]pyridine-2-carboxamide, 4-[[3-chloro-2-fluoro-6-[2-methoxy-4- (trifluoromethoxy)phenoxy]benzoyl]amino]pyridine-2-carboxamide, 4-[[2-fluoro-6-[2- (trideuteriomethoxy)-4-(trifluoromethoxy)phenoxy]-3-(trifluoromethyl)benzoyl]amino]pyridine-2- carboxamide, N-(3-carbamoyl-4-fluoro-phenyl)-3-(difluoromethyl)-2-fluoro-6-[2-methoxy-4- (trifluoromethoxy)phenoxy]benzamide, 4-[[2-fluoro-6-[2-(trideuteriomethoxy)-4- (trifluoromethoxy)phenoxy]-3-(trifluoromethoxy)benzoyl]amino]pyridine-2-carboxamide, N-(3- carbamoyl-4-fluoro-phenyl)-6-[2-chloro-4-(trifluoromethoxy)phenoxy]-2-fluoro-3- (trifluoromethyl)benzamide, N-(3-carbamoyl-4-fluoro-phenyl)-2-fluoro-6-[2-methyl-4- (trifluoromethoxy)phenoxy]-3-(trifluoromethyl)benzamide, N-(3-carbamoyl-4-fluoro-phenyl)-2,3,4- trifluoro-6-[2-methoxy-4-(trifluoromethoxy)phenoxy]benzamide, N-(2-carbamoyl-4-pyridyl)-3- fluoro-5-[2-methoxy-4-(trifluoromethoxy)phenoxy]-2-(trifluoromethyl)pyridine-4-carboxamide, 4- [[6-[2-(difluoromethoxy)-4-(trifluoromethoxy)phenoxy]-2-fluoro-3- (trifluoromethyl)benzoyl]amino]pyridine-2-carboxamide, N-(3-carbamoyl-4-fluoro-phenyl)-6-[3- chloro-4-(trifluoromethoxy)phenoxy]-2-fluoro-3-(trifluoromethyl)benzamide, N-(3-carbamoyl-4- fluoro-phenyl)-2-fluoro-6-[4-(trifluoromethoxy)phenoxy]-3-(trifluoromethyl)benzamide, N-(4- carbamoyl-3-fluoro-phenyl)-2-fluoro-6-[2-methoxy-4-(trifluoromethoxy)phenoxy]-3- (trifluoromethyl)benzamide, 4-[[2-fluoro-6-[2-(trideuteriomethoxy)-4-(trifluoromethoxy)phenoxy]-4- (trifluoromethyl)benzoyl]amino]pyridine-2-carboxamide, N-(3-carbamoyl-4-fluoro-phenyl)-2-fluoro-6-[3-fluoro-4-(trifluoromethoxy)phenoxy]-3-(trifluoromethyl)benzamide, N-(3-carbamoyl-4-fluoro- phenyl)-2-[2-methoxy-4-(trifluoromethoxy)phenoxy]-5-(1,1,2,2,2-pentafluoroethyl)benzamide, 4-[[4- (difluoromethoxy)-2-fluoro-6-[2-methoxy-4-(trifluoromethoxy)phenoxy]benzoyl]amino]pyridine-2- carboxamide, N-(3-carbamoyl-4-fluoro-phenyl)-2-fluoro-6-[2-fluoro-4-(trifluoromethoxy)phenoxy]- 3-(trifluoromethyl)benzamide, 4-[[4-cyclopropyl-2-fluoro-6-[2-methoxy-4- (trifluoromethoxy)phenoxy]benzoyl]amino]pyridine-2-carboxamide, N-(3-carbamoyl-4-fluoro- phenyl)-5-fluoro-2-[2-methoxy-4-(trifluoromethoxy)phenoxy]-4-(trifluoromethyl)benzamide, 5-[[2- fluoro-6-[2-(trideuteriomethoxy)-4-(trifluoromethoxy)phenoxy]-3- (trifluoromethyl)benzoyl]amino]pyridine-2-carboxamide, N-(3-carbamoyl-4-fluoro-phenyl)-2-fluoro- 6-(4-fluorophenoxy)-3-(trifluoromethyl)benzamide, or 4-[[2-fluoro-6-[3-fluoro-2-methoxy-4- (trifluoromethoxy)phenoxy]-3-(trifluoromethyl)benzoyl]amino]pyridine-2-carboxamide;

[0236] (40) a combined NaV1.7 and NaV1.8 blocker, such as DSP-2230, Lohocla201 or BL-1021;

[0237] (41) a 5-HT3 antagonist, such as ondansetron;

[0238] (42) a TPRV 1 receptor agonist, such as capsaicin (NeurogesX®, Qutenza®); and the pharmaceutically acceptable salts and solvates thereof;

[0239] (43) a nicotinic receptor antagonist, such as varenicline;

[0240] (44) an N-type calcium channel antagonist, such as Z-160;

[0241] (45) a nerve growth factor antagonist, such as tanezumab;

[0242] (46) an endopeptidase stimulant, such as senrebotase;

[0243] (47) an angiotensin II antagonist, such as EMA-401;

[0244] (48) acetaminophen (including without limitation intravenous acetaminophen (e.g., Ofirmev®));

[0245] (49) bupivacaine (including without limitation bupivacaine liposome injectable suspension (e.g., Exparel®) bupivacaine ER (Posimir), bupivacaine collagen (Xaracoll) and transdermal bupivacaine (Eladur®)); and

[0246] (50) bupivacaine and meloxicam combination (e.g., HTX-011).

[0247] In one embodiment, the additional appropriate therapeutic agents are selected from V- 116517, Pregabalin, controlled release Pregabalin, Ezogabine (Potiga®). Ketamine / amitriptyline topical cream (Amiket®), AVP-923, Perampanel (E-2007), Ralfinamide, transdermal bupivacaine (Eladur®), CNV1014802, JNJ-10234094 (Carisbamate), BMS-954561 or ARC-4558.

[0248] In another embodiment, the additional appropriate therapeutic agents are selected from N- (6-amino-5-(2,3,5-trichlorophenyl)pyridin-2-yl)acetamide; N-(6-amino-5-(2-chloro-5- methoxyphenyl)pyridin-2-yl)-1-methyl-1H-pyrazole-5-carboxamide; or 3-((4-(4- (trifluoromethoxy)phenyl)-1H-imidazol-2-yl)methyl)oxetan-3-amine.

[0249] In another embodiment, the additional therapeutic agent is selected from a GlyT2 / 5HT2 inhibitor, such as Operanserin (VVZ149), a TRPV modulator such as CA008, CMX-020, NEO6860, FTABS, CNTX4975, MCP101, MDR16523, or MDR652, a EGR1 inhibitor such as Brivoglide(AYX1), an NGF inhibitor such as Tanezumab, Fasinumab, ASP6294, MEDI7352, a Mu opioid agonist such as Cebranopadol, NKTR181 (oxycodegol), a CB-1 agonist such as NEO1940 (AZN1940), an imidazoline 12 agonist such as CR4056 or a p75NTR-Fc modulator such as LEVI-04.

[0250] In another embodiment, the additional therapeutic agent is oliceridine or ropivacaine (TLC590).

[0251] In another embodiment, the additional therapeutic agent is a NaV1.7 blocker such as ST- 2427, ST-2578 and those disclosed in WO2010 / 129864, WO2015 / 157559, WO2017 / 059385, WO2018 / 183781, WO2018 / 183782, WO2020 / 072835, and / or WO2022 / 036297 the entire contents of each application hereby incorporated by reference.

[0252] In another embodiment, the additional therapeutic agent is selected from ASP18071, CC- 8464, ANP-230, ANP-231, NOC-100, NTX-1175, ASN008, NW3509, AM-6120, AM-8145, AM- 0422, BL-017881, NTM-006, Opiranserin (UnafraTM), brivoligide, SR419, NRD.E1, LX9211, LY3016859, ISC-17536, NFX-88, LAT-8881, AP-235, NYX 2925, CNTX-6016, S-600918, S- 637880, RQ-00434739, KLS-2031, MEDI 7352, and XT-150.

[0253] In another embodiment, the additional therapeutic agent is selected from Olinvyk, Zynrelef, Seglentis, Neumentum, Nevakar, HTX-034, CPL-01, ACP-044, HRS-4800, Tarlige, BAY2395840, LY3526318, Eliapixant, TRV045, RTA901, NRD1355-E1, MT-8554, LY3556050, AP-325, tetrodotoxin, Otenaproxesul, CFTX-1554, Funapide, iN1011-N17, JMKX000623 / ODM- 111, ETX-801, OLP-1002, ANP-230 / DSP-2230, iN1011-N17, DSP-3905 and ACD440.

[0254] In another embodiment, the additional therapeutic agent is selected from HRS4800, ODM-111 / JMKX000623, LX9211, LY3556050, LY3857210, CFTX01554 / CFTX-1554, MEDI7352, MEDI0618, BAY3178275, BAY2395840, GSK3858279, STC-004, HALNEURON, OLP-1002, ATX01, ANP230, CC-8464, iN1011-N17, ST-2427, MSD199, FZ008, VYNAV-01, BL-017881, Profervia (Cilnidipine), LS-04, vixotrigine, FX301 / PCRX-301, PF-04531083, PF-01247324, and DSP-3905.

[0255] In another embodiment, the additional therapeutic agent is a sodium channel inhibitor (also known as a sodium channel blocker), such as the NaV1.7 and NaV1.8 blockers identified above.

[0256] The amount of additional therapeutic agent present in the compositions of this invention may be no more than the amount that would normally be administered in a composition comprising that therapeutic agent as the only active agent. The amount of additional therapeutic agent in the presently disclosed compositions may range from about 10% to 100% of the amount normally present in a composition comprising that agent as the only therapeutically active agent.

[0257] The compounds and salts of this invention or pharmaceutically acceptable compositions thereof may also be incorporated into compositions for coating an implantable medical device, such as prostheses, artificial valves, vascular grafts, stents and catheters. Accordingly, the invention, in another aspect, includes a composition for coating an implantable device comprising a compound or salt of the invention as described generally above, and in classes and subclasses herein, and a carriersuitable for coating said implantable device. In still another aspect, the invention includes an implantable device coated with a composition comprising a compound or salt of the invention as described generally above, and in classes and subclasses herein, and a carrier suitable for coating said implantable device. Suitable coatings and the general preparation of coated implantable devices are described in US Patents 6,099,562; 5,886,026; and 5,304,121. The coatings are typically biocompatible polymeric materials such as a hydrogel polymer, polymethyldisiloxane, polycaprolactone, polyethylene glycol, polylactic acid, ethylene vinyl acetate, and mixtures thereof. The coatings may optionally be further covered by a suitable topcoat of fluorosilicone, polysaccharides, polyethylene glycol, phospholipids or combinations thereof to impart controlled release characteristics in the composition.

[0258] Another aspect of the invention relates to inhibiting NaV1.8 activity in a biological sample or a subject, which method comprises administering to the subject, or contacting said biological sample with a compound of the invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof. The term “biological sample,” as used herein, includes, without limitation, cell cultures or extracts thereof; biopsied material obtained from a mammal or extracts thereof; and blood, saliva, urine, feces, semen, tears, or other body fluids or extracts thereof.

[0259] Inhibition of NaV1.8 activity in a biological sample is useful for a variety of purposes that are known to one of skill in the art. Examples of such purposes include, but are not limited to, the study of sodium channels in biological and pathological phenomena; and the comparative evaluation of new sodium channel inhibitors. Synthesis of the Compounds of the Invention

[0260] The compounds of the invention can be prepared from known materials by the methods described in the Examples, other similar methods, and other methods known to one skilled in the art. As one skilled in the art would appreciate, the functional groups of the intermediate compounds in the methods described below may need to be protected by suitable protecting groups. Protecting groups may be added or removed in accordance with standard techniques, which are well-known to those skilled in the art. The use of protecting groups is described in detail in T.G.M. Wuts et al., Greene’s Protective Groups in Organic Synthesis (4th ed.2006). Radiolabeled Analogs of the Compounds of the Invention

[0261] In another aspect, the invention relates to radiolabeled analogs of the compounds of the invention. As used herein, the term “radiolabeled analogs of the compounds of the invention” refers to compounds that are identical to the compounds of the invention, as described herein, including all embodiments thereof, except that one or more atoms has been replaced with a radioisotope of the atom present in the compounds of the invention.

[0262] As used herein, the term “radioisotope” refers to an isotope of an element that is known to undergo spontaneous radioactive decay. Examples of radioisotopes include3H,14C,32P,35S,18F,36Cl, and the like, as well as the isotopes for which a decay mode is identified in V.S. Shirley & C.M. Lederer, Isotopes Project, Nuclear Science Division, Lawrence Berkeley Laboratory, Table of Nuclides (January 1980).

[0263] The radiolabeled analogs can be used in a number of beneficial ways, including in various types of assays, such as substrate tissue distribution assays. For example, tritium (3H)- and / or carbon- 14 (14C)-labeled compounds may be useful for various types of assays, such as substrate tissue distribution assays, due to relatively simple preparation and excellent detectability.

[0264] In another aspect, the invention relates to pharmaceutically acceptable salts of the radiolabeled analogs, in accordance with any of the embodiments described herein in connection with the compounds of the invention.

[0265] In another aspect, the invention relates to pharmaceutical compositions comprising the radiolabeled analogs, or pharmaceutically acceptable salts thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle, in accordance with any of the embodiments described herein in connection with the compounds of the invention.

[0266] In another aspect, the invention relates to methods of inhibiting voltage-gated sodium channels and methods of treating or lessening the severity of various diseases and disorders, including pain, in a subject comprising administering an effective amount of the radiolabeled analogs, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, in accordance with any of the embodiments described herein in connection with the compounds of the invention.

[0267] In another aspect, the invention relates to radiolabeled analogs, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, for use, in accordance with any of the embodiments described herein in connection with the compounds of the invention.

[0268] In another aspect, the invention relates to the use of the radiolabeled analogs, or pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, for the manufacture of medicaments, in accordance with any of the embodiments described herein in connection with the compounds of the invention.

[0269] In another aspect, the radiolabeled analogs, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, can be employed in combination therapies, in accordance with any of the embodiments described herein in connection with the compounds of the invention. ENUMERATED EMBODIMENTS

[0270] Further embodiments of the disclosure are set out in the following numbered clauses: 1. A compound of formula (I-A):; or a pharmaceutically acceptable salt thereof, wherein: X1is C-R1or N; X2is C-R2, N, or N+-O-; X3is C-R3, N, or N+-O-; X5is C-R5, N, or N+-O-; p, Xa, and Xbare defined as follows: (i) p is 1, Xais C-R11R12, and Xbis O; (ii) p is 1, Xais O, and Xbis C-R13R14; or (iii) p is 0 and Xbis O; Xsis C-Rsor N; Xtis C-Rtor N; R1is H, OH, halo, CN, C1-C6alkyl, C1-C6haloalkyl, C1-C6alkoxy, C1-C6haloalkoxy, –(CH2)mOn(CH2)oOCH3, –(CH2)mRa, –C(O)(CH2)mRa, –C(O)ORb, –C(O)Rb, –C(O)NRbRc, –NRbRc, –CRdReRf, –CRbRcNRgC(O)CRhRiRj, –NRbC(O)CRcRgRj, C3-C6cycloalkyl, 5-6 membered heteroaryl, or 4-10 membered heterocyclyl, wherein said C3-C6cycloalkyl, 5-6 membered heteroaryl, or 4-10 membered heterocyclyl may be unsubstituted or may be substituted with 1-4 substituents independently selected from halo, C1-C6alkyl, C1-C6haloalkyl, C1-C6alkoxy, and C1-C6haloalkoxy; R2, R3, R4, and R5are each independently H, OH, CN, halo, C1-C6alkyl, C1-C6alkoxy, C1-C6haloalkyl, –NHS(O)2(C1-C6alkyl), –C(O)ORb, –C(O)NRbRc, –(CH2)mO(CH2)oCH3, 5-6 membered heteroaryl, or 5-6 membered heterocyclyl, wherein said 5-6 membered heteroaryl or 5-6 membered heterocyclyl may be unsubstituted or may be substituted with 1-4 substituents independently selected from C1-C6alkyl and –C(O)NRbRc; R6, R7, R8, and R9are defined as follows: (i) R6and R7are each independently H, OH, C1-C6alkyl, C1-C6haloalkyl, C3-C6cycloalkyl, or C1-C6alkoxy; and R8and R9are each independently H, OH, C1-C6alkyl, C1-C6haloalkyl, C3-C6cycloalkyl, or C1-C6alkoxy; or(ii) R6and R7are each independently H, OH, C1-C6alkyl, C1-C6haloalkyl, C3-C6cycloalkyl, or C1-C6alkoxy; and R8and R9, together with the carbon atom to which they are attached, form a C3-C6cycloalkyl; or (iii) R6, R7, R8, and R9, together with the carbon atom to which they are attached, form a fused C6-C10aryl optionally substituted with 1-3 Ry; R10is H or CH3; R11and R12are each independently H, OH, C1-C6alkyl, C1-C6haloalkyl, C3-C6cycloalkyl, or C1-C6alkoxy; R13and R14are each independently H, OH, C1-C6alkyl, C1-C6haloalkyl, C3-C6cycloalkyl, or C1-C6alkoxy; Rsand Rtare each independently H, OH, halo, C1-C6alkyl, C1-C6alkoxy, C1-C6haloalkyl, C1-C6haloalkoxy, C3-C6cycloalkyl, –O-C3-C6cycloalkyl, –NRbRc, –NO2, –SO3H, –(CH2)mORb, or –O(CH2)mOCH3, or Rsand Rt, together with the carbon atoms to which they are attached, form a ring of formula:Y is O or CH2; Ru, Rv, and Rware each independently H, OH, halo, C1-C6alkyl, C1-C6alkoxy, C1-C6haloalkyl, C1-C6haloalkoxy, –NRbRc, –NO2, –SO3H, –(CH2)mORb, or –O(CH2)mOCH3; each Rxis independently H, halo, C1-C6alkyl, or C1-C6haloalkyl; each Ryis independently H, OH, C1-C6alkyl, C1-C6haloalkyl, C3-C6cycloalkyl, or C1-C6alkoxy; Rais OH, halo, C1-C6alkoxy, or –NRbRc; Rb, Rc, Rg, Rh, and Riare each independently H or C1-C6alkyl, or Rband Rc, together with the nitrogen atom to which they are attached, form a 3-6 membered heterocyclyl; Rd, Re, and Rfare each independently H, OH, halo, C1-C6alkyl, or C1-C6alkoxy; Rjis H, C1-C6alkyl, –NRbRc, or –N(CH3)3+; m and o are each independently 0, 1, 2, or 3; and n is 0 or 1. 2. The compound of clause 1, or a pharmaceutically acceptable salt thereof, wherein: Xais CH2; Xbis O;R6and R7are each independently H, OH, C1-C6alkyl, C1-C6haloalkyl, C3-C6cycloalkyl, or C1-C6alkoxy; R8and R9are each independently H, OH, C1-C6alkyl, C1-C6haloalkyl, C3-C6cycloalkyl, or C1-C6alkoxy; or R8and R9, together with the carbon atom to which they are attached, form a C3-C6cycloalkyl; Rsand Rtare each independently H, OH, halo, C1-C6alkyl, C1-C6alkoxy, C1-C6haloalkyl, C1-C6haloalkoxy, –NRbRc, –NO2, –SO3H, –(CH2)mORb, or –O(CH2)mOCH3, or Rsand Rt, together with the carbon atoms to which they are attached, form a ring of formula:p is 0 or 1. 3. The compound of clause 1 or 2, or a pharmaceutically acceptable salt thereof, wherein: R1is H, OH, halo, CN, C1-C6alkyl, C1-C6alkoxy, C1-C6haloalkoxy, or –C(O)ORb; R10is H; and Rsand Rtare each independently H, OH, halo, C1-C6alkyl, C1-C6alkoxy, C1-C6haloalkyl, C1-C6haloalkoxy, –NRbRc, –NO2, –SO3H, –(CH2)mORa, or –O(CH2)mOCH3, or Rsand Rt, together with the carbon atoms to which they are attached, form a ring of formula:4. The compound of any one of clauses 1 to 3, or a pharmaceutically acceptable salt thereof, wherein p is 0. 5. The compound of any one of clauses 1 to 3, or a pharmaceutically acceptable salt thereof, wherein p is 1. 6. The compound of any one of clauses 1 to 3, or a pharmaceutically acceptable salt thereof, wherein p is 1, Xais CR11R12, and Xbis O. 7. The compound of clause 6, or a pharmaceutically acceptable salt thereof, wherein R11is H. 8. The compound of clause 6 or 7, or a pharmaceutically acceptable salt thereof, wherein R12is H. 9. The compound of any one of clauses 1 to 3, or a pharmaceutically acceptable salt thereof, wherein p is 1, Xais O, and Xbis CR13R14.10. The compound of clause 9, or a pharmaceutically acceptable salt thereof, wherein R13is C1-C6alkyl or C1-C6haloalkyl. 11. The compound of clause 10, or a pharmaceutically acceptable salt thereof, wherein R13is – CH3or –CF3. 12. The compound of any one of clauses 9 to 11, or a pharmaceutically acceptable salt thereof, wherein R14is C1-C6alkyl or C1-C6haloalkyl. 13. The compound of clause 12, or a pharmaceutically acceptable salt thereof, wherein R14is – CH3or –CF3. 14. The compound of any one of clauses 1 to 5, or a pharmaceutically acceptable salt thereof, wherein the compound has a formula (I-A-1):. 15. The compound of any one of clauses 1 to 14, or a pharmaceutically acceptable salt thereof, wherein X1is N. 16. The compound of any one of clauses 1 to 15, or a pharmaceutically acceptable salt thereof, wherein X1is C-R1, and R1is H, CN, C1-C6alkyl, C1-C6alkoxy, or –C(O)ORb. 17. The compound of clause 16, or a pharmaceutically acceptable salt thereof, wherein R1is H, CN, –CH3, –OCH3, –C(O)OCH3, or –C(O)OCH2CH3. 18. The compound of any one of clauses 1 to 17, or a pharmaceutically acceptable salt thereof, wherein X2is N. 19. The compound of any one of clauses 1 to 17, or a pharmaceutically acceptable salt thereof, wherein X2is C-R2, and R2is H, OH, CN, halo, C1-C6alkyl, C1-C6alkoxy, –NHS(O)2(C1-C6alkyl), –C(O)ORb, –C(O)NRbRc, 5-6 membered heteroaryl, or 5-6 membered heterocyclyl, wherein said 5-6 membered heteroaryl or 5-6 membered heterocyclyl may be unsubstituted or may be substituted with 1-4 substituents independently selected from C1-C6alkyl and –C(O)NRbRc.20. The compound of clause 19, or a pharmaceutically acceptable salt thereof, wherein R2is H, Cl, F, OH, CN, –CH3, –OCH3, –C(O)OH, –C(O)NH2, –C(O)N(H)CH3, –N(H)S(O)2(CH3),. 21. The compound of any one of clause 1 to 20, or a pharmaceutically acceptable salt thereof, wherein X3is N. 22. The compound of any one of clauses 1 to 20, or a pharmaceutically acceptable salt thereof, wherein X3is C-R3, and R3is H, CN, halo, C1-C6alkoxy, –C(O)ORb, or –C(O)NRbRc. 23. The compound of clause 22, or a pharmaceutically acceptable salt thereof, wherein R3is H, Cl, F, CN, –OCH3, –C(O)OCH3or –C(O)N(CH3)2. 24. The compound of any one of clauses 1 to 23, or a pharmaceutically acceptable salt thereof, wherein R4is H, halo, C1-C6alkyl, –C(O)ORb, or –C(O)NRbRc. 25. The compound of clause 24, or a pharmaceutically acceptable salt thereof, wherein R4is H, Cl, F, –CH3, –C(O)OCH2CH3or –C(O)NH2. 26. The compound of any one of clause 1 to 25, or a pharmaceutically acceptable salt thereof, wherein X5is N. 27. The compound of any one of clauses 1 to 25, or a pharmaceutically acceptable salt thereof, wherein X5is CR5, and R5is H, halo, or –C(O)NRbRc. 28. The compound of clause 27, or a pharmaceutically acceptable salt thereof, wherein R5is H, F, or –C(O)NH2. 29. The compound of any one of clauses 1 to 28, or a pharmaceutically acceptable salt thereof, wherein R7is H, OH, C1-C6alkyl, C3-C6cycloalkyl, or C1-C6alkoxy. 30. The compound of clause 29, or a pharmaceutically acceptable salt thereof, wherein R7is H, OH, –OCH3, –CH3, or cyclopropyl.31. The compound of any one of clauses 1 to 30, or a pharmaceutically acceptable salt thereof, wherein R8and R9are each independently H, C1-C6alkyl, C1-C6haloalkyl, or C3-C6cycloalkyl, or R8and R9, together with the carbon atom to which they are attached, form a C3-C6cycloalkyl. 32. The compound of any one of clauses 1 to 31, or a pharmaceutically acceptable salt thereof, wherein R8is H or C1-C6alkyl. 33. The compound of clause 32, or a pharmaceutically acceptable salt thereof, wherein R8is H, –CH3, or –CH2CH3. 34. The compound of any one of clauses 1 to 33, or a pharmaceutically acceptable salt thereof, wherein R9is H, C1-C6alkyl, or C1-C6haloalkyl. 35. The compound of clause 34, or a pharmaceutically acceptable salt thereof, wherein R9is H, –CH3, or –CF3. 36. The compound of any of clauses 1 to 31, or a pharmaceutically acceptable salt thereof, wherein R8and R9, together with the carbon atom to which they are attached, form a C3-C6cycloalkyl. 37. The compound of clause 36, or a pharmaceutically acceptable salt thereof, wherein R8and R9, together with the carbon atom to which they are attached, form a cyclobutane. 38. The compound of any one of clauses 1 to 13 or 15 to 28, or a pharmaceutically acceptable salt thereof, wherein R6, R7, R8, and R9, together with the carbon atom to which they are attached, form a fused C6-C10 aryl optionally substituted with 1-3 Ry. 39. The compound of clause 38, or a pharmaceutically acceptable salt thereof, wherein R6, R7, R8, and R9, together with the carbon atom to which they are attached, form a fused phenyl. 40. The compound of any one of clauses 1 to 39, or a pharmaceutically acceptable salt thereof, wherein R10is H. 41. The compound of any one of clause 1 to 40, or a pharmaceutically acceptable salt thereof, wherein Xsis N. 42. The compound of any one of clauses 1 to 40, or a pharmaceutically acceptable salt thereof, wherein Xsis C-Rs, and Rsis H, OH, halo, C1-C6alkyl, C1-C6alkoxy, C3-C6cycloalkyl, –(CH2)mORb, or –O(CH2)mOCH3.43. The compound of clause 42, or a pharmaceutically acceptable salt thereof, wherein Xsis C-Rs, and Rsis H, F, Cl, OH, –CH3, –CH2OH, –CH2OCH3, –OCH3, cyclopropyl, –OCH(CH3)2, or –OCH2CH2OCH3. 44. The compound of any one of clauses 1 to 40, or a pharmaceutically acceptable salt thereof, wherein Xsis C-Rs, and Rsis H, OH, halo, C1-C6alkyl, C1-C6alkoxy, –(CH2)mORb, or – O(CH2)mOCH3. 45. The compound of clause 44, or a pharmaceutically acceptable salt thereof, wherein Rsis H, F, OH, –CH3, –CH2OH, –OCH3, –OCH(CH3)2, or –OCH2CH2OCH3. 46. The compound of any one of clause 1 to 45, or a pharmaceutically acceptable salt thereof, wherein Xtis N. 47. The compound of any one of clauses 1 to 45, wherein Xtis C-Rt, and Rtis H, halo, C1-C6alkyl, C1-C6alkoxy, or C3-C6cycloalkyl. 48. The compound of clause 47, wherein Xtis C-Rt, and Rtis H, Cl, F, –CH3, –OCH3, or cyclopropyl. 49. The compound of any one of clauses 1 to 45, wherein Xtis C-Rt, and Rtis H, halo, C1-C6alkyl, or C1-C6alkoxy. 50. The compound of clause 49, wherein Rtis H, Cl, F, –CH3, or –OCH3. 51. The compound of any one of clause 1 to 40, or a pharmaceutically acceptable salt thereof, wherein Rsand Rt, together with the carbon atoms to which they are attached, form a ring of formula:. 52. The compound of clause 51, or a pharmaceutically acceptable salt thereof, wherein Rsand Rt, together with the carbon atoms to which they are attached, form a ring of formula:53. The compound of any of clauses 1 to 52, or a pharmaceutically acceptable salt thereof, wherein Ruis H, halo, C1-C6alkyl, C1-C6alkoxy, C1-C6haloalkyl.54. The compound of clause 53, or a pharmaceutically acceptable salt thereof, wherein Ruis H, F, or –CH3. 55. The compound of any of clauses 1 to 54, or a pharmaceutically acceptable salt thereof, wherein Rvis H, halo, or C1-C6alkyl. 56. The compound of clause 55, or a pharmaceutically acceptable salt thereof, wherein Rvis H, F, or –CH3. 57. The compound of any one of clauses 1 to 54, or a pharmaceutically acceptable salt thereof, wherein Rvis H or C1-C6alkyl. 58. The compound of clause 57, or a pharmaceutically acceptable salt thereof, wherein Rvis H or –CH3. 59. The compound of any of clauses 1 to 58, or a pharmaceutically acceptable salt thereof, wherein Rwis H. 60. The compound of any one of clauses 1 to 5, or a pharmaceutically acceptable salt thereof, wherein the compound has a formula (I-A-2):. 61. The compound of any one of clauses 1 to 5 and 60, or a pharmaceutically acceptable salt thereof, wherein R7is H, C1-C6alkyl, or C1-C6alkoxy. 62. The compound of clause 60, or a pharmaceutically acceptable salt thereof, wherein R7is H, –CH3, or –OCH3. 63. The compound of any one of clauses 1 to 5 and 60, or a pharmaceutically acceptable salt thereof, wherein R7is H or C1-C6alkoxy.64. The compound of clause 63, or a pharmaceutically acceptable salt thereof, wherein R7is H or –OCH3. 65. The compound of any one of clauses 1 to 5 and 60 to 64, or a pharmaceutically acceptable salt thereof, wherein Rsis H, halo, C1-C6alkyl, C1-C6alkoxy, C3-C6cycloalkyl, or –(CH2)mORb. 66. The compound of clause 65, or a pharmaceutically acceptable salt thereof, wherein Rsis H, F, Cl, –CH3, –OCH3, cyclopropyl, or –CH2OCH3. 67. The compound of any one of clauses 1 to 5 and 60 to 64, or a pharmaceutically acceptable salt thereof, wherein Rsis C1-C6alkyl or C1-C6alkoxy. 68. The compound of clause 67, or a pharmaceutically acceptable salt thereof, wherein Rsis –CH3or –OCH3. 69. The compound of any one of clauses 1 to 5 and 60 to 68, or a pharmaceutically acceptable salt thereof, wherein Rtis H, halo, C1-C6alkyl, or C3-C6cycloalkyl. 70. The compound of clause 69, or a pharmaceutically acceptable salt thereof, wherein Rtis H, F, Cl, –CH3, or cycloproyl. 71. The compound of any one of clauses 1 to 5 and 60 to 68, or a pharmaceutically acceptable salt thereof, wherein Rtis H or halo. 72. The compound of clause 71, or a pharmaceutically acceptable salt thereof, wherein Rtis H or F. 73. A compound selected from Table A, or a pharmaceutically acceptable salt thereof. 74. A compound selected from Table B, or a pharmaceutically acceptable salt thereof. 75. A compound selected from Table C, or a pharmaceutically acceptable salt thereof. 76. A compound selected from Table D, or a pharmaceutically acceptable salt thereof. 77. The compound of any one of clauses 1 to 76 in non-salt form. 78. A pharmaceutical composition comprising a therapeutically effective amount of the compound of any one of clauses 1 to 76, or a pharmaceutically acceptable salt thereof, or the compound of clause 77, and one or more pharmaceutically acceptable carriers or vehicles.79. A pharmaceutical composition comprising the compound of any one of clauses 1 to 76, or a pharmaceutically acceptable salt thereof, or the compound of clause 77, and one or more pharmaceutically acceptable carriers or vehicles. 80. A method of inhibiting a voltage-gated sodium channel in a subject comprising administering to the subject the compound of any one of clauses 1 to 76, or a pharmaceutically acceptable salt thereof, the compound of clause 77, or the pharmaceutical composition of clause 78 or 79. 81. The method of clause 80, wherein the voltage-gated sodium channel is NaV1.8. 82. A method of treating or lessening the severity in a subject of chronic pain, gut pain, neuropathic pain, musculoskeletal pain, acute pain, inflammatory pain, cancer pain, idiopathic pain, postsurgical pain, visceral pain, multiple sclerosis, Charcot-Marie-Tooth syndrome, incontinence, pathological cough, or cardiac arrhythmia comprising administering to the subject an effective amount of the compound of any one of clauses 1 to 76, or a pharmaceutically acceptable salt thereof, the compound of clause 77, or the pharmaceutical composition of clause 78 or 79. 83. The method of clause 82, where the method comprises treating or lessening the severity in the subject of neuropathic pain. 84. The method of clause 83, wherein the neuropathic pain comprises post-herpetic neuralgia. 85. The method of clause 83, wherein the neuropathic pain comprises small-fiber neuropathy. 86. The method of clause 83, wherein the neuropathic pain comprises idiopathic small-fiber neuropathy. 87. The method of clause 83, wherein the neuropathic pain comprises diabetic neuropathy. 88. The method of clause 87, wherein the diabetic neuropathy comprises diabetic peripheral neuropathy. 89. The method of clause 82, wherein the method comprises treating or lessening the severity in the subject of musculoskeletal pain. 90. The method of clause 89, wherein the musculoskeletal pain comprises osteoarthritis pain. 91. The method of clause 82, wherein the method comprises treating or lessening the severity in the subject of acute pain. 92. The method of clause 91, wherein the acute pain comprises acute post-operative pain.93. The method of clause 82, wherein the method comprises treating or lessening the severity in the subject of postsurgical pain. 94. The method of clause 93, wherein the postsurgical pain comprises bunionectomy pain. 95. The method of clause 93, wherein the postsurgical pain comprises abdominoplasty pain. 96. The method of clause 93, wherein the postsurgical pain comprises herniorrhaphy pain. 97. The method of clause 82, wherein the method comprises treating or lessening the severity in the subject of visceral pain. 98. The method of any one of clauses 80 to 97, wherein said subject is treated with one or more additional therapeutic agents administered concurrently with, prior to, or subsequent to treatment with the compound, pharmaceutically acceptable salt, or pharmaceutical composition. 99. Use of the compound of any one of clauses 1 to 76, or a pharmaceutically acceptable salt thereof, the compound of clause 77, or the pharmaceutical composition of clause 78 or 79, as a medicament. EXAMPLES

[0271] General methods.1H NMR spectra were obtained as solutions in an appropriate deuterated solvent such as dimethyl sulfoxide-d6(DMSO-d6).

[0272] Compound purity, retention time, and electrospray mass spectrometry (ESI-MS) data were determined by LC / MS analysis.

[0273] LC / MS Method:Abbreviations

[0274] Unless otherwise noted, or where the context dictates otherwise, the following abbreviations shall be understood to have the following meanings: Abbreviation Meaning NMR Nuclear magnetic resonance ESI-MS Electrospray mass spectrometry LC / MS Liquid chromatography-mass spectrometry UPLC Ultra performance liquid chromatography HPLC / MS / MS High performance liquid chromatography / tandem mass spectrometry IS Internal standardAbbreviation Meaning HPLC High performance liquid chromatography SFC Supercritical fluid chromatography ESI Electrospray ionization cm centimeters g grams mg milligrams L Liter(s) mL Milliliters μL Microliters nL nanoliters mmol millimoles hr, h hours min Minutes ms millisecond mm Millimeters μm Micrometers nm nanometer MHz Megahertz Hz Hertz N Normal (concentration) M Molar (concentration) mM Millimolar (concentration) μM Micromolar (concentration) μW Microwave ppm Parts per million % w / v Weight-volume concentration % w / w Weight-weight concentration AcOH Acetic acid (Bpin)2tBis(pinacolato)diboron BuOH tert-butyl alcohol CPME Cyclopentyl methyl ether CataCXium®A Pd G3 Mesylate[(di(1-adamantyl)-nbutylphosphine)-2-(2′-amino-1,1′- biphenyl)]palladium(II) CDI 1,1′-Carbonyldiimidazole DCM Dichloromethane DCE Dichloroethane DEA Diethanolamine DIAD Diisopropyl azodicarboxylate DIEA, DIPEA N, N-Diisopropyl ethyl amine DMA N,N-Dimethylacetamide DMF N,N-Dimethylformamide DMSO Dimethyl sulfoxide DRG Dorsal root ganglia EtOH Ethanol EtOAc ethyl acetate HATU 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate EDCI 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide TFA Trifluoroacetic acid Tf2O Triflic anhydride T3P Propylphosphonic anhydride, i.e., 2,4,6-tripropyl-1,3,5,2,4,6- trioxatriphosphinane 2,4,6-trioxide MeOH Methanol MeCN, ACN AcetonitrileAbbreviation Meaning mCPBA 3-chloroperbenzoic acid 2-MeTHF 2-Methyltetrahydrofuran MTBE Methyl tert-butyl ether NMP N-Methylpyrrolidone PTSA p-Toluenesulfonic acid Phosphazene base P2-Et 1-Ethyl-2,2,4,4,4-pentakis(dimethylamino)-2λ5,4λ5- i catenadi(phosphazene) (PrO)Bpin 2-Isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane POCl3c Phosphorus oxychloride PrOSO2CF3Cyclopropyl trifluoromethanesulfonate TBAF Tetrabutylammonium fluoride THF Tetrahydrofuran Tf Trifluoromethanesulfonyl TFA Trifluoroacetic acid TMSCN Trimethylsilyl cyanide TMSOTf Trimethylsilyl trifluoromethanesulfonate RB Round bottom (flask) RT Ambient temperature r.t. Retention time LED Light Emitting Diode ca. Circa (approximately) µwave Microwave E-VIPR Electrical stimulation voltage ion probe reader HEK Human embryonic kidney KIR2.1 Inward-rectifier potassium ion channel 2.1 DMEM Dulbecco's Modified Eagle's Medium FBS Fetal bovine serum NEAA Non-essential amino acids HEPES 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid DiSBAC6(3) Bis-(1,3-dihexyl-thiobarbituric acid) trimethine oxonol CC2-DMPE Chlorocoumarin-2-dimyristoyl phosphatidylethanolamine VABSC-1 Voltage Assay Background Suppression Compound HS Human serum BSA Bovine Serum Albumin Example 1 2-((2R,3S,4S,5R)-3-(3,4-Difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran- 2-yl)-1,6-naphthyridin-4(1H)-one (1)

[0275] Step 1:

[0276] To a heat-gun-dried 20-mL vial, equipped with a stir bar, was added (2R,3S,4S,5R)-3- (3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxylic acid (Intermediate A, 96 mg, 0.27 mmol), 4-benzyloxy-2-chloro-1,6-naphthyridine (Intermediate K, 100 mg, 0.369 mmol), K2CO3(75 mg, 0.543 mmol), 4-methoxy-2-(4-methoxy-2-pyridyl)pyridine (6 mg, 0.028 mmol), nickel(II) chloride dimethoxyethane adduct (6 mg, 0.027 mmol) and (Ir[dF(CF3)ppy]2(dtbpy))PF6(6 mg, 0.005 mmol). DMF (5.3 mL) was then injected into the tube by syringe under a nitrogen atmosphere. The mixture was degassed for 15 min by bubbling with nitrogen, then sealed with parafilm. The solution was then stirred at 30 °C under irradiation of a blue LED (450 nm) using a Penn OC Photoreactor M2 for 17 h. The mixture was diluted with water (10 mL) and brine (100 mL), and the organic layer was extracted with EtOAc (3 x 50 mL). The combined organic extracts were dried (Na2SO4), filtered, and concentrated in vacuo. Purification by preparative reverse phase HPLC (C18column, 30 to 99 % ACN in water with 5 mM HCl modifier over 30 min) gave 4-(benzyloxy)-2-((2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5- (trifluoromethyl)tetrahydrofuran-2-yl)-1,6-naphthyridine (61.2 mg, 41%) as a pale yellow solid. ESI- MS m / z calc.544.179, found 545.3 (M+1)+; Retention time: 2.62 minutes using LC / MS method Q.

[0277] Step 2:

[0278] A solution of 4-(benzyloxy)-2-((2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5- dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-yl)-1,6-naphthyridine (61.2 mg) in EtOAc (2.7 mL) was added to a 20-mL vial containing Pd / C (10 wt % loading, wet, Degussa, 15 mg, 0.014 mmol). The reaction mixture was degassed with nitrogen for 5 min and stirred under a hydrogen atmosphere for 5 min. The mixture was heated to 40 °C for 15 min under an atmosphere of hydrogen. The reaction mixture was filtered through a pad of Celite®and washed with EtOAc. The filtrates were concentrated in vacuo to give a yellow solid. Purification by preparative reverse phase HPLC (C18column, 1 to 99% ACN in water with 5 mM HCl modifier over 30 min) gave 2-((2R,3S,4S,5R)-3-(3,4- difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-yl)-1,6-naphthyridin- 4(1H)-one (1, 9.4 mg, 8%) as a pale yellow solid.1H NMR (400 MHz, DMSO-d6) δ 12.53 (s, 1H), 9.27 (s, 1H), 8.69 (s, 1H), 8.09 (s, 1H), 7.30 (ddd, J = 8.3, 5.8, 2.0 Hz, 1H), 7.21 - 7.09 (m, 1H), 6.57 (s, 1H), 5.55 (d, J = 11.3 Hz, 1H), 4.39 (dd, J = 11.3, 8.3 Hz, 1H), 3.92 (d, J = 2.1 Hz, 3H), 2.89 (q, J = 7.7 Hz, 1H), 1.75 (s, 3H), 0.81 - 0.74 (m, 3H) ppm. ESI-MS m / z calc.454.132, found 455.3 (M+1)+; Retention time: 1.81 minutes using LC / MS method Q.

[0279] The following compounds were made using methods similar to those described in Example 1, except that different coupling partners were used in step 1. In step 2, EtOH or MeOH were used as the solvent instead of EtOAc, and the reaction was carried out at ambient temperature:

[0280] The following compound was made using the method described in Example 1, except that different coupling partners were used in step 1, and step 2 was not required:

[0281] The following compound was made using the method described in Example 1, except that a different coupling partner was used in step 1, and the debenzylation step 2 was carried out using TFA, in a similar manner to Example 3, step 3:

[0282] The following compound was made using the method described in Example 1, except that step 1 was carried out using the conditions outlined below:

[0283] Nickel Photochemistry: To an oven-dried 20-mL vial, equipped with a stir bar, was added (R)-1-phenylethan-1-aminium (2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl- 5-(trifluoromethyl)tetrahydrofuran-2-carboxylate (Intermediate A) (100 mg, 0.2 mmol), 4- (benzyloxy)-2-chloroquinoline (110 mg, 0.408 mmol), K2CO3(55 mg, 0.40 mmol), 2,2'-bipyridine (4 mg, 0.026 mmol), Nickel(II) bromide (5 mg, 0.023 mmol), and 2,4,5,6-tetra(9H-carbazol-9- yl)isophthalonitrile (8 mg, 0.01 mmol) in DMF (13 mL) under a nitrogen atmosphere. The mixture was degassed for 15 min by bubbling nitrogen through, then sealed with parafilm. The solution was stirred at ambient temperature under the irradiation of a blue LED (450 nm) using a Penn OC Photoreactor M1 for 17 h. After reaction completion, the mixture was quenched by addition of water (30 mL), then extracted with EtOAc (3 x 10 mL). The combined organic layers were dried (Na2SO4), filtered, and concentrated in vacuo. Purification by preparative reverse phase HPLC (C18column, 1 to 99% ACN in water with HCl modifier over 15 min) gave 4-(benzyloxy)-2-((2R,3S,4S,5R)-3-(3,4- difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-yl)quinoline (54 mg, 44%) as a white solid. ESI-MS m / z calc.543.183, found 544.6 (M+1)+; Retention time: 2.74 minutes using LC / MS method Q.

[0284] The following compound was made using the method described in Example 1, except that different coupling partners were used in step 1. Step 2 was not required. A final nitrile hydrolysis step was introduced using the method described in Example 15 step 5:Example 2 2-((2R,3S,4S,5R)-3-(3,4-Difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran- 2-yl)-8-fluoroquinolin-4(1H)-one (10)

[0285] Step 1:

[0286] N,N'-diisopropylmethanediimine (190 µL, 1.21 mmol) was added to a stirred mixture of (2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2- carboxylic acid (Intermediate A, 390 mg, 1.04 mmol), 2-hydroxyisoindoline-1,3-dione (215 mg, 1.32 mmol), and DMAP (135 mg, 1.105 mmol) in DCM (7.8 mL) under nitrogen. The reaction mixture was stirred at ambient temperature under a nitrogen atmosphere for 19 h. Upon reaction completion, the mixture was concentrated in vacuo and purification by flash column chromatography (SiO2, 1 to 100% EtOAc in hexanes) gave 1,3-dioxoisoindolin-2-yl (2R,3S,4S,5R)-3-(3,4-difluoro-2- methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxylate (240 mg, 46%) as a clear oil.1H NMR (400 MHz, Chloroform-d) δ 7.85 (dd, J = 5.5, 3.1 Hz, 2H), 7.78 (dd, J = 5.5, 3.1 Hz, 2H), 7.06 - 6.97 (m, 1H), 6.95 - 6.84 (m, 1H), 5.29 (d, J = 9.2 Hz, 1H), 4.44 (t, J = 8.9 Hz, 1H), 4.07 (s, 3H), 2.91 - 2.68 (m, 1H), 1.67 (s, 3H), 0.83 (dq, J = 7.3, 2.3 Hz, 3H) ppm. ESI-MS m / z calc. 499.105, found 500.0 (M+1)+; Retention time: 2.11 minutes using LC / MS method D.

[0287] Step 2:

[0288] 4-Chloro-8-fluoroquinoline (15 mg, 0.083 mmol) and 2,4,5,6-tetra(carbazol-9- yl)benzene-1,3-dicarbonitrile (1 mg, 0.001 mmol) were successively added to a stirring solution of 1,3-dioxoisoindolin-2-yl (2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5- (trifluoromethyl)tetrahydrofuran-2-carboxylate (51 mg, 0.10 mmol) in a mixture of DMSO (900 µL) and TFA (13 µL, 0.17 mmol). Nitrogen gas was vigorously bubbled through the solution for 5 min. The solution was sealed and placed in a Hepatochem photoreactor (450 nM, 30W). The reaction was stirred and irradiated with blue light for 3 h at ambient temperature. Purification by flash column chromatography (SiO2, 1 to 100% EtOAc in hexanes) gave 4-chloro-2-((2R,3S,4S,5R)-3-(3,4- difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-yl)-8-fluoroquinoline, which was used in the next step without further purification.

[0289] Step 3:

[0290] A reaction vial was charged with 4-chloro-2-((2R,3S,4S,5R)-3-(3,4-difluoro-2- methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-yl)-8-fluoroquinoline and tBuBrettPhos Pd G3 (7 mg, 0.008 mmol) in a mixture of water (22 µL, 1.2 mmol) and THF (750 µL). The mixture was degassed for 5 min by bubbling nitrogen through the mixture. Phosphazene base P2- Et (82 µL, 0.25 mmol) was added and the reaction mixture was stirred at ambient temperature for 2 h. The reaction mixture was diluted with DMSO (5 mL) and filtered. Purification by reverse phase preparative HPLC (C18column, 1 to 99% MeCN in water with 5 mM HCl) gave 2-((2R,3S,4S,5R)-3- (3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-yl)-8- fluoroquinolin-4(1H)-one (10, 3.1 mg, 8% over 2 steps) as a white solid.1H NMR (400 MHz, Methanol-d4) δ 8.04 (d, J = 8.2, 1.3 Hz, 1H), 7.74 - 7.57 (m, 1H), 7.56 - 7.43 (m, 1H), 7.31 - 7.14 (m, 1H), 7.09 - 6.92 (m, 1H), 6.72 - 6.58 (m, 1H), 5.72 (d, J = 11.3 Hz, 1H), 4.29 (dd, J = 11.2, 8.1 Hz, 1H), 3.94 (d, J = 2.5 Hz, 3H), 2.97 - 2.81 (m, 1H), 1.73 (d, J = 1.4 Hz, 3H), 0.92 (d, J = 7.6, 2.5 Hz, 3H) ppm. ESI-MS m / z calc.471.127, found 472.1 (M+1)+; Retention time: 1.80 minutes using LC / MS method D.

[0291] The following compounds were made using methods similar to those described in Example 2, except that different coupling partners were used in step 2:

[0292] The following compounds were made using methods similar to those described in Example 2, except that (Ir[dF(CF3)ppy]2(dtbpy))PF6 was used as catalyst in step 2 in place of 2,4,5,6- tetra(carbazol-9-yl)benzene-1,3-dicarbonitrile. A different coupling partner was used in step 2 for compound 19, and DMA was used as the solvent instead of DMSO:

[0293] The following compounds were made using the method described in Example 2, except that rac-(2R,3S,4S,5R)-4-cyclopropyl-3-(3,4-difluoro-2-methoxyphenyl)-5-methyl-5- (trifluoromethyl)tetrahydrofuran-2-carboxylic acid was used as starting material in step 1. In step 2, (Ir[dF(CF3)ppy]2(dtbpy))PF6was used as catalyst in place of 2,4,5,6-tetra(carbazol-9-yl)benzene-1,3- dicarbonitrile. The product of step 3 was further purified by chiral SFC using a (R,R)-Whelk-O®1 column, 5 µm particle size, 5.0 cm x 3.0 mm from Regis Technologies to give First Eluting Isomer 20 (rt = 2.74 minutes) and Second Eluting Isomer 21 (rt = 8.29 minutes):

[0294] The following compounds were made using the method described in Example 2, except that methyl 5-methoxy-4-oxo-1,4-dihydro-quinoline-3-carboxylate and 4-benzyloxy-5- chloroquinoline were respectively used as coupling partners in step 2. Step 3 was not required:

[0295] The following compounds were made using the method described in Example 2, except that 4-benzyloxy-6-chloroquinoline and 4-benzyloxy-5,7-dimethyl-1,6-naphthyridine were respectively used as coupling partners in step 2. Step 3 was omitted. A final hydrogenation deprotection step was carried out at ambient temperature using Pd / C in EtOH:

[0296] The following compound was made using the method described in Example 2, except that in step 2, 8-benzyloxy-2-methoxy-1,5-naphthyridine was used as the coupling partner and (Ir[dF(CF3)ppy]2(dtbpy))PF6was used in place of 2,4,5,6-tetra(carbazol-9-yl)benzene-1,3- dicarbonitrile. Step 3 was omitted. A final hydrogenation step was carried out in 1,4-dioxane using conditions similar to those described in Example 1 step 2 with the addition of HCl:

[0297] The following compound was made using the method described in Example 2, except that 4-chloroquinoline-5-carbonitrile was used as the coupling partner in step 2. Step 3 was omitted and replaced by a SNAr step, which was carried out with benzyl alcohol using conditions similar to those described in Intermediate K, step 1. A final benzyl deprotection step was carried out using conditions similar to those described in Example 1, step 2:

[0298] The following compound was made using methods similar to those described in Example 2, except that, in step 2, 4-benzyloxy-5-chloro-8-fluoro-1,6-naphthyridine was used as the coupling partner and (Ir[dF(CF3)ppy]2(dtbpy))PF6was used in place of 2,4,5,6-tetra(carbazol-9-yl)benzene-1,3- dicarbonitrile. The product of step 2 was subjected to the conditions outlined below. A final benzyl deprotection step was carried out using conditions similar to those described in Example 1, step 2:

[0299] Negishi reaction: 4-(Benzyloxy)-5-chloro-2-((2R,3S,4S,5R)-3-(3,4-difluoro-2- methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-yl)-8-fluoro-1,6-naphthyridine(26 mg, 0.044 mmol) and Ni(dppp)Cl2(5 mg, 0.009 mmol) were dissolved in THF (500 µL) under a nitrogen atmosphere and cooled to 0 °C. MeMgBr (22 µL, 3 M solution in Et2O, 0.07 mmol) was added dropwise at 0 °C. The reaction mixture was warmed to ambient temperature and stirred overnight. THF (500 µL), Ni(dppp)Cl2(5 mg, 0.009 mmol) and MeMgBr (22 µL, 3 M solution in Et2O, 0.07 mmol) were added to the reaction mixture which was stirred for 24 h. The mixture was quenched with 1 M HCl (2 mL) and poured over water (10 mL). The mixture was extracted with EtOAc (3 x 10 mL). The combined organic layers were washed with brine (10 mL), dried (MgSO4), and concentrated in vacuo. Purification by flash column chromatography (12 g SiO2, 0 to 50% EtOAc in heptane) gave 4-(benzyloxy)-2-((2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5- (trifluoromethyl)tetrahydrofuran-2-yl)-8-fluoro-5-methyl-1,6-naphthyridine (7.6 mg, 30%) as a colourless oil.

[0300] The following compound was made using the method described in Example 2, except that methyl 4-chloroquinoline-6-carboxylate was used as the coupling partner in step 2. The product of step 2 was hydrolysed and subjected to amidation conditions before carrying out step 3, as outlined below:

[0301] Hydrolysis: Methyl 4-chloro-2-((2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5- dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-yl)quinoline-6-carboxylate was dissolved in a mixture of MeOH (1 mL), THF (5 mL) and 1 N aqueous LiOH and stirred at ambient temperature overnight. The mixture was concentrated in vacuo.1 N HCl (1 mL) was added, and product was extracted with DCM. The organic phase was separated and concentrated in vacuo to give 4-chloro-2-((2R,3S,4S,5R)- 3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-yl)quinoline-6- carboxylic acid (36.2 mg, 70%) as a pale brown solid. ESI-MS m / z calc.515.092, found 516.0 (M+1)+; Retention time: 3.03 minutes using LC / MS method Q.

[0302] Amidation: 4-Chloro-2-((2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl- 5-(trifluoromethyl)tetrahydrofuran-2-yl)quinoline-6-carboxylic acid (10 mg, 0.019 mmol), dimethylamine hydrochloride (7.9 mg, 8.4 µL, 0.096 mmol) and DIEA (20 mg, 27 µL, 0.16 mmol) were combined in THF (1 mL) and stirred for 5 min. HATU (22 mg, 0.058 mmol) was added and the mixture was stirred at ambient temperature for 2 h before being concentrated in vacuo. Purification by reverse phase preparative HPLC (C18column, 1 to 99% acetonitrile in water) gave 4-chloro-2- ((2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2- yl)-N,N-dimethylquinoline-6-carboxamide as a clear colourless solid. ESI-MS m / z calc.542.140, found 543.0 (M+1)+; Retention time: 1.75 minutes using LC / MS method D.Example 3 2-((2R,3S,4S,5R)-3-(3,4-Difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran- 2-yl)-4-oxo-1,4-dihydro-1,6-naphthyridine-5-carboxamide (30)

[0303] Step 1:

[0304] To a solution of 4-(benzyloxy)-2-((2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5- dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-yl)-1,6-naphthyridine (1.0 g, 1.84 mmol) in DCM (10mL) at 0 °C was added mCPBA (453 mg, 1.84 mmol). The reaction mixture was stirred at ambient temperature for 2 h. The mixture was diluted with DCM (200 mL) and washed with a saturated aqueous NaHCO3solution (100 mL). The organic layer was separated, dried (Na2SO4), filtered, and concentrated in vacuo. Purification by flash column chromatography (SiO2, 1 to 10% MeOH in DCM) gave 4-(benzyloxy)-2-((2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5- (trifluoromethyl)tetrahydrofuran-2-yl)-1,6-naphthyridine 6-oxide (980 mg, 95%) as an off-white solid. ESI-MS m / z calc.560.173, found 561.1 (M+1)+; Retention time: 1.93 minutes using LC / MS method D.

[0305] Step 2:

[0306] To a solution of 4-(benzyloxy)-2-((2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5- dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-yl)-1,6-naphthyridine 6-oxide (980 mg, 1.75 mmol) in DCM (20 mL) under an atmosphere of nitrogen were successively added trimethylsilyl cyanide (285 µL, 2.28 mmol) and Et3N (490 µL, 3.52 mmol). The reaction mixture was stirred at ambient temperature for 19 h and concentrated in vacuo. Purification by flash chromatography (SiO2, 1 to 100% EtOAc in hexanes) gave 4-(benzyloxy)-2-((2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)- 4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-yl)-1,6-naphthyridine-5-carbonitrile (740 mg, 74%) as a white solid.1H NMR (400 MHz, Methanol-d4) δ 8.74 (d, J = 5.8 Hz, 1H), 7.97 (d, J = 5.8 Hz, 1H), 7.71 - 7.55 (m, 2H), 7.48 - 7.32 (m, 4H), 7.33 - 7.19 (m, 1H), 7.01 - 6.82 (m, 1H), 5.66 - 5.59 (m, 3H), 4.18 - 4.11 (m, 1H), 3.83 (d, J = 2.3 Hz, 3H), 2.94 - 2.75 (m, 1H), 1.74 - 1.61 (m, 3H), 0.94 - 0.78 (m, 3H) ppm. ESI-MS m / z calc.569.174, found 570.2 (M+1)+; Retention time: 2.23 minutes using LC / MS method D.

[0307] Step 3:

[0308] A solution of 4-(benzyloxy)-2-((2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5- dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-yl)-1,6-naphthyridine-5-carbonitrile (100 mg, 0.176 mmol) and trifluoroacetic acid (1.1 mL, 14 mmol) in toluene (1 mL) was heated at 70 °C under nitrogen for 2 h. The reaction was concentrated in vacuo, diluted with DMSO (500 µL), filtered, and purified by reverse phase preparative chromatography (C18, 1 to 99% acetonitrile in water containing 5 mM hydrochloric acid) to give 2-((2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5- (trifluoromethyl)tetrahydrofuran-2-yl)-4-oxo-1,4-dihydro-1,6-naphthyridine-5-carboxamide (30, 30 mg, 33%) as a white solid.1H NMR (400 MHz, Methanol-d4) δ 8.82 (d, J = 6.3 Hz, 1H), 8.25 (d, J = 6.3 Hz, 1H), 7.32 - 7.16 (m, 1H), 7.12 - 6.89 (m, 1H), 6.76 (s, 1H), 5.70 (d, J = 11.2 Hz, 1H), 4.34 (dd, J = 11.2, 8.6 Hz, 1H), 3.97 (d, J = 2.6 Hz, 3H), 3.02 - 2.80 (m, 1H), 1.75 (s, 3H), 1.03 - 0.81 (m, 3H) ppm. ESI-MS m / z calc.497.137, found 498.1 (M+1)+; Retention time: 1.42 minutes using LC / MS method D.

[0309] The HPLC purification also afforded 2-((2R,3S,4S,5R)-3-(3,4-difluoro-2- methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-yl)-4-oxo-1,4-dihydro-1,6- naphthyridine-5-carbonitrile (31, 14 mg, 16%) as a white solid.1H NMR (400 MHz, Methanol-d4) δ8.69 (d, J = 5.9 Hz, 1H), 7.90 (d, J = 5.9 Hz, 1H), 7.27 - 7.12 (m, 1H), 7.08 - 6.89 (m, 1H), 6.31 (s, 1H), 5.52 (d, J = 11.2 Hz, 1H), 4.25 (dd, J = 11.2, 8.5 Hz, 1H), 3.95 (d, J = 2.6 Hz, 3H), 2.96 - 2.81 (m, 1H), 1.72 (s, 3H), 0.98 - 0.78 (m, 3H) ppm; NH pyridone not observed. ESI-MS m / z calc. 479.127, found 480.1 (M+1)+; Retention time: 1.63 minutes using LC / MS method D.

[0310] The following compounds were made using the method described in Example 1, step 1 followed by Example 3, except that for compound 32 and compound 33, (2R,3R,4S,5R)-3-(3,4- difluoro-2-methoxyphenyl)-4-methoxy-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxylic acid was used as the starting material. Compound 33 was isolated as a minor product in step 3. In the case of compound 34 and compound 35, rac-(2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4-methyl-5- (trifluoromethyl)tetrahydrofuran-2-carboxylic acid (Intermediate C) was used as the starting material. A final SFC purification was carried out using a Chiralpak IG (250 x 20 mm), 5 µm particle size, 250 x 20 mm column from Daicel Corporation to give First Eluting Isomer (rt = 1.90 minutes) 34 and Second Eluting Isomer (rt = 3.60 minutes) 35:Example 4 2-((2R,3S,4S,5R)-3-(3,4-Difluoro-2-methylphenyl)-4-methoxy-5-methyl-5- (trifluoromethyl)tetrahydrofuran-2-yl)-4-oxo-1,4-dihydro-1,6-naphthyridine-5-carboxamide (36)

[0311] Step 1:

[0312] To a solution of (2R,3R,4S,5R)-3-(3,4-difluoro-2-methylphenyl)-4-methoxy-5-methyl-5- (trifluoromethyl)tetrahydrofuran-2-carboxylic acid (Intermediate B, 1.1 g, 2.9 mmol) in DCM (10 mL) under a nitrogen atmosphere was added DMF (11 µL, 0.14 mmol) followed by oxalyl chloride (3 mL, 2.0 M solution in DCM, 6 mmol). The reaction mixture was stirred for 1 h and then concentrated in vacuo. The residue was dissolved in DCM and concentrated in vacuo to remove residual oxalyl chloride (x 3). The acid chloride was dissolved in DCM (10 mL) and added dropwise to solution of 1- (4-aminopyridin-3-yl)ethan-1-one (458 mg, 3.36 mmol) and Et3N (820 µL, 5.88 mmol) in DCM (10 mL). The reaction mixture was stirred at ambient temperature for 1 h. The mixture was quenched with water (20 mL) and washed with a saturated NaHCO3solution (20 mL) and 1 M citric acid (20 mL). The organic layer was dried (MgSO4), filtered, and concentrated in vacuo to give (2R,3R,4S,5R)-N-(3- acetylpyridin-4-yl)-3-(3,4-difluoro-2-methylphenyl)-4-methoxy-5-methyl-5- (trifluoromethyl)tetrahydrofuran-2-carboxamide (1.31 g, 95%) as an off-white solid.1H NMR (400 MHz, Chloroform-d) δ 12.90 (s, 1H), 9.22 (s, 1H), 8.90 (d, J = 6.5 Hz, 1H), 8.58 (d, J = 6.5 Hz, 1H), 7.36 - 7.32 (m, 1H), 7.12 (q, J = 8.8 Hz, 1H), 5.19 (d, J = 11.5 Hz, 1H), 3.85 (d, J = 4.7 Hz, 1H), 3.74 (dd, J = 11.5, 4.7 Hz, 1H), 2.96 (s, 3H), 2.80 (s, 3H), 2.31 (d, J = 2.4 Hz, 3H), 1.81 (s, 3H) ppm; ESI- MS m / z calc.472.142, found 473.0 (M+1)+; Retention time: 3.37 minutes using LC / MS method A.

[0313] Step 2:

[0314] Under a nitrogen atmosphere, NaOtBu (20.32 g, 211.4 mmol) was added to a solution of (2R,3R,4S,5R)-N-(3-acetylpyridin-4-yl)-3-(3,4-difluoro-2-methylphenyl)-4-methoxy-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide (51.21 g, 104.4 mmol) in 1,4-dioxane (500 mL), causing an exotherm from 23 °C to 27.5 °C. The reaction mixture was heated at 56 °C for 10 min and then cooled to ambient temperature and quenched by the addition of water (100 mL). The pH of the solution was adjusted to 5 by careful addition of 2 M HCl. The aqueous phase was extracted with EtOAc (500 mL then 2 x 100 mL). The combined organic phases were dried (MgSO4), filtered, and concentrated in vacuo to give an orange solid. The solid (58.28 g) was triturated with a 1:1 mixture of DCM (125 mL) and heptane (125 mL). The mixture was aged for 1 h. The pale pink solid was collected by filtration, rinsing with a mixture of 1:1 DCM:heptane, to give 2-((2R,3S,4S,5R)-3-(3,4- difluoro-2-methylphenyl)-4-methoxy-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-yl)-1,6- naphthyridin-4(1H)-one (37.022 g, 78%) as an off-white solid.1H NMR (400 MHz, Chloroform-d) δ 9.38 (s, 1H), 8.52 (d, J = 6.2 Hz, 1H), 7.75 (d, J = 6.2 Hz, 1H), 7.25 (ddd, J = 8.9, 4.9, 1.7 Hz, 1H), 7.03 (p, J = 8.7 Hz, 1H), 6.08 (s, 1H), 5.53 (d, J = 11.1 Hz, 1H), 3.97 (dd, J = 11.3, 4.9 Hz, 1H), 3.86 (d, J = 5.0 Hz, 1H), 2.96 (s, 3H), 2.36 - 2.24 (m, 3H), 1.71 (s, 3H) ppm; NH pyridone not observed.19F NMR (376 MHz, Chloroform-d) δ -75.13, -137.68 (d, J = 21.1 Hz), -138.56 (d, J = 21.1 Hz) ppm. ESI-MS m / z calc.454.132, found 455.2 (M+1)+; 453.2 (M-1)-; Retention time: 0.76 minutes using LC / MS method C.

[0315] Step 3:

[0316] To a suspension of 2-((2R,3S,4S,5R)-3-(3,4-difluoro-2-methylphenyl)-4-methoxy-5- methyl-5-(trifluoromethyl)tetrahydrofuran-2-yl)-1,6-naphthyridin-4(1H)-one (5 g, 11 mmol) in MeCN (50 mL) was added formamide (9 mL, 226 mmol) and the mixture was stirred until complete dissolution. The reaction mixture was heated at 75 °C. A solution of (NH4)2S2O8(5.58 g, 24.5 mmol) in water (7 mL) was added over 6 min via an addition funnel. The mixture was heated at 75 °C until complete disappearance of starting material. An additional amount of (NH4)2S2O8(1.26 g, 5.521 mmol) in water (1.5 mL) was added to the reaction mixture and the reaction was cooled to ambient temperature. The pH of the solution was adjusted to pH 8 by addition of a saturated NaHCO3solution. The mixture was extracted with EtOAc (3 x 10 mL). The organic extracts were concentrated in vacuo. Purification by flash chromatography (40 g SiO2, 0 to 60% EtOAc in heptane, then 100% EtOAc) gave 2-((2R,3S,4S,5R)-3-(3,4-difluoro-2-methylphenyl)-4-methoxy-5-methyl-5- (trifluoromethyl)tetrahydrofuran-2-yl)-4-oxo-1,4-dihydro-1,6-naphthyridine-5-carboxamide (36, 1.35 g, 24%).1H NMR (400 MHz, Methanol-d4) δ 8.53 (d, J = 6.0 Hz, 1H), 7.67 (d, J = 6.1 Hz, 1H), 7.39 (ddd, J = 9.0, 5.0, 1.7 Hz, 1H), 7.17 (q, J = 9.0 Hz, 1H), 6.22 (s, 1H), 5.53 (d, J = 11.2 Hz, 1H), 4.16 (d, J = 5.0 Hz, 1H), 3.93 (dd, J = 11.2, 4.9 Hz, 1H), 2.99 (s, 3H), 2.32 (d, J = 2.4 Hz, 3H), 1.74 (d, J = 1.3 Hz, 3H) ppm; NH pyridone and NH2amide not observed. ESI-MS m / z calc.497.137, found 498.2 (M+1)+; Retention time: 2.50 minutes using LC / MS method A.

[0317] 2-((2R,3S,4S,5R)-3-(3,4-Difluoro-2-methylphenyl)-4-methoxy-5-methyl-5- (trifluoromethyl)tetrahydrofuran-2-yl)-4-oxo-1,4-dihydro-1,6-naphthyridine-7,8-dicarboxamide (37,765 mg, 2.41%) was also isolated. ESI-MS m / z calc.540.439, found 541.1 (M+1)+; Retention time: 2.71 minutes using LC / MS method H. Example 5 7-((2R,3S,4S,5R)-3-(3,4-Difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran- 2-yl)pyrido[2,3-d]pyrimidin-5(8H)-one (38) and 7-((2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran- 2-yl)-5-oxo-5,8-dihydropyrido[2,3-d]pyrimidine-4-carboxamide (39)

[0318] Step 1:

[0319] To a solution of (2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5- (trifluoromethyl)tetrahydrofuran-2-carboxylic acid (Intermediate A, 500 mg, 1.41 mmol) in DCM (5 mL) was added DMF (6 µL, 0.08 mmol) and oxalyl chloride (250 µL, 2.87 mmol) and the resulting mixture was stirred at ambient temperature for 20 min. The mixture was concentrated in vacuo and azeotroped with DCM (2 x 5 mL) to give (2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5- dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl chloride, which was used without further purification.

[0320] (2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5- (trifluoromethyl)tetrahydrofuran-2-carbonyl chloride was dissolved in DCM (5 mL) and added dropwise to a solution of Et3N (400 µL, 2.87 mmol) and 1-(4-aminopyrimidin-5-yl)ethan-1-one (213 mg, 1.55 mmol) in DCM (5 mL). The reaction mixture was stirred at ambient temperature for 1 h, after which the reaction mixture was taken on to the next step.

[0321] Step 2:

[0322] Et3N (1.38 mL, 9.901 mmol) and TMSOTf (1.53 mL, 8.467 mmol) were added to the reaction mixture from Step 1 above, and the mixture was heated at 45 °C for 16 h. The mixture was cooled to ambient temperature, poured over a saturated aqueous NaHCO3solution (50 mL) and diluted with DCM (50 mL). The aqueous layer was separated and extracted with DCM (50 mL). The combined organic extracts were washed with brine (50 mL), dried (MgSO4), filtered, and concentrated in vacuo. Purification by flash chromatography (40 g SiO2,0 to 100% EtOAc in heptane) gave 7- ((2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2- yl)pyrido[2,3-d]pyrimidin-5(8H)-one (38, 268 mg, 42% over 2 steps) as an off-white solid.1H NMR (500 MHz, DMSO-d6) δ 12.55 (s, 1H), 9.25 (s, 1H), 9.15 (s, 1H), 7.27 - 7.23 (m, 1H), 7.18 - 7.12 (m, 1H), 6.55 (s, 1H), 5.45 (d, J = 11.3 Hz, 1H), 4.38 (dd, J = 11.3, 8.3 Hz, 1H), 3.90 (d, J = 1.9 Hz, 3H), 2.85 (dq, J = 7.8 Hz, 1H), 1.71 (s, 3H), 0.76 (d, J = 5.3 Hz, 3H) ppm.19F NMR (471 MHz, DMSO-d6) δ -73.15, -137.96, -154.82 ppm. ESI-MS m / z calc.455.127, found 456.3 (M+1)+; 454.2 (M-1)-; Retention time: 2.52 minutes using LC / MS method A.

[0323] Step 3:

[0324] 7-((2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5- (trifluoromethyl)tetrahydrofuran-2-yl)pyrido[2,3-d]pyrimidin-5(8H)-one (100 mg, 0.220 mmol) and K2S2O8 (131 mg, 0.485 mmol) were suspended in MeCN (200 µL) and water (40 µL). The mixture was heated to 75 °C and formamide (350 µL, 8.78 mmol) was added. The resulting mixture was stirred at 75 °C for 2 h. The reaction mixture was quenched by addition of a saturated aqueous NaHCO3solution (2 mL), poured over a saturated aqueous NaHCO3solution (10 mL), and diluted with EtOAc (10 mL). The aqueous layer was separated and extracted with EtOAc (2 x 10 mL). The combined organic extracts were washed with brine (10 mL), dried (MgSO4), and concentrated in vacuo. Purification by reverse phase HPLC (C18X-bridge column, 15.8 to 30.5% MeCN in H2O with 0.1% ammonium hydroxide) gave 7-((2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl- 5-(trifluoromethyl)tetrahydrofuran-2-yl)-5-oxo-5,8-dihydropyrido[2,3-d]pyrimidine-4-carboxamide (39, 12.9 mg, 12%).1H NMR (500 MHz, DMSO-d6) δ 12.56 (s, 1H), 9.08 (s, 1H), 7.64 (s, 1H), 7.53 (s, 1H), 7.27 - 7.23 (m, 1H), 7.18 - 7.11 (m, 1H), 6.53 (s, 1H), 5.44 (d, J = 11.3 Hz, 1H), 4.37 (dd, J = 11.3, 8.3 Hz, 1H), 3.90 (d, J = 1.9 Hz, 3H), 2.85 (p, J = 7.7 Hz, 1H), 1.71 (s, 3H), 0.76 (d, J = 7.4 Hz, 3H) ppm.19F NMR (471 MHz, DMSO-d6) δ -73.13, -137.86, -154.75 ppm. ESI-MS m / z calc. 498.133, found 499.4 (M+1)+; 497.2 (M-1)-; Retention time: 2.39 minutes using LC / MS method A.

[0325] The following compound was made using the method described in Example 5 except that the conditions used in step 1 were those of Example 6 step 1 and (2R,3S,4S,5R)-3-(3-fluoro-2- methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxylic acid (Intermediate H) was used in place of (2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5- (trifluoromethyl)tetrahydrofuran-2-carboxylic acid (Intermediate A):

[0326] The following compounds were made using the method described in Example 5, except that, in step 1, rac-(2R,3S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-5-methyl-5- (trifluoromethyl)tetrahydrofuran-2-carboxylic acid was used as the starting material and 1-(4- aminopyridin-3-yl)ethan-1-one as the coupling partner. In step 2, DIPEA was used as the base in place of triethylamine. The product of step 3 was further purified by chiral SFC using a Chiralpak IB column (250 x 20 mm), 5 µm particle size, 250 x 20 mm column from Daicel Corporation to give First Eluting Isomer 41 (rt = 2.99 minutes) and Second Eluting Isomer 42 (rt = 4.49 minutes):Example 6 2-((2R,3R,4S,5R)-3-(3,4-Difluoro-2-methylphenyl)-4-hydroxy-5-methyl-5- (trifluoromethyl)tetrahydrofuran-2-yl)-4-oxo-1,4-dihydro-1,6-naphthyridine-5-carboxamide (43)

[0327] Step 1:

[0328] To a solution of (2R,3R,4S,5R)-3-(3,4-difluoro-2-methylphenyl)-4-(methoxymethoxy)-5- methyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxylic acid (Intermediate I, 460 mg, 1.20 mmol) in EtOAc (15 mL) at ambient temperature was added 1-(4-aminopyridin-3-yl)ethan-1-one (500 mg, 3.67 mmol) and Et3N (1.2 mL, 8.6 mmol). T3P (3.5 mL, 50 % w / w solution in EtOAc, 5.9 mmol) was added dropwise and the reaction mixture was stirred at ambient temperature for 2 h. The mixture was quenched by addition of a saturated NaHCO3solution (20 mL). The mixture was extracted with EtOAc (2 x 15 mL) and the combined organic extracts were dried (MgSO4), filtered, and concentrated in vacuo. Purification by flash chromatography (24 g SiO2, 0 to 100% EtOAc in heptane) gave (2R,3R,4S,5R)-N-(3-acetylpyridin-4-yl)-3-(3,4-difluoro-2-methylphenyl)-4-hydroxy-5-methyl-5- (trifluoromethyl)tetrahydrofuran-2-carboxamide (270 mg, 45%). ESI-MS m / z calc.502.153, found 503.2 (M+1)+; 501.1 (M-1)-; Retention time: 0.97 minutes using LC / MS method C.

[0329] Step 2:

[0330] Potassium tert-butoxide (130 mg, 1.16 mmol) was added to a stirring solution of (2R,3R,4S,5R)-N-(3-acetylpyridin-4-yl)-3-(3,4-difluoro-2-methylphenyl)-4-hydroxy-5-methyl-5- (trifluoromethyl)tetrahydrofuran-2-carboxamide (270 mg, 0.537 mmol) in 1,4-dioxane (5 mL) at ambient temperature and the reaction mixture was heated at 50 ºC for 1 h. The mixture was quenched by addition of a saturated NH4Cl solution (10 mL) and extracted with EtOAc (10 mL). The organic layer was separated, dried (MgSO4), filtered, and concentrated in vacuo to give 2-((2R,3S,4S,5R)-3- (3,4-difluoro-2-methylphenyl)-4-(methoxymethoxy)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2- yl)-1,6-naphthyridin-4(1H)-one (260 mg, 100%), which was used without further purification in thenext step. ESI-MS m / z calc.484.142, found 485.2 (M+1)+; 483.2 (M-1)-; Retention time: 0.74 minutes using LC / MS method C.

[0331] Steps 3 and 4:

[0332] Potassium persulfate (100 mg, 0.370 mmol) was added to a solution of 2-((2R,3S,4S,5R)- 3-(3,4-difluoro-2-methylphenyl)-4-(methoxymethoxy)-5-methyl-5-(trifluoromethyl)tetrahydrofuran- 2-yl)-1,6-naphthyridin-4(1H)-one (160 mg, 0.330 mmol) and formamide (600 µL, 15.05 mmol) in a mixture of MeCN (2 mL) and water (0.5 mL) and the mixture was heated at 75 ºC for 1 h. The reaction mixture was quenched by addition of water and diluted with EtOAc. The aqueous phase was separated and extracted with EtOAc (2 x 10 mL). The combined organic layers were dried (MgSO4), filtered, and concentrated in vacuo to give 2-((2R,3S,4S,5R)-3-(3,4-difluoro-2-methylphenyl)-4- (methoxymethoxy)-5-methyl-5-(trifluoromethyl)tetrahydrofuran-2-yl)-4-oxo-1,4-dihydro-1,6- naphthyridine-5-carboxamide, which was used without further purification in the next step. ESI-MS m / z calc.527.148, found 528.2 (M+1)+; 526.2 (M-1)-; Retention time: 0.67 minutes using LC / MS method C.

[0333] 2-((2R,3S,4S,5R)-3-(3,4-difluoro-2-methylphenyl)-4-(methoxymethoxy)-5-methyl-5- (trifluoromethyl)tetrahydrofuran-2-yl)-4-oxo-1,4-dihydro-1,6-naphthyridine-5-carboxamide was dissolved in a mixture of toluene (1 mL) and TFA (1 mL) and heated at 75 ºC for 1 h. The reaction mixture was neutralised by addition of a saturated NaHCO3solution and extracted with EtOAc (3 x 10 mL). The combined organic extracts were dried (MgSO4), filtered and concentrated in vacuo. Purification by flash chromatography (12 g SiO2, 0 to 100% 3:1 EtOAc:EtOH in heptane) gave 2- ((2R,3R,4S,5R)-3-(3,4-difluoro-2-methylphenyl)-4-hydroxy-5-methyl-5- (trifluoromethyl)tetrahydrofuran-2-yl)-4-oxo-1,4-dihydro-1,6-naphthyridine-5-carboxamide (43, 24 mg, 15% over 2 steps).1H NMR (500 MHz, Methanol-d4) δ 8.52 (d, J = 6.0 Hz, 1H), 7.66 (d, J = 6.0 Hz, 1H), 7.33 (ddd, J = 9.1, 4.9, 1.7 Hz, 1H), 7.11 (q, J = 8.9 Hz, 1H), 6.23 (s, 1H), 5.56 (d, J = 11.2 Hz, 1H), 4.46 (d, J = 4.8 Hz, 1H), 3.89 (dd, J = 11.2, 4.8 Hz, 1H), 2.26 (d, J = 2.3 Hz, 3H), 1.70 (s, 3H) ppm; NH pyridone, NH2amide and OH alcohol not observed.19F NMR (471 MHz, Methanol-d4) δ -76.03, -142.02 - -142.30 (m), -142.74 - -143.01 (m) ppm. ESI-MS m / z calc.483.122, found 484.1 (M+1)+; 482.2 (M-1)-; Retention time: 1.79 minutes using LC / MS method A.

[0334] The following compound was made using the method described in Example 6 except that (2R,3R,4S,5R)-3-(3,4-difluoro-2-((methoxymethoxy)methyl)phenyl)-4-methoxy-5-methyl-5- (trifluoromethyl)tetrahydrofuran-2-carboxylic acid (Intermediate J) was used as the starting material in step 1:

[0335] The following compound was made using methods similar to those described in Example 6 except that, in step 1, (2R,3R,4S,5R)-3-(3,4-difluoro-2-methoxy-phenyl)-4-(methoxymethoxy)-5- methyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxylic acid was used as the starting material. Steps 3 and 4 were omitted. After step 2 the formamide portion of the compound was installed following procedures from Example 3:Example 7 2-((2R,3S,4S,5R)-3-(3,4-Difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran- 2-yl)pyrido[4,3-d]pyrimidin-4(1H)-one (46)

[0336] Step 1:

[0337] (2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5- (trifluoromethyl)tetrahydrofuran-2-carboxylic acid (Intermediate A, 400 mg, 1.13 mmol) was dissolved in a mixture of DCM (10 mL) and DMF (10 µL, 0.13 mmol) cooled to 0 ºC. Oxalyl chloride (990 µL, 11.4 mmol) was then added dropwise over 2 min, and the mixture was stirred for 1 h. The reaction mixture was concentrated in vacuo. The residue was dissolved in DCM (10 mL) and added dropwise to an ice-cold solution of methyl 4-aminonicotinate (172 mg, 1.13 mmol), DMAP (3 mg, 0.024 mmol) and DIPEA (200 µL, 1.15 mmol) in DCM (10 mL). The mixture was stirred for 90 min, then slowly warmed to ambient temperature. The mixture was quenched with a saturated aqueous NaHCO3solution (50 mL). The aqueous layer was separated and extracted with DCM (50 mL). The combined organic extracts were dried (MgSO4), filtered, and concentrated in vacuo to give methyl 4- ((2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2- carboxamido)nicotinate (530 mg, 96%) as a brown waxy solid.1H NMR (400 MHz, DMSO-d6) δ 11.72 (s, 1H), 9.07 (s, 1H), 8.62 (d, J = 5.9 Hz, 1H), 8.44 (d, J = 5.8 Hz, 1H), 7.37 (ddd, J = 8.5, 5.9, 2.1 Hz, 1H), 7.18 (ddd, J = 10.1, 8.9, 7.7 Hz, 1H), 5.30 (d, J = 11.0 Hz, 1H), 4.19 (dd, J = 11.0, 7.5 Hz, 1H), 4.08 (s, 1H), 3.92 (d, J = 2.1 Hz, 3H), 1.71 (s, 3H), 0.95 (d, J = 6.6 Hz, 3H), 0.73 (dd, J = 7.5, 2.5 Hz, 3H) ppm. ESI-MS m / z calc.488.137, found 489.1 (M+1)+; 487.2 (M-1)-; Retention time: 1.05 minutes using LC / MS method C.

[0338] Step 2:

[0339] Methyl 4-((2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5- (trifluoromethyl)tetrahydrofuran-2-carboxamido)nicotinate (530 mg, 1.085 mmol) was dissolved in ammonia (10 mL, 7 M solution in MeOH, 70 mmol) and stirred overnight at ambient temperature. The reaction mixture was concentrated in vacuo. The residue was dissolved in EtOAc and washed with a saturated brine solution. The organic layer was separated, dried (MgSO4), filtered and concentrated in vacuo. Purification by flash chromatography (24 g SiO2, 20 to 100% EtOAc in heptane) followed by preparative reverse phase HPLC (C18X-bridge column from Waters, 47 to 95%MeCN in H2O with 1% ammonium hydroxide) gave 2-((2R,3S,4S,5R)-3-(3,4-difluoro-2- methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-yl)pyrido[4,3-d]pyrimidin-4(1H)- one (46, 180 mg, 35%) as a white solid.1H NMR (400 MHz, Chloroform-d) δ 10.06 (s, 1H), 9.40 (s, 1H), 8.73 (d, J = 5.6 Hz, 1H), 7.30 (d, J = 5.6 Hz, 1H), 7.12 (ddd, J = 8.3, 5.5, 2.2 Hz, 1H), 6.83 (td, J = 9.1, 7.3 Hz, 1H), 5.33 (d, J = 10.9 Hz, 1H), 4.11 (dd, J = 10.9, 8.5 Hz, 1H), 3.90 (d, J = 2.9 Hz, 3H), 2.78 (p, J = 7.8 Hz, 1H), 1.66 (s, 3H), 0.78 (dq, J = 7.6, 2.3 Hz, 3H) ppm. ESI-MS m / z calc.455.127, found 456.1 (M+1)+; 454.1 (M-1)-; Retention time: 0.78 minutes using LC / MS method C. Example 8 2-((2R,3S,4S,5R)-3-(3-Chloro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2- yl)-4-oxo-1,4-dihydro-1,6-naphthyridine-5-carboxamide (47)

[0340] Step 1:

[0341] The starting material, 2-((2R,3S,4S,5R)-3-(3-chloro-2-methoxyphenyl)-4,5-dimethyl-5- (trifluoromethyl)tetrahydrofuran-2-yl)-4-((4-methoxybenzyl)oxy)-1,6-naphthyridine-5-carbonitrile, was prepared using methods similar to those described in Example 1 step 1 followed by Example 3, steps 1 and 2, except that (2R,3S,4S,5R)-3-(3-chloro-2-methoxyphenyl)-4,5-dimethyl-5- (trifluoromethyl)tetrahydrofuran-2-carboxylic acid (Intermediate G) was used as the acid starting material and 2-chloro-4-((4-methoxybenzyl)oxy)-1,6-naphthyridine as the coupling partner in Example 1 step 1.

[0342] The crude residue of 2-((2R,3S,4S,5R)-3-(3-chloro-2-methoxyphenyl)-4,5-dimethyl-5- (trifluoromethyl)tetrahydrofuran-2-yl)-4-((4-methoxybenzyl)oxy)-1,6-naphthyridine-5-carbonitrile was dissolved in DMSO (2 mL). NaOH (285 µL, 6 M aqueous solution, 1.7 mmol) and hydrogen peroxide (350 µL, 30 % w / w solution in water, 3.43 mmol) were added and the mixture was stirred at ambient temperature for 2 h. The mixture was diluted with EtOAc, washed with brine. The organic layer was separated, dried (MgSO4), filtered, and concentrated in vacuo to give 2-((2R,3S,4S,5R)-3-(3- chloro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-yl)-4-((4- methoxybenzyl)oxy)-1,6-naphthyridine-5-carboxamide.

[0343] Step 2:

[0344] To a solution of 2-((2R,3S,4S,5R)-3-(3-chloro-2-methoxyphenyl)-4,5-dimethyl-5- (trifluoromethyl)tetrahydrofuran-2-yl)-4-((4-methoxybenzyl)oxy)-1,6-naphthyridine-5-carboxamidein DCM (2 mL) was added TFA (1 mL, 13 mmol) and the mixture was stirred at ambient temperature for 30 min. Purification by preparative reverse phase HPLC (C18Sunfire column from Waters, 38 to 53% MeCN in H2O with 0.1% trifluoroacetic acid) gave 2-((2R,3S,4S,5R)-3-(3-chloro-2- methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-yl)-4-oxo-1,4-dihydro-1,6- naphthyridine-5-carboxamide (47, 12.2 mg, 4% over 2 steps) as a pale yellow solid.1H NMR (400 MHz, DMSO-d6) δ 11.47 (s, 1H), 8.49 (d, J = 5.8 Hz, 1H), 7.56 (d, J = 5.9 Hz, 1H), 7.42 (s, 1H), 7.22 (q, J = 4.3, 2.8 Hz, 3H), 6.40 (s, 1H), 5.52 (d, J = 11.1 Hz, 1H), 4.22 (dd, J = 11.1, 7.8 Hz, 1H), 2.94 (p, J = 7.5 Hz, 1H), 2.28 (d, J = 2.3 Hz, 3H), 1.73 (s, 3H), 0.77 - 0.70 (m, 3H) ppm; NH pyridone not observed. ESI-MS m / z calc.481.143, found 482.1 (M+1)+; 480.1 (M-1)-; Retention time: 2.71 minutes using LC / MS method A.

[0345] The following compound was made using methods similar to those described in Example 8, except 2-((2R,3S,4S,5R)-3-(3,4-difluoro-2-methylphenyl)-4,5-dimethyl-5- (trifluoromethyl)tetrahydrofuran-2-yl)-4-((4-methoxybenzyl)oxy)-1,6-naphthyridine was used as the starting material:

[0346] The following compound was made using methods similar to those described in Example 8, except that 2-((2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5- (trifluoromethyl)tetrahydrofuran-2-yl)pyrido[4,3-d]pyrimidin-4(1H)-one (46) was used as the starting material in step 1 and step 2 was not required:Example 92-((2R,35.4S,5R)-3-(3,4-Difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-yl)-Ar-methyl-4-oxo-l,4-dihydro-l,6-naphthyridine-5-carboxamide 2,2,2-trifluoroacetate (50)

[0347] Steps 1 and 2:

[0348] An ice-cold mixture of hydrogen peroxide (180 pL. 5.87 mmol) and ethyl 2- oxopropanoate (295 μL, 2.66 mmol) was added to an ice-cold and vigorously stirred suspension of 2- ((2R,3S,45,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2- yl)-l,6-naphthyridin-4(1H)-one (1, 80 mg, 0.18 mmol), FeSO4.7H2O (490 mg, 1.76 mmol) and sulfuric acid (325 μL, 6.10 mmol) in a mixture of DCM (15 mL) and water (1.5 mL). After reaction completion, the mixture was diluted with ice-water (100 mL) and extracted with EtOAc (50 mL x 2). The combined organic extracts were concentrated in vacuo. The residue was dissolved in methylamine (5 mL, 33 % w / w solution in ethanol) and stirred overnight at ambient temperature. The mixture was concentrated in vacuo. Purification by preparative reverse phase HPLC (C18Sunfire column from Waters, 38 to 53% MeCN in H2O with 0.1% trifluoroacetic acid) gave 2-((2R,3S.4S.5R)- 3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-yl)-N-methyl-4- oxo-1, 4-dihydro-l,6-naphthyridine-5-carboxamide 2,2,2-trifluoroacetate (50, 9.0 mg, 8% over 2steps).1H NMR (400 MHz, Chloroform-d) δ 9.23 (s, 1H), 8.72 (s, 2H), 7.20 (s, 1H), 7.07 (s, 1H), 6.81 (q, J = 8.9, 8.3 Hz, 1H), 5.76 (d, J = 10.4 Hz, 1H), 4.20 (t, J = 9.4 Hz, 1H), 3.90 (s, 1H), 3.85 (d, J = 2.7 Hz, 3H), 3.42 (s, 3H), 3.13 (d, J = 3.3 Hz, 3H), 2.84 - 2.74 (m, 1H), 0.89 - 0.77 (m, 3H) ppm. ESI- MS m / z calc.511.153, found 512.2 (M+1)+; 510.2 (M-1)-; Retention time: 2.77 minutes using LC / MS method B. Example 10 2-((2R,3S,4S,5R)-3-(3,4-Difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran- 2-yl)-3-methoxy-1,6-naphthyridin-4(1H)-one (51)

[0349] Step 1:

[0350] Recrystallised NBS (37 mg, 0.21 mmol) was added to a solution of 2-((2R,3S,4S,5R)-3- (3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-yl)-1,6- naphthyridin-4(1H)-one (1, 100 mg, 0.198 mmol) in a mixture of DCM (0.8 mL) and acetic acid (0.4 mL) at 0 °C. The reaction mixture was warmed to ambient temperature. After 20 min, the mixture was diluted with DCM (10 mL) and washed with a half-saturated NaHCO3solution (10 mL). The aqueous layer was extracted with DCM (10 mL). The combined organic extracts were washed with a saturated Na2S2O3solution, dried (MgSO4), filtered, and concentrated in vacuo. Purification by flash chromatography (12 g SiO2, 0 to 20% 3:1 EtOAc:EtOH in heptane) gave 3-bromo-2-((2R,3S,4S,5R)- 3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-yl)-1,6- naphthyridin-4(1H)-one (72 mg, 68%) as a bright yellow solid.1H NMR (400 MHz, DMSO-d6) δ 11.79 (s, 1H), 9.21 (s, 1H), 8.68 (s, 1H), 7.67 (s, 1H), 7.19 (d, J = 9.0 Hz, 1H), 7.09 (s, 1H), 5.93 (d, J = 10.9 Hz, 1H), 4.58 (s, 1H), 3.87 (s, 3H), 3.04 (s, 1H), 1.75 (s, 3H), 0.80 (d, J = 7.6 Hz, 3H) ppm. ESI-MS m / z calc.532.042, found 535.1 (M+1)+; Retention time: 0.77 minutes using LC / MS method C.

[0351] Step 2:

[0352] 3-Bromo-2-((2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5- (trifluoromethyl)tetrahydrofuran-2-yl)-1,6-naphthyridin-4(1H)-one (218 mg, 0.409 mmol) and CuI (85 mg, 0.45 mmol) were suspended in CPME (1.7 mL) and the mixture was purged with nitrogen.NaOMe (0.28 mL, 25 % w / w solution in MeOH) was added and the reaction mixture was heated at 70 °C for 64 h. The mixture was cooled to ambient temperature, diluted with EtOAc, filtered through a plug of Celite®, and concentrated in vacuo. Purification by reverse phase chromatography (C18column, 25 to 50% MeCN in water with 0.1% NH3OH) gave 2-((2R,3S,4S,5R)-3-(3,4-difluoro-2- methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-yl)-3-methoxy-1,6-naphthyridin- 4(1H)-one (51, 98 mg, 49%) as a yellow solid.1H NMR (400 MHz, Methanol-d4) δ 9.37 (s, 1H), 8.58 (s, 1H), 7.69 (s, 1H), 7.15 (ddd, J = 8.2, 5.6, 2.2 Hz, 1H), 6.98 (ddd, J = 10.0, 8.9, 7.6 Hz, 1H), 5.89 (d, J = 11.2 Hz, 1H), 4.42 (dd, J = 11.2, 9.4 Hz, 1H), 3.93 (d, J = 2.5 Hz, 3H), 3.82 (s, 3H), 3.07 - 2.90 (m, 1H), 1.78 (d, J = 1.3 Hz, 3H), 0.89 (dt, J = 7.6, 2.3 Hz, 3H) ppm; NH pyridone not observed. ESI-MS m / z calc.484.142, found 485.3 (M+1)+; 483.3 (M-1)-; Retention time: 0.85 minutes using LC / MS method A.

[0353] The following compound was made by subjecting 2-((2R,3S,4S,5R)-3-(3,4-difluoro-2- methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-yl)-3-methoxy-1,6-naphthyridin- 4(1H)-one (51) to a benzyl protection step followed by the conditions described in Example 3:Example 11 6-((2R,3S,4S,5R)-3-(3,4-Difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran- 2-yl)-8-oxo-5,8-dihydro-1,5-naphthyridine 1-oxide (53)

[0354] Step 1:

[0355] 2-((2R,3S,4S,5R)-3-(3,4-Difluoro-2-methoxyphenyl)-4,5-dimethyl-5- (trifluoromethyl)tetrahydrofuran-2-yl)-1,5-naphthyridin-4(1H)-one (6.7 mg, 0.015 mmol) in DCM (1 mL) was treated with mCPBA (5.2 mg, 0.030 mmol) and stirred at ambient temperature under nitrogen. The mixture was stirred for 16 h, then concentrated in vacuo. Purification by preparative reverse phase HPLC (C18X-bridge column, 47% to 95% MeCN in H2O with 0.1% ammoniumhydroxide) gave 6-((2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5- (trifluoromethyl)tetrahydrofuran-2-yl)-8-oxo-5,8-dihydro-1,5-naphthyridine 1-oxide (53, 3.1 mg, 43%).1H NMR (400 MHz, DMSO-d6) δ 16.74 (s, 1H), 8.61 (d, J = 6.0 Hz, 1H), 8.07 - 7.95 (m, 1H), 7.72 (dd, J = 8.9, 6.1 Hz, 1H), 7.31 (ddd, J = 8.5, 5.9, 2.1 Hz, 1H), 7.23 (s, 1H), 7.11 (ddd, J = 10.1, 8.9, 7.7 Hz, 1H), 5.60 (d, J = 11.0 Hz, 1H), 4.34 (dd, J = 11.1, 7.5 Hz, 1H), 3.90 (d, J = 2.1 Hz, 3H), 2.84 (p, J = 7.5 Hz, 1H), 1.69 (s, 3H), 0.83 - 0.75 (m, 3H) ppm. ESI-MS m / z calc.470.127, found 471.6 (M+1)+; Retention time: 3.75 minutes using LC / MS method A.

[0356] The following compound was made using methods similar to those described in Example 11 except that 2-((2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5- (trifluoromethyl)tetrahydrofuran-2-yl)-4-oxo-1,4-dihydro-1,6-naphthyridine-5-carboxamide (30), was used as the starting material.Example 12 N-(2-((2R,3S,4S,5R)-3-(3,4-Difluoro-2-methoxyphenyl)-4,5-dimethyl-5- (trifluoromethyl)tetrahydrofuran-2-yl)-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)methanesulfonamide

[0357] Step 1:

[0358] 4-(Benzyloxy)-2-((2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5- (trifluoromethyl)tetrahydrofuran-2-yl)-1,6-naphthyridine 6-oxide (154 mg, 0.275 mmol) was dissolved in POCl3(1.0 mL, 10.7 mmol) and the resulting mixture was stirred at ambient temperature for 1 h. The reaction mixture was concentrated in vacuo and diluted with DCM (20 mL). The mixture was poured over a saturated aqueous NaHCO3solution (20 mL) and stirred for 10 min. The aqueous layer was separated and extracted with DCM (2 x 10 mL). The combined organic extracts were washed with brine (10 mL), dried (MgSO4), filtered, and concentrated in vacuo. Purification by flash chromatography (12 g SiO2, 0 to 100% EtOAc in heptane) gave 4-(benzyloxy)-5-chloro-2- ((2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2- yl)-1,6-naphthyridine (91.7 mg, 58%) as a cloudy oil.1H NMR (400 MHz, Chloroform-d) δ 8.36 (d, J = 5.7 Hz, 1H), 7.58 (d, J = 5.7 Hz, 1H), 7.56 - 7.52 (m, 2H), 7.45 - 7.36 (m, 3H), 7.25 - 7.20 (m, 1H), 7.18 (s, 1H), 6.86 - 6.78 (m, 1H), 5.56 (d, J = 10.8 Hz, 1H), 5.45 - 5.35 (m, 2H), 4.02 (dd, J = 10.8, 7.8 Hz, 1H), 3.86 (d, J = 2.6 Hz, 3H), 2.78 (dq, J = 7.8, 7.5 Hz, 1H), 1.66 (s, 3H), 0.88 - 0.84 (m, 3H) ppm.19F NMR (376 MHz, Chloroform-d) δ -74.50, -137.58, -154.81 ppm. ESI-MS m / z calc.578.140, found 579.6 (M+1)+; Retention time: 4.24 minutes using method LC / MS A.

[0359] Step 2:

[0360] 4-(Benzyloxy)-5-chloro-2-((2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5- dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-yl)-1,6-naphthyridine (46 mg, 0.079 mmol), methanesulfonamide (12 mg, 0.13 mmol), Pd(OAc)2(1 mg, 0.004 mmol), Xantphos (5 mg, 0.008mmol), and Cs2CO3(52 mg, 0.16 mmol) were suspended in 1,4-dioxane (500 µL) and heated at 100 °C for 16 h. The reaction mixture was cooled to ambient temperature. Purification by flash chromatography (12 g SiO2, 0 to 100% EtOAc in heptane) gave N-(4-(benzyloxy)-2-((2R,3S,4S,5R)- 3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-yl)-1,6- naphthyridin-5-yl)methanesulfonamide (32 mg, 63%) as a white solid. ESI-MS m / z calc.637.167, found 636.6 (M-1)-; Retention time: 1.16 minutes using LC / MS method C.

[0361] Step 3:

[0362] N-(4-(Benzyloxy)-2-((2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5- (trifluoromethyl)tetrahydrofuran-2-yl)-1,6-naphthyridin-5-yl)methanesulfonamide was dissolved in EtOAc (2 mL) before adding Pd / C (5 mg, 10 % w / w wet, Degussa, 0.005 mmol). N2followed by hydrogen were flushed through the mixture for 5 min each. The mixture was stirred under a hydrogen atmosphere for 1.5 h. N2was flushed through the solution for 5 min and the mixture was filtered using a syringe filter, rinsing with EtOAc. The filtrates were concentrated in vacuo. Purification by reverse phase HPLC (C18X-bridge column, MeCN in H2O with 0.1% ammonium hydroxide) followed by flash chromatography (12 g SiO2, 0 to 100% EtOAc in heptane) gave N-(2-((2R,3S,4S,5R)-3-(3,4- difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-yl)-4-oxo-1,4-dihydro- 1,6-naphthyridin-5-yl)methanesulfonamide (55, 12.0 mg, 27%) as a white solid.1H NMR (400 MHz, DMSO-d6) δ 12.92 (s, 1H), 11.95 (s, 1H), 8.25 (d, J = 6.0 Hz, 1H), 7.27 - 7.20 (m, 2H), 7.19 - 7.11 (m, 1H), 6.51 (s, 1H), 5.48 (d, J = 11.3 Hz, 1H), 4.26 (dd, J = 11.3, 8.2 Hz, 1H), 3.91 (d, J = 2.2 Hz, 3H), 3.41 (s, 3H), 2.91 - 2.82 (m, 1H), 1.70 (s, 3H), 0.78 (d, J = 6.5 Hz, 3H) ppm.19F NMR (376 MHz, DMSO-d6) δ -73.11, -137.75, -154.68 ppm. ESI-MS m / z calc.547.120, found 548.6 (M+1)+; 546.5 (M-1)-; Retention time: 3.27 minutes using LC / MS method A.

[0363] Using a similar procedure, the following compounds were isolated in addition to the product described above:

[0364] 5-Chloro-2-((2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5- (trifluoromethyl)tetrahydrofuran-2-yl)-1,6-naphthyridin-4(1H)-one hydrochloride (56, 2 mg, 2%) was isolated as a white solid.1H NMR (400 MHz, Methanol-d4) δ 8.24 (d, J = 5.6 Hz, 1H), 7.25 (d, J = 5.6 Hz, 1H), 6.91 (dd, J = 9.5, 6.3 Hz, 2H), 6.69 (s, 1H), 6.60 ( d, J = 10.7 H z, 1H), 4.26 ( dd, J = 10.7, 7.6 Hz, 1H), 4.07 (d, J = 2.6 Hz, 3H), 2.89 (p, J = 7.0 Hz , 1H), 1.56 (s, 3H), 0.92 (d t, J = 7.6, 2.5 Hz, 3H) ppm; NH pyridone not observed. ESI-MS m / z calc.488.093, found 489.0 (M+1)+; Retention time: 2.49 minutes using LC / MS method D.

[0365] 2-((2R,3S,4S,5R)-3-(3,4-Difluoro-2-methoxyphenyl)-4,5-dimethyl-5- (trifluoromethyl)tetrahydrofuran-2-yl)-4-oxo-1,4-dihydro-1,6-naphthyridine 6-oxide hydrochloride (57, 3.1 mg, 3%) was isolated as a clear, colourless solid.1H NMR (400 MHz, Methanol-d4) δ 9.05 (d, J = 2.1 Hz, 1H), 8.59 (dd, J = 7.3, 2.1 Hz, 1H), 7.55 (d, J = 7.3 Hz, 1H), 7.03 - 6.89 (m, 2H), 6.55 (d, J = 1.0 Hz, 1H), 5.90 (d, J = 11.0 Hz, 1H), 4.37 (dd, J = 11.0, 8.0 Hz, 1H), 4.08 (d, J = 2.7 Hz, 3H), 2.95 (p, J = 7.7 Hz, 1H), 1.60 (s, 3H), 0.94 (dt, J = 7.6, 2.3 Hz, 3H) ppm; NH pyridone not observed.ESI-MS m / z calc.470.127, found 471.1 (M+1)+; Retention time: 1.86 minutes using LC / MS method D.

[0366] 2-((2R,3S,4S,5R)-3-(3,4-Difluoro-2-methoxyphenyl)-4,5-dimethyl-5- (trifluoromethyl)tetrahydrofuran-2-yl)-5-hydroxy-1,6-naphthyridin-4(1H)-one (58, 2.1 mg).1H NMR (400 MHz, Chloroform-d) δ 12.72 (s, 1H), 9.00 (s, 1H), 7.23 (ddt, J = 9.2, 5.8, 3.0 Hz, 1H), 7.19 (s, 1H), 7.06 (s, 1H), 6.90 - 6.79 (m, 1H), 6.68 (d, J = 7.4 Hz, 1H), 5.51 (d, J = 11.0 Hz, 1H), 4.11 (dd, J = 11.0, 7.7 Hz, 1H), 3.94 (d, J = 2.5 Hz, 3H), 2.82 (p, J = 7.6 Hz, 1H), 1.74 (d, J = 1.1 Hz, 3H), 0.88 (dt, J = 7.4, 2.4 Hz, 3H) ppm. ESI-MS m / z calc.470.127, found 471.1 (M+1)+; 469.2 (M-1); Retention time: 3.38 minutes using LC / MS method B. Example 13 2-((2R,3S,4S,5R)-3-(3,4-Difluoro-2-hydroxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran- 2-yl)-4-oxo-1,4-dihydro-1,6-naphthyridine-5-carboxamide (59)

[0367] Step 1:

[0368] To an ice-cold solution of 2-((2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5- dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-yl)-4-oxo-1,4-dihydro-1,6-naphthyridine-5- carboxamide (50 mg, 0.098 mmol) in DCM (2 mL) was added BBr3(300 µL, 1 M solution in heptane, 0.3 mmol). The mixture was stirred under nitrogen and warmed to ambient temperature. After 19 h, additional BBr3(300 µL, 1 M solution in heptane, 0.3 mmol) was added and the mixture was stirred at ambient temperature for 3 h. The reaction mixture was quenched with brine. The aqueous layer was separated and extracted with DCM. The combined organic extracts were dried (MgSO4), filtered and concentrated in vacuo. Purification by flash chromatography (4 g SiO2, 0 to 44% 3:1 EtOAc:EtOH with 2% NH4OH in heptane) gave 2-((2R,3S,4S,5R)-3-(3,4-difluoro-2-hydroxyphenyl)-4,5-dimethyl- 5-(trifluoromethyl)tetrahydrofuran-2-yl)-4-oxo-1,4-dihydro-1,6-naphthyridine-5-carboxamide (59, 24.4 mg, 49%).1H NMR (500 MHz, Methanol-d4) δ 8.51 (d, J = 6.0 Hz, 1H), 7.71 (d, J = 6.0 Hz, 1H), 7.03 (ddd, J = 8.4, 5.6, 2.2 Hz, 1H), 6.71 (ddd, J = 9.9, 8.8, 7.4 Hz, 1H), 6.31 (s, 1H), 5.54 (d, J = 11.3 Hz, 1H), 4.27 (dd, J = 11.3, 8.3 Hz, 1H), 2.93 (p, J = 7.7 Hz, 1H), 1.71 (s, 3H), 0.90 (dt, J = 7.8, 2.1 Hz, 3H) ppm; NH pyridone and NH2amide not observed. ESI-MS m / z calc.483.122, found 484.6 (M+1)+; Retention time: 2.15 minutes using LC / MS method A.

[0369] The following compound was made using the method described in Example 13, except that, in step 1, 2-((2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4-methoxy-5-methyl-5- (trifluoromethyl)tetrahydrofuran-2-yl)-4-oxo-1,4-dihydro-1,6-naphthyridine-5-carboxamide was used as the starting material in place of 2-((2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl- 5-(trifluoromethyl)tetrahydrofuran-2-yl)-4-oxo-1,4-dihydro-1,6-naphthyridine-5-carboxamide:Example 14 2-((2R,3S,4S,5R)-3-(3,4-difluoro-2-methylphenyl)-4-methoxy-5-methyl-5- (trifluoromethyl)tetrahydrofuran-2-yl)-4-oxo-1,4-dihydro-1,6-naphthyridine-5-carboxylic acid (61)

[0370] Step 1:

[0371] Starting material 2-((2R,3S,4S,5R)-3-(3,4-difluoro-2-methylphenyl)-4-methoxy-5-methyl- 5-(trifluoromethyl)tetrahydrofuran-2-yl)-4-oxo-1,4-dihydro-1,6-naphthyridine-5-carbonitrile was made using methods described in Example 3 except that compound 7 was used as the starting material in step 1 in place of 4-(benzyloxy)-2-((2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl- 5-(trifluoromethyl)tetrahydrofuran-2-yl)-1,6-naphthyridine. Step 3 was omitted.

[0372] NaOH (85 mg, 2.1 mmol) was added in one portion to a stirring solution of 2- ((2R,3S,4S,5R)-3-(3,4-difluoro-2-methylphenyl)-4-methoxy-5-methyl-5- (trifluoromethyl)tetrahydrofuran-2-yl)-4-oxo-1,4-dihydro-1,6-naphthyridine-5-carbonitrile (50 mg, 0.104 mmol) in a mixture of EtOH (0.5 mL) and water (0.1 mL). The reaction mixture was heated to 100 ºC in a sealed vial for 10 min. The mixture was cooled to ambient temperature, quenched by addition of water, and slowly acidified to pH 0 by addition of a 1 M HCl solution. The mixture was extracted with DCM (3 x 10 mL). The combined organic extracts were dried (MgSO4) andconcentrated in vacuo to give 2-((2R,3S,4S,5R)-3-(3,4-difluoro-2-methylphenyl)-4-methoxy-5- methyl-5-(trifluoromethyl)tetrahydrofuran-2-yl)-4-oxo-1,4-dihydro-1,6-naphthyridine-5-carboxylic acid (61, 51 mg, 94%).1H NMR (500 MHz, DMSO-d6) δ 13.07 (s, 1H), 11.63 (s, 1H), 8.52 (d, J = 5.9 Hz, 1H), 7.60 (d, J = 5.9 Hz, 1H), 7.38 - 7.14 (m, 2H), 6.39 (s, 1H), 5.50 (d, J = 11.3 Hz, 1H), 4.25 (d, J = 4.8 Hz, 1H), 4.05 (ddd, J = 21.4, 12.2, 6.0 Hz, 1H), 2.85 (s, 3H), 2.35 (d, J = 2.3 Hz, 3H), 1.70 (s, 3H) ppm.19F NMR (471 MHz, DMSO-d6) δ -73.92, -139.86 - -140.13 (m), -140.83 (d, J = 32.7 Hz). ESI-MS m / z calc.498.121, found 499.0 (M+1)+; 497.0 (M-1)-; Retention time: 2.14 minutes using LC / MS method A. Example 15 2-((3R,4R,6R)-4-(3,4-Difluoro-2-methoxyphenyl)-6-methyl-6-(trifluoromethyl)tetrahydro-2H-pyran- 3-yl)-4-oxo-1,4-dihydro-1,6-naphthyridine-5-carboxamide (62)

[0373] Step 1:

[0374] DMF (38 mg, 40 μL, 0.52 mmol) was added to a stirring solution of (3S,4R,6R)-4-(3,4- difluoro-2-methoxyphenyl)-6-methyl-6-(trifluoromethyl)tetrahydro-2H-pyran-3-carboxylic acid (C - 20a, 1.925 g, 5.434 mmol) in SOCl2(6.5 g, 4 mL, 55 mmol) and the reaction mixture was heated at 60 °C for 1h. The reaction was cooled to ambient temperature, concentrated in vacuo, and the residue was azeotroped with toluene (2 x 10 mL). The residue was dissolved in DCM (54 mL) and the mixture cooled in an ice-bath.1-(4-Aminopyridin-3-yl)ethan-1-one (890 mg, 6.54 mmol) was added, followed by pyridine (1.8 g, 1.8 mL, 22 mmol) and the mixture was warmed up to ambient temperature and stirred for 4 h. The reaction was diluted with EtOAc (100 mL). The organic phase was separated, washed with a saturated NH4Cl solution (40 mL), a NaHCO3solution (40 mL) and a half-saturated brine solution (40 mL), dried (Na2SO4), filtered and concentrated in vacuo to give (3S,4R,6R)-N-(3-acetylpyridin-4-yl)-4-(3,4-difluoro-2-methoxyphenyl)-6-methyl-6- (trifluoromethyl)tetrahydro-2H-pyran-3-carboxamide (2.917 g, 100%) as a colourless gum. ESI-MS m / z calc.472.142, found 473.2 (M+1)+; Retention time: 1.04 minutes using LC / MS method P.

[0375] Step 2:

[0376] Et3N (0.045 mL, 0.32 mmol) and TMSOTf (0.12 mL, 0.66 mmol) were successively added to a solution of (3S,4R,6R)-N-(3-acetylpyridin-4-yl)-4-(3,4-difluoro-2-methoxyphenyl)-6-methyl-6-(trifluoromethyl)tetrahydro-2H-pyran-3-carboxamide (50 mg, 0.106 mmol) in DCE (1 mL). The reaction was sealed and heated at 95 °C for 2.5 h. The reaction was cooled to ambient temperature and diluted with 2 N K2CO3(30 mL). The aqueous phase was separated and extracted with DCM. The combined organic layers were dried (MgSO4), filtered and concentrated in vacuo. Purification by flash chromatography (SiO2, 0 to 10% MeOH in DCM) gave 2-((3R,4R,6R)-4-(3,4- difluoro-2-methoxyphenyl)-6-methyl-6-(trifluoromethyl)tetrahydro-2H-pyran-3-yl)-1,6-naphthyridin- 4(1H)-one (48 mg, 94%). ESI-MS m / z calc.454.132, found 455.1 (M+1)+; Retention time: 1.61 minutes using LC / MS method Q.

[0377] Step 3:

[0378] mCPBA (140 mg, 0.625 mmol) was added to a suspension of 2-((3R,4R,6R)-4-(3,4- difluoro-2-methoxyphenyl)-6-methyl-6-(trifluoromethyl)tetrahydro-2H-pyran-3-yl)-1,6-naphthyridin- 4(1H)-one (147.2 mg, 0.324 mmol) in DCM (3.5 mL) and the reaction mixture was stirred at ambient temperature for 4 h. The reaction was partitioned between a saturated aqueous KHCO3solution (40 mL), brine (100 mL) and EtOAc (50 mL). The aqueous layer was separated and extracted with EtOAc (2 x 50 mL). The combined organic layers were dried (Na2SO4), filtered and concentrated in vacuo to give 2-((3R,4R,6R)-4-(3,4-difluoro-2-methoxyphenyl)-6-methyl-6-(trifluoromethyl)tetrahydro-2H- pyran-3-yl)-4-oxo-1,4-dihydro-1,6-naphthyridine 6-oxide (72 (below), 173.3 mg, 100%) as a brown solid, which was used without further purification in the next step. ESI-MS m / z calc.470.127, found 471.1 (M+1)+; Retention time: 1.99 minutes using LC / MS method S.

[0379] Step 4:

[0380] TMSCN (13.0 mL, 97.5 mmol) and dimethylcarbamyl chloride (9.0 mL, 97.8 mmol) were successively added to a stirring solution of 2-((3R,4R,6R)-4-(3,4-difluoro-2-methoxyphenyl)-6- methyl-6-(trifluoromethyl)tetrahydro-2H-pyran-3-yl)-4-oxo-1,4-dihydro-1,6-naphthyridine 6-oxide (72 (below), 23 g, 48.9 mmol) in DCM (230 mL) and the cloudy solution was stirred at ambient temperature for 14h. Additional dimethylcarbamyl chloride (2.25 mL, 24.4 mmol) was added and the mixture was stirred at ambient temperature for a further 24 h. KHCO3(230 mL, 1 M aqueous solution, 230 mmol) was added and the reaction was stirred at ambient temperature for 15 min. Most of the DCM was removed in vacuo at 30 °C and the suspension was filtered, washing the solid with water. The solid was suspended in a mixture of DCM (250 mL) and EtOH (250 mL) to give a yellow orange solution. Most of the DCM was removed in vacuo at 70 - 80 °C. The resulting suspension was stirred at ambient temperature for 30 min, filtered, washed with EtOH and dried in a vacuum oven at 40 °C with a nitrogen bleed over the weekend to give 2-((3R,4R,6R)-4-(3,4-difluoro-2- methoxyphenyl)-6-methyl-6-(trifluoromethyl)tetrahydro-2H-pyran-3-yl)-4-oxo-1,4-dihydro-1,6- naphthyridine-5-carbonitrile (70 (below), 19.3 g, 82%) as an off-white solid.1H NMR (400 MHz, DMSO-d6) δ 12.02 (s, 1H), 8.66 (d, J = 5.8 Hz, 1H), 7.65 (d, J = 5.8 Hz, 1H), 7.21 (ddd, J = 8.3, 5.9, 2.0 Hz, 1H), 7.17 - 7.00 (m, 1H), 6.38 (s, 1H), 4.10 (dd, J = 11.5, 4.3 Hz, 1H), 4.04 - 3.80 (m, 5H),3.39 - 3.33 (m, 1H), 2.00 - 1.78 (m, 2H), 1.68 (s, 3H) ppm. ESI-MS m / z calc.479.127, found 480.4 (M+1)+; Retention time: 2.26 minutes using LC / MS method Q.

[0381] Step 5:

[0382] TFA (212 mL, 2.75 mol) was added to a stirring suspension of 2-((3R,4R,6R)-4-(3,4- difluoro-2-methoxyphenyl)-6-methyl-6-(trifluoromethyl)tetrahydro-2H-pyran-3-yl)-4-oxo-1,4- dihydro-1,6-naphthyridine-5-carbonitrile (70 (below), 21.2 g, 44.2 mmol) in toluene (212 mL) and the resulting solution was heated to reflux for 23 h. The mixture was concentrated in vacuo and co- evaporated with toluene (2 x). The residue was partitioned between 2-MeTHF (250 mL) and a saturated NaHCO3solution (250 mL) and the mixture stirred in a warm water bath for 3 h. The organic phase was separated and washed with a saturated NaHCO3solution (200 mL) and brine (200 mL). The aqueous phases were back-extracted with 2-MeTHF (200 mL) and the combined organic phases were dried, filtered and concentrated in vacuo. Purification by recrystallisation from DCM and EtOH gave 2-((3R,4R,6R)-4-(3,4-difluoro-2-methoxyphenyl)-6-methyl-6-(trifluoromethyl)tetrahydro- 2H-pyran-3-yl)-4-oxo-1,4-dihydro-1,6-naphthyridine-5-carboxamide (62, 22.48 g, 94%) as a colourless solid.1H NMR (400 MHz, DMSO-d6) δ 11.60 (s, 1H), 8.43 (d, J = 5.8 Hz, 1H), 7.51 - 7.28 (m, 2H), 7.30 - 7.13 (m, 2H), 7.08 (q, J = 9.1 Hz, 1H), 6.21 (s, 1H), 4.07 (dd, J = 11.6, 4.3 Hz, 1H), 4.02 - 3.80 (m, 5H), 3.31 - 3.19 (m, 1H), 1.95 - 1.75 (m, 2H), 1.68 (s, 3H) ppm. ESI-MS m / z calc. 497.137, found 498.5 (M+1)+; Retention time: 1.91 minutes using LC / MS method Q.

[0383] The following compounds were made using methods similar to those described in Example 15, except that different coupling partners were used in step 1. In step 1, both the activation and the amide coupling were carried out at ambient temperature. Cyanation step 4 was carried out using conditions similar to those described in Example 17 step 4. In the case of 64, the product of step 5 was further purified by chiral SFC using a LuxTMCellulose-4 column, 5 µm particle size, 25 cm x 21.2 mm from Phenomenex Inc. (Mobile phase: 40% MeOH (supplemented with 20 mM ammonia), 60% CO2; Flow rate 75 mL / min) to give Second Eluting Isomer 64 (rt = 6.55 minutes):

[0384] The following compounds were made using methods similar to those described in Example 15, except that different coupling partners were used in step 1. In step 1, both the activation and the amide coupling were carried out at ambient temperature. Cyclisation step 2 was carried out in toluene as the solvent. Cyanation step 4 was carried out using conditions similar to those described in Example 17 step 4:

[0385] The following compound was made using methods similar to those described in Example 15, except that a different coupling partner was used in step 1 and the amide coupling was carried out at ambient temperature. Cyanation step 4 was carried out using conditions similar to those described in Example 17 step 4:

[0386] The following compounds were made using methods similar to those described in Example 15, except that a different coupling partner was used in step 1 and the amide coupling was carried out at ambient temperature. Cyclisation step 2 was carried out in toluene as the solvent. Cyanation step 4 was carried out using conditions similar to those described in Example 17 step 4. In the case of compound 68, the product of step 5 was further purified by chiral SFC using a LuxTMCellulose-4 column, 5 μm particle size, 25 cm x 21.2 mm from Phenomenex Inc. (Mobile phase: 38%MeOH (supplemented with 20 mM ammonia), 62% CO2; Flow rate 74 mL / min) to give Second Eluting Isomer 68 (rt = 7.53 minutes):

[0387] The following compound was made using methods similar to those described in Example 15, except that step 5 was not required:

[0388] The following compound was made using methods similar to those described in Example 15, except that steps 3 to 5 were not required:

[0389] The following compound was made using methods similar to those described in Example 15, except that steps 4 and 5 were not required:

[0390] The following compounds were made using methods similar to those described in Example 15, except that a different coupling partner was used in step 1. In step 1, both the activation and the amide coupling steps were carried out from 0 °C to ambient temperature using conditions similar to those described in Example 16 step 1. N-Oxide formation step 3 was carried out from 0 °C to ambient temperature. Cyanation step 4 was carried out from 0 °C to ambient temperature using conditions similar to those described in Example 17 step 4. In the case of compound 73, the product of step 5 was further purified by chiral SFC using a LuxTMCellulose-4 column, 5 µm particle size, 25 cm x 21.2 mm from Phenomenex Inc. (Mobile phase: 40% MeOH (supplemented with 0.1 % DEA), 60% CO2; Flow rate 60 mL / min) to give First Eluting Isomer 73 (rt = 6.40 minutes). In the case of compound 74, the product of step 5 was further purified by chiral SFC using a LuxTMCellulose-4 column, 5 µm particle size, 25 cm x 21.2 mm from Phenomenex Inc. (Mobile phase: 45% MeOH(supplemented with 0.1 % DEA), 55% CO2; Flow rate 65 mL / min) to give First Eluting Isomer 74 (rt = 7.22 minutes):Example 16 2-((3R,4R,6R)-4-(3,4-Difluoro-2-methylphenyl)-6-methyl-6-(trifluoromethyl)tetrahydro-2H-pyran-3- yl)-4-oxo-1,4-dihydro-1,6-naphthyridine-5-carboxamide (75)

[0391] Step 1:

[0392] Oxalyl chloride (122 mL, 1.40 mol) was added over 45 min to a solution of (3S,4R,6R)-4- (3,4-difluoro-2-methylphenyl)-6-methyl-6-(trifluoromethyl)tetrahydro-2H-pyran-3-carboxylic acid (C - 20b, 451.2 g, 1.334 mol) and DMF (5.2 mL, 67 mmol) in DCM (3.4 L) and the reaction mixture was stirred at ambient temperature for 3 h. The mixture was cooled to 5 °C and added to a suspension of1-(4-aminopyridin-3-yl)ethan-1-one (218.0 g, 1.601 mol) and Et3N (651 mL, 4.67 mol) in DCM (3.4 L) at 5 °C using a solvent pump, at such a rate to keep the temperature below 14 °C. The resulting suspension was stirred at ambient temperature overnight. The mixture was poured onto an aqueous KHSO4solution (5.87 L, 1 M aqueous solution, 5.87 mol). The organic phase was separated, washed with KHSO4(4.0 L, 1 M aqueous solution, 4.0 mol) and K2CO3(4.0 L, 1 M aqueous solution, 4.0 mol), dried (MgSO4), filtered and concentrated in vacuo. Purification by recrystallisation from EtOH gave (3S,4R,6R)-N-(3-acetylpyridin-4-yl)-4-(3,4-difluoro-2-methylphenyl)-6-methyl-6- (trifluoromethyl)tetrahydro-2H-pyran-3-carboxamide (565 g, 91%).1H NMR (400 MHz, DMSO-d6) δ 11.39 (s, 1H), 9.05 (s, 1H), 8.55 (d, J = 5.8 Hz, 1H), 8.08 (d, J = 5.7 Hz, 1H), 7.34 (dd, J = 8.8, 3.0 Hz, 1H), 7.20 (q, J = 9.0 Hz, 1H), 4.21 (dd, J = 11.7, 4.5 Hz, 1H), 3.86 (t, J = 11.2 Hz, 1H), 3.65 - 3.49 (m, 1H), 3.29 (dd, J = 11.0, 4.6 Hz, 1H), 2.60 (s, 3H), 2.30 (s, 3H), 1.88 - 1.74 (m, 2H), 1.57 (s, 3H) ppm. ESI-MS m / z calc.456.147, found 457.5 (M+1)+; Retention time: 2.24 minutes using LC / MS method Q.

[0393] Step 2:

[0394] TMSOTf (2.38 mL, 13.2 mmol) was added to a stirring solution of (3S,4R,6R)-N-(3- acetylpyridin-4-yl)-4-(3,4-difluoro-2-methylphenyl)-6-methyl-6-(trifluoromethyl)tetrahydro-2H- pyran-3-carboxamide (1 g, 2.2 mmol) and Et3N (932 µL, 6.69 mmol) in toluene (10 mL) at ambient temperature, causing an exotherm to 30 °C. The reaction mixture was heated at 110 °C for 20 h. The mixture was poured onto K2CO3(10 mL, 2 M aqueous solution, 20 mmol) and stirred at ambient temperature for 2 h. The gelatinous mixture was filtered and washed with water and toluene. Purification by reverse phase chromatography (C18column, 5 to 100% MeCN in water) gave 2- ((3R,4R,6R)-4-(3,4-difluoro-2-methylphenyl)-6-methyl-6-(trifluoromethyl)tetrahydro-2H-pyran-3-yl)- 1,6-naphthyridin-4(1H)-one (757 mg, 77%) as a cream solid.1H NMR (400 MHz, DMSO-d6) δ 11.69 (s, 1H), 9.04 (s, 1H), 8.54 (d, J = 5.9 Hz, 1H), 7.41 - 7.28 (m, 1H), 7.28 - 7.09 (m, 2H), 6.32 (s, 1H), 4.11 (dd, J = 11.6, 4.3 Hz, 1H), 3.97 (t, J = 11.2 Hz, 1H), 3.79 (td, J = 12.1, 3.6 Hz, 1H), 3.36 (dt, J = 11.6, 5.7 Hz, 1H), 2.31 (d, J = 2.5 Hz, 3H), 1.89 (dd, J = 13.2, 3.6 Hz, 1H), 1.71 (s, 4H) ppm. ESI- MS m / z calc.438.137, found 439.4 (M+1)+; Retention time: 1.82 minutes using LC / MS method Q.

[0395] Step 3:

[0396] mCPBA (85.4 mg, 0.381 mmol) was added to a suspension of 2-((3R,4R,6R)-4-(3,4- difluoro-2-methylphenyl)-6-methyl-6-(trifluoromethyl)tetrahydro-2H-pyran-3-yl)-1,6-naphthyridin- 4(1H)-one (84 mg, 0.191 mmol) in DCM (2 mL) and the reaction mixture was stirred at ambient temperature for 19.5 h. The mixture was partitioned between a saturated aqueous NaHCO3solution (30 mL) and EtOAc (20 mL). The aqueous layer was separated and extracted with EtOAc (20 mL). The combined organic extracts were washed with brine (30 mL), dried (Na2SO4), filtered and concentrated in vacuo to give 2-((3R,4R,6R)-4-(3,4-difluoro-2-methylphenyl)-6-methyl-6- (trifluoromethyl)tetrahydro-2H-pyran-3-yl)-4-oxo-1,4-dihydro-1,6-naphthyridine 6-oxide (116 mg,100%) as an amber oil, which was used without further purification in the next step. ESI-MS m / z calc. 454.132, found 455.2 (M+1)+; Retention time: 1.97 minutes using LC / MS method S.

[0397] Step 4:

[0398] TMSCN (372 µL, 2.79 mmol) and dimethylcarbamyl chloride (257 µL, 2.79 mmol) were successively added to a suspension of 2-((3R,4R,6R)-4-(3,4-difluoro-2-methylphenyl)-6-methyl-6- (trifluoromethyl)tetrahydro-2H-pyran-3-yl)-4-oxo-1,4-dihydro-1,6-naphthyridine 6-oxide (610 mg, 1.27 mmol) in DCM (6 mL) and the reaction mixture was stirred at ambient temperature for 24 h. The reaction was quenched by addition of a 1 M aqueous KHCO3solution (6 mL) and the mixture was stirred at ambient temperature for 5 min. DCM was distilled off in vacuo at 40 °C. The suspension was stirred at ambient temperature for 20 min, filtered, washed with water and dried to give 2- ((3R,4R,6R)-4-(3,4-difluoro-2-methylphenyl)-6-methyl-6-(trifluoromethyl)tetrahydro-2H-pyran-3-yl)- 4-oxo-1,4-dihydro-1,6-naphthyridine-5-carbonitrile (70 (above), 588 mg, 90%) as a cream solid. ESI- MS m / z calc.463.132, found 464.4 (M+1)+; Retention time: 2.28 minutes using LC / MS method Q.

[0399] Step 5:

[0400] TFA (105 mL, 1.36 mol) was added to a stirring solution of 2-((3R,4R,6R)-4-(3,4- difluoro-2-methylphenyl)-6-methyl-6-(trifluoromethyl)tetrahydro-2H-pyran-3-yl)-4-oxo-1,4-dihydro- 1,6-naphthyridine-5-carbonitrile (70 (above), 10.5 g, 21.5 mmol) in toluene (105 mL) and the solution was heated at reflux for 19 h. The reaction was concentrated in vacuo and co-evaporated with toluene (2 x). The residue was partitioned between 2-MeTHF (100 mL) and a saturated NaHCO3solution (100 mL) and the emulsion was stirred at 40 to 45 °C for 1.5 h. The organic phase was separated and washed with a saturated NaHCO3solution (100 mL) and brine (100 mL). The combined aqueous phases were back-extracted with 2-MeTHF (200 mL). The combined organic phases were dried, filtered and concentrated in vacuo. Purification by recrystallisation from EtOH followed by purification by chiral SFC using a Chiralpak®IC column, 5 μm particle size, 25 cm x 20 mm from Daicel Corporation (Mobile phase: 40% MeOH (supplemented with 0.1% ammonia), 60% CO2; Flow rate 100 mL / min) gave 2-((3R,4R,6R)-4-(3,4-difluoro-2-methylphenyl)-6-methyl-6- (trifluoromethyl)tetrahydro-2H-pyran-3-yl)-4-oxo-1,4-dihydro-1,6-naphthyridine-5-carboxamide (75, 8.2 g, 79%) as an off-white solid.1H NMR (400 MHz, DMSO-d6) δ 11.63 (s, 1H), 8.43 (d, J = 5.8 Hz, 1H), 7.47 - 7.29 (m, 2H), 7.18 (dt, J = 10.0, 5.0 Hz, 3H), 6.30 (s, 1H), 4.16 - 4.03 (m, 1H), 3.95 (t, J = 11.2 Hz, 1H), 3.88 - 3.70 (m, 1H), 3.39 - 3.33 (m, 1H), 2.31 (d, J = 2.3 Hz, 3H), 1.89 (dd, J = 13.0, 3.5 Hz, 1H), 1.71 (s, 4H) ppm. ESI-MS m / z calc.481.143, found 482.6 (M+1)+; Retention time: 1.93 minutes using LC / MS method Q.

[0401] The following compound was made using methods similar to those described in Example 16, except that steps 4 and 5 were not required:Example 17 2-((3R,4R,6R)-4-(4-Fluoro-2-methoxyphenyl)-6-methyl-6-(trifluoromethyl)tetrahydro-2H-pyran-3- yl)-4-oxo-1,4-dihydro-1,6-naphthyridine-5-carboxamide (77)

[0402] Step 1:

[0403] HATU (1.8 g, 4.7 mmol) was added to a solution of (3S,4R,6R)-4-(4-fluoro-2- methoxyphenyl)-6-methyl-6-(trifluoromethyl)tetrahydro-2H-pyran-3-carboxylic acid (C - 20e, 1.335 g, 3.970 mmol), 1-(4-aminopyridin-3-yl)ethan-1-one hydrochloride (822 mg, 4.76 mmol) and DIPEA (2.2 mL, 12.6 mmol) in DMF (36 mL) and the reaction was stirred at ambient temperature for 75 min. The mixture was diluted with EtOAc, washed with water and brine. The organic layer was dried (Na2SO4), filtered and concentrated in vacuo. Purification by flash chromatography (0 to 60% EtOAc in hexanes) gave (3S,4R,6R)-N-(3-acetylpyridin-4-yl)-4-(4-fluoro-2-methoxyphenyl)-6-methyl-6- (trifluoromethyl)tetrahydro-2H-pyran-3-carboxamide (1.80 g, 100%) as a sticky, light yellow solid.1H NMR (400 MHz, Chloroform-d) δ 11.60 (s, 1H), 9.01 (s, 1H), 8.52 (d, J = 5.8 Hz, 1H), 8.46 (d, J = 5.9 Hz, 1H), 7.13 (dd, J = 8.5, 6.5 Hz, 1H), 6.62 - 6.45 (m, 2H), 4.18 - 4.07 (m, 1H), 4.00 (t, J = 11.4 Hz, 1H), 3.81 (s, 3H), 3.68 - 3.57 (m, 1H), 3.22 - 3.10 (m, 1H), 2.64 (s, 3H), 2.24 (t, J = 13.2 Hz, 1H),1.73 (dd, J = 13.2, 4.0 Hz, 1H), 1.60 (s, 3H) ppm. ESI-MS m / z calc.454.152, found 455.3 (M+1)+; Retention time: 1.94 minutes using LC / MS method Q.

[0404] Step 2:

[0405] KOtBu (1.03 g, 9.18 mmol) was added to a stirring solution of (3S,4R,6R)-N-(3- acetylpyridin-4-yl)-4-(4-fluoro-2-methoxyphenyl)-6-methyl-6-(trifluoromethyl)tetrahydro-2H-pyran- 3-carboxamide (1.8 g, 4.0 mmol) in 1,4-dioxane (35 mL) and the reaction mixture was stirred at 100 °C for 17 h under a nitrogen atmosphere. The reaction was cooled to ambient temperature and the mixture was partitioned between a saturated aqueous NH4Cl solution and EtOAc. The aqueous layer was separated and extracted with EtOAc (2x). The combined organic extracts were dried (Na2SO4), filtered and concentrated in vacuo. Purification by flash chromatography (SiO2, 0 to 10% MeOH in DCM) gave 2-((3R,4R,6R)-4-(4-fluoro-2-methoxyphenyl)-6-methyl-6-(trifluoromethyl)tetrahydro- 2H-pyran-3-yl)-1,6-naphthyridin-4(1H)-one (90 (below), 620 mg, 36%) as a light yellow solid.1H NMR (400 MHz, DMSO-d6) δ 11.64 (s, 1H), 9.04 (s, 1H), 8.55 (d, J = 5.8 Hz, 1H), 7.37 (d, J = 5.9 Hz, 1H), 7.30 (dd, J = 8.5, 6.8 Hz, 1H), 6.80 (dd, J = 11.4, 2.6 Hz, 1H), 6.66 (td, J = 8.5, 2.5 Hz, 1H), 6.16 (s, 1H), 4.13 - 4.03 (m, 1H), 3.98 - 3.83 (m, 2H), 3.77 (s, 3H), 3.32 - 3.28 (m, 1H), 2.02 - 1.87 (m, 1H), 1.86 - 1.75 (m, 1H), 1.66 (s, 3H) ppm. ESI-MS m / z calc.436.141, found 437.3 (M+1)+; Retention time: 1.14 minutes using LC / MS method D.

[0406] Step 3:

[0407] mCPBA (466 mg, 2.70 mmol) was added to a solution of 2-((3R,4R,6R)-4-(4-fluoro-2- methoxyphenyl)-6-methyl-6-(trifluoromethyl)tetrahydro-2H-pyran-3-yl)-1,6-naphthyridin-4(1H)-one (90 (below), 592 mg, 1.36 mmol) in DCM (15 mL) and the reaction mixture was stirred at ambient temperature for 2h. The reaction was partitioned between a saturated aqueous KHCO3solution, brine and EtOAc. The aqueous layer was separated and extracted with EtOAc (3 x). The combined organic extracts were dried (Na2SO4), filtered and concentrated in vacuo to give 2-((3R,4R,6R)-4-(4-fluoro-2- methoxyphenyl)-6-methyl-6-(trifluoromethyl)tetrahydro-2H-pyran-3-yl)-4-oxo-1,4-dihydro-1,6- naphthyridine 6-oxide (612 mg, 100%) as a light brown solid. ESI-MS m / z calc.452.136, found 453.2 (M+1)+; Retention time: 1.24 minutes using LC / MS method D.

[0408] Step 4:

[0409] Et3N (2.9 mL, 21 mmol) and TMSCN (1.8 mL, 13.5 mmol) were successively added to a stirring solution of 2-((3R,4R,6R)-4-(4-fluoro-2-methoxyphenyl)-6-methyl-6- (trifluoromethyl)tetrahydro-2H-pyran-3-yl)-4-oxo-1,4-dihydro-1,6-naphthyridine 6-oxide (612 mg) in DCM (20 mL) and the reaction mixture was stirred at ambient temperature for 18 h. The mixture was partitioned between a saturated aqueous NaHCO3solution and EtOAc. The aqueous layer was separated and extracted with EtOAc (2x). The combined organic extracts were washed with brine and water, dried (Na2SO4), filtered and concentrated in vacuo. Purification by flash chromatography (SiO2, 0 to 100% EtOAc in hexanes) gave 2-((3R,4R,6R)-4-(4-fluoro-2-methoxyphenyl)-6-methyl-6- (trifluoromethyl)tetrahydro-2H-pyran-3-yl)-4-oxo-1,4-dihydro-1,6-naphthyridine-5-carbonitrile (317mg, 51%) as a white solid.1H NMR (400 MHz, DMSO-d6) δ 12.05 (s, 1H), 8.64 (d, J = 5.8 Hz, 1H), 7.65 (d, J = 5.8 Hz, 1H), 7.29 (dd, J = 8.6, 6.7 Hz, 1H), 6.80 (dd, J = 11.4, 2.5 Hz, 1H), 6.66 (td, J = 8.4, 2.5 Hz, 1H), 6.28 (s, 1H), 4.06 (dd, J = 11.5, 4.4 Hz, 1H), 3.96 - 3.86 (m, 2H), 3.77 (s, 4H), 1.96 - 1.86 (m, 1H), 1.79 (dd, J = 12.9, 3.7 Hz, 1H), 1.65 (s, 3H) ppm. ESI-MS m / z calc.461.136, found 462.3 (M+1)+; Retention time: 1.45 minutes using LC / MS method D.

[0410] Step 5:

[0411] Water (20 µL, 1.1 mmol) and TFA (16 mL, 208 mmol) were successively added to a suspension of 2-((3R,4R,6R)-4-(4-fluoro-2-methoxyphenyl)-6-methyl-6-(trifluoromethyl)tetrahydro- 2H-pyran-3-yl)-4-oxo-1,4-dihydro-1,6-naphthyridine-5-carbonitrile (312 mg, 0.676 mmol) in toluene (18 mL) and the reaction mixture was stirred at 70 °C for 16 h. The reaction mixture was cooled to ambient temperature and concentrated in vacuo. The residue was dissolved in EtOAc and washed with a saturated aqueous NaHCO3solution. The aqueous layer was extracted with EtOAc (2x). The combined organic extracts were dried (Na2SO4), filtered and concentrated in vacuo. Purification by reverse phase chromatography (C18column, 1 to 99% MeCN in 5 mM aqueous HCl) gave 2- ((3R,4R,6R)-4-(4-fluoro-2-methoxyphenyl)-6-methyl-6-(trifluoromethyl)tetrahydro-2H-pyran-3-yl)-4- oxo-1,4-dihydro-1,6-naphthyridine-5-carboxamide (77, 265.5 mg, 80%) as an off-white solid.1H NMR (400 MHz, DMSO-d6) δ 11.60 (s, 1H), 8.43 (d, J = 5.8 Hz, 1H), 7.47 - 7.33 (m, 2H), 7.30 (t, J = 7.7 Hz, 1H), 7.19 (s, 1H), 6.85 - 6.77 (m, 1H), 6.71 - 6.62 (m, 1H), 6.13 (s, 1H), 4.09 - 4.00 (m, 2H), 3.90 (t, J = 11.0 Hz, 2H), 3.79 (s, 3H), 1.96 - 1.88 (m, 1H), 1.84 - 1.76 (m, 1H), 1.65 (s, 3H) ppm. ESI-MS m / z calc.479.147, found 480.3 (M+1)+; Retention time: 1.77 minutes using LC / MS method Q.

[0412] The following compounds were made using methods similar to those described in Example 17, except that different coupling partners were used in step 1:

[0413] The following compounds were made using methods similar to those described in Example 17, except that different coupling partners were used in step 1. Step 5 was carried out in absence of water. In the case of compound 86, hydrolysis step 5 was carried out at 60 °C:

[0414] The following compound was made using methods similar to those described in Example 17, except that a different coupling partner was used in step 1. Cyanation step 4 was carried out using DIPEA as the base in place of Et3N. Step 5 was carried out in absence of water:

[0415] The following compounds were made using methods similar to those described in Example 17, except that steps 3 to 5 were not required. In the case of compound 89, a different coupling partner was used in step 1:

[0416] The following compound was made using methods similar to those described in Example 17, except that a different coupling partner was used in step 1. Step 5 was not required:

[0417] The following compound was made using methods similar to those described in Example 17 except that step 1 was carried out using conditions similar to those described in Example 15 step 1, using respectively a different coupling partner, 1-(4-aminopyridin-3-yl)propan-1-one hydrochloride and DIPEA in place of (3S,4R,6R)-4-(3,4-difluoro-2-methoxyphenyl)-6-methyl-6- (trifluoromethyl)tetrahydro-2H-pyran-3-carboxylic acid (C - 20a), 1-(4-aminopyridin-3-yl)ethan-1- one hydrochloride and pyridine and both the activation and the amide coupling were carried out at ambient temperature. Step 5 was carried out at 80 °C in absence of water:

[0418] The following compounds were made using methods similar to those described in Example 17, except that different coupling partners were used in step 1. Cyclisation step 2 was carried out using conditions similar to those described in Example 15, step 2. In the case of compound 93, the product of step 5 was further purified by chiral SFC using a LuxTMCellulose-5 column, 5 μm particle size, 25 cm x 30 mm from Phenomenex Inc. (Mobile phase: 40% MeOH, 60% CO2; Flow rate 100 mL / min) to give Second Eluting Isomer 93 (rt = 7.03 minutes). In the case of compound 95, a step was introduced between steps 4 and 5 to separate the diastereomers by chiral SFC using a LuxTMi- Cellulose-5 column, 5 μm particle size, 25 cm x 30 mm from Phenomenex Inc. (Mobile phase: 30% MeOH, 70% CO2; Flow rate 100 mL / min) to give First Eluting Isomer, precursor of 95 (rt = 3.90 minutes):

[0419] The following compounds were made using methods similar to those described in Example 17, except that different coupling partners were used in step 1. Cyclisation step 2 was carried out using conditions similar to those described in Example 16 step 2 and the reaction was respectively carried out at 90 °C in the case of 96 and 99, and at 95 °C in the case of 97 and 98. In the case of 96, the product of step 5 was further purified by chiral SFC using a LuxTMCellulose-2 column, 5 µm particle size, 25 cm x 30 mm from Phenomenex Inc. (Mobile phase: 60% MeOH, 40% CO2; Flow rate 100 mL / min) to give Second Eluting Isomer 96 (rt = 2.12 minutes):

[0420] The following compounds were made using methods similar to those described in Example 17, except that different coupling partners were used in step 1. Cyclisation step 2 was carried out using conditions similar to those described in Example 16 step 2 and the reaction was carried out at 95 °C. Step 5 was carried out in absence of water. The product of step 5 was further purified by chiral SFC using a Chiralpak®IC column, 5 µm particle size, 25 cm x 21.2 mm from Daicel Corporation (Mobile phase: 28% MeOH (supplemented with 20 mM ammonia), 72% CO2; Flow rate 68 mL / min) to give Second Eluting Isomer 100 (rt = 6.20 minutes) and Fourth Eluting Isomer 101 (rt = 9.54 minutes):

[0421] The following compounds were made using methods similar to those described in Example 17, except that different coupling partners were used in step 1 and the reaction was carried out in DCM as the solvent in place of DMF. Cyclisation step 2 was carried out using conditions similar to those described in Example 16 step 2 and the reaction was carried out at 95 °C. Step 5 was carried out in absence of water. In the case of 103 and 104, the product of step 5 was further purified by chiral SFC using a Chiralpak®AD column, 5 µm particle size, 25 cm x 21.2 mm from Daicel Corporation (Mobile phase: 24% MeOH (supplemented with 20 mM ammonia), 76% CO2; Flow rate 70 and 72 mL / min respectively) to give First Eluting Isomer 103 (rt = 2.35 minutes) and First Eluting Isomer 104 (rt = 3.26 minutes). In the case of 105, the product of step 5 was further purified by chiral SFC using a Chiralpak®AD column, 5 µm particle size, 25 cm x 21.2 mm from Daicel Corporation (Mobile phase: 20% MeOH (supplemented with 20 mM ammonia), 80% CO2; Flow rate 70 mL / min) to give First Eluting Isomer 105 (rt = 2.95 minutes). In the case of 106, the product of step 5 was further purified by chiral SFC using a Chiralpak®AD column, 5 µm particle size, 25 cm x 21.2 mm from Daicel Corporation (Mobile phase: 22% MeOH (supplemented with 20 mM ammonia), 78% CO2; Flow rate 70 mL / min) to give First Eluting Isomer 106 (rt = 3.10 minutes). In the case of 107, the product of step 5 was further purified by chiral SFC using a Chiralpak®IG column, 5 µm particle size, 25 cm x 21.2 mm from Daicel Corporation (Mobile phase: 30% MeOH (supplemented with 20 mM ammonia), 70% CO2; Flow rate 70 mL / min) to give First Eluting Isomer 107 (rt = 2.51 minutes):

[0422] The following compound was made using methods similar to those described in Example 17, except that a different coupling partner was used in step 1 and the reaction was carried out in a mixture of DCM and DMF as the solvent. Cyclisation step 2 was carried out using conditions similar to those described in Example 16 step 2 and the reaction was carried out at 95 °C. Steps 3 to 5 were not required:

[0423] The following compounds were made using methods similar to those described in Example 17, except that different coupling partners were used in step 1 and the reaction was carried out in DCM as the solvent in place of DMF. Cyclisation step 2 was carried out using conditions similar to those described in Example 16 step 2 and the reaction was carried out at 95 °C. Hydrolysis step 5 was carried out at 90 °C. In the case of 109, the product of step 5 was further purified by chiral SFC using a Chiralpak®IG column, 5 µm particle size, 25 cm x 21.2 mm from Daicel Corporation (Mobile phase: 24% MeOH (supplemented with 20 mM ammonia), 76% CO2; Flow rate 70 mL / min) to give First Eluting Isomer 109 (rt = 2.75 minutes). In the case of 110, the product of step 5 was further purified by chiral SFC using a (R,R)-Whelk-O®1 column, 5 µm particle size, 25 cm x 21.1 mm from Regis Technologies, Inc. (Mobile phase: 45% MeOH (supplemented with 0.1 % DEA), 55% CO2; Flow rate 70 mL / min) to give Second Eluting Isomer 110 (rt = 5.54 minutes):

[0424] The following compound was made using methods similar to those described in Example 17, except that a different coupling partner was used in step 1 and the reaction was carried out in DCM as the solvent in place of DMF. Cyclisation step 2 was carried out using conditions similar to those described in Example 16 step 2 and the reaction was carried out at 100 °C. Step 5 was carried out in absence of water. The product of step 5 was further purified by chiral SFC using a (R,R)- Whelk-O®1 column, 5 μm particle size, 25 cm x 30 mm from Regis Technologies, Inc. (Mobile phase: 45% MeOH (supplemented with 0.1 % DEA), 55% CO2; Flow rate 70 mL / min) to give Second Eluting Isomer 111 (rt = 3.39 minutes):

[0425] The following compound was made using methods similar to those described in Example 17, except that different coupling partners were used in step 1 and the reaction was carried out in a mixture of DCM and DMF as the solvent. Cyclisation step 2 was carried out using conditions similar to those described in Example 16 step 2 and the reaction was carried out at 95 °C. Hydrolysis step 5 was carried out at 90 °C. The product of step 5 was further purified by chiral SFC using a Chiralpak®AD-H column, 5 μm particle size, 25 cm x 30 mm from Daicel Corporation (Mobile phase: 20%MeOH (supplemented with 0.1 % DEA), 80% CO2; Flow rate 75 mL / min) to give First Eluting Isomer 112 (rt = 2.95 minutes):Example 18 2-((3R,4R,6R)-4-(3,4-Difluoro-2-hydroxyphenyl)-6-methyl-6-(trifluoromethyl)tetrahydro-2H-pyran- 3-yl)-4-oxo-1,4-dihydro-1,6-naphthyridine-5-carboxamide (113)

[0426] Step 1:

[0427] A solution of 2-((3R,4R,6R)-4-(3,4-difluoro-2-methoxyphenyl)-6-methyl-6- (trifluoromethyl)tetrahydro-2H-pyran-3-yl)-4-oxo-1,4-dihydro-1,6-naphthyridine-5-carboxamide (62, 200 mg, 0.402 mmol) and NaI (95 mg, 0.63 mmol) in HBr (1.9 mL, 30 % w / v in AcOH, 7.1 mmol) was stirred at 50 °C for 7 h. The reaction mixture was quenched by addition of water and extracted with EtOAc (3x). The combined organic extracts were washed with a saturated aqueous NaHCO3solution, dried (MgSO4), filtered and concentrated in vacuo. Purification by flash chromatography (SiO2, 0 to 100% EtOAc in hexanes) followed by reverse phase chromatography (C18column, 0 to 40% MeCN in water with HCl) gave 2-((3R,4R,6R)-4-(3,4-difluoro-2-hydroxyphenyl)-6-methyl-6- (trifluoromethyl)tetrahydro-2H-pyran-3-yl)-4-oxo-1,4-dihydro-1,6-naphthyridine-5-carboxamide (113, 67 mg, 34%).1H NMR (400 MHz, Chloroform-d) δ 15.84 (s, 1H), 10.46 (s, 1H), 8.92 (s, 1H), 8.70 (d, J = 5.7 Hz, 1H), 8.19 (d, J = 5.7 Hz, 1H), 6.94 - 6.87 (m, 1H), 6.86 (s, 1H), 6.71 - 6.60 (m, 1H), 6.19 (s, 1H), 4.14 - 3.98 (m, 2H), 3.68 (t, J = 11.5 Hz, 1H), 3.29 (td, J = 11.2, 4.7 Hz, 1H), 2.33(t, J = 13.1 Hz, 1H), 1.83 (dd, J = 13.3, 3.7 Hz, 1H), 1.60 (s, 3H) ppm. ESI-MS m / z calc.483.122, found 484.5 (M+1)+; Retention time: 1.60 minutes using LC / MS method Q. Example 19 2-((3R,4R,6R)-4-(3,4-Difluoro-2-methoxyphenyl)-6-methyl-6-(trifluoromethyl)tetrahydro-2H-pyran- 3-yl)-N-methyl-4-oxo-1,4-dihydro-1,6-naphthyridine-5-carboxamide (114)

[0428] Step 1:

[0429] NaOH (50 mg, 1.25 mmol) was added to a stirring solution of 2-((3R,4R,6R)-4-(3,4- difluoro-2-methoxyphenyl)-6-methyl-6-(trifluoromethyl)tetrahydro-2H-pyran-3-yl)-4-oxo-1,4- dihydro-1,6-naphthyridine-5-carbonitrile (70, 50 mg, 0.10 mmol) in EtOH (1 mL) and the reaction mixture was heated at reflux for 30 min. The reaction was cooled to ambient temperature, diluted with water (10 mL) and acidified to pH 5 by addition of 1 N aqueous HCl. The mixture was extracted with EtOAc (2x). The combined organic extracts were dried (MgSO4), filtered and concentrated in vacuo to give 2-((3R,4R,6R)-4-(3,4-difluoro-2-methoxyphenyl)-6-methyl-6-(trifluoromethyl)tetrahydro-2H- pyran-3-yl)-4-oxo-1,4-dihydro-1,6-naphthyridine-5-carboxylic acid, which was used without further purification in the next step. ESI-MS m / z calc.498.121, found 499.1 (M+1)+; Retention time: 0.60 minutes using LC / MS method T.

[0430] Step 2:

[0431] HATU (50 mg, 0.13 mmol), DIPEA (0.05 mL, 0.29 mmol) and methanamine hydrochloride (7 mg, 0.104 mmol) were successively added to a solution of 2-((3R,4R,6R)-4-(3,4- difluoro-2-methoxyphenyl)-6-methyl-6-(trifluoromethyl)tetrahydro-2H-pyran-3-yl)-4-oxo-1,4- dihydro-1,6-naphthyridine-5-carboxylic acid in DCM (1 mL) and the reaction mixture was stirred at ambient temperature for 1 h. The reaction was diluted with water and the phases were separated. The aqueous phase was extracted with EtOAc. The combined organic layers were washed with brine, dried (MgSO4), filtered and concentrated in vacuo. Purification by flash chromatography (SiO2, 0 to 10% MeOH in DCM) gave 2-((3R,4R,6R)-4-(3,4-difluoro-2-methoxyphenyl)-6-methyl-6- (trifluoromethyl)tetrahydro-2H-pyran-3-yl)-N-methyl-4-oxo-1,4-dihydro-1,6-naphthyridine-5- carboxamide (114, 13.3 mg, 24%).1H NMR (400 MHz, DMSO-d6) δ 11.62 (s, 1H), 8.43 (d, J = 5.8 Hz, 1H), 7.80 (d, J = 5.5 Hz, 1H), 7.36 (d, J = 5.8 Hz, 1H), 7.28 - 7.17 (m, 1H), 7.15 - 7.02 (m, 1H), 6.17 (s, 1H), 4.08 (dd, J = 11.6, 4.3 Hz, 1H), 4.00 - 3.85 (m, 5H), 3.31 - 3.26 (m, 1H), 2.69 (d, J = 4.4Hz, 3H), 1.94 - 1.78 (m, 2H), 1.68 (s, 3H) ppm. ESI-MS m / z calc.511.153, found 512.2 (M+1)+; Retention time: 1.80 minutes using LC / MS method Q. Example 20 2-((3R,4R,6R)-4-(3,4-Difluoro-2-methoxyphenyl)-6-methyl-6-(trifluoromethyl)tetrahydro-2H-pyran- 3-yl)-5-(1,5-dimethyl-1H-1,2,3-triazol-4-yl)-1,6-naphthyridin-4(1H)-one (115)

[0432] Step 1:

[0433] POCl3(3.3 g, 2 mL, 21.5 mmol) was added to a solution of 2-((3R,4R,6R)-4-(3,4- difluoro-2-methoxyphenyl)-6-methyl-6-(trifluoromethyl)tetrahydro-2H-pyran-3-yl)-4-oxo-1,4- dihydro-1,6-naphthyridine 6-oxide (72, 500 mg, 0.964 mmol) in DCM (20 mL) and the reaction mixture was stirred at ambient temperature for 6 h. The reaction was quenched by addition of ice-cold water (20 mL). The mixture was extracted with DCM (2 x 30 mL). The combined organic extracts were washed with water (20 mL) and brine (20 mL), dried (Na2SO4), filtered and concentrated in vacuo. Purification by flash chromatography (SiO2, 2 to 10% MeOH in EtOAc) gave 4-chloro-2- ((3R,4R,6R)-4-(3,4-difluoro-2-methoxyphenyl)-6-methyl-6-(trifluoromethyl)tetrahydro-2H-pyran-3- yl)-1,6-naphthyridine 6-oxide (350 mg, 71%) as an off-white solid.1H NMR (400 MHz, Chloroform- d) δ 8.94 (d, J = 1.8 Hz, 1H), 8.27 (dd, J = 7.3, 2.3 Hz, 1H), 7.79 (d, J = 7.3 Hz, 1H), 7.25 (s, 1H), 6.88 - 6.83 (m, 1H), 6.74 (td, J = 8.9, 7.3 Hz, 1H), 4.11 - 3.98 (m, 3H), 3.88 (d, J = 12.3 Hz, 3H), 3.51 (td, J = 11.1, 4.9 Hz, 1H), 2.05 (t, J = 13.1 Hz, 1H), 1.84 (dd, J = 13.3, 3.7 Hz, 1H), 1.68 (s, 3H) ppm. ESI-MS m / z calc.488.093, found 489.1 (M+1)+; Retention time: 0.98 minutes using LC / MS method P.

[0434] Step 2:

[0435] NaH (30 mg, 60 % w / w in mineral oil, 0.75 mmol) was added to a stirring solution of 4- chloro-2-((3R,4R,6R)-4-(3,4-difluoro-2-methoxyphenyl)-6-methyl-6-(trifluoromethyl)tetrahydro-2H- pyran-3-yl)-1,6-naphthyridine 6-oxide (238 mg, 0.464 mmol) and benzyl alcohol (75 mg, 0.69 mmol) in a mixture of THF (12 mL) and DMF (2 mL) at 0 °C under argon and the mixture was stirred at 0 °C for 2 h. The reaction was quenched by addition of ice-cold water (10 mL) and diluted with water (15 mL). The mixture was extracted with EtOAc (2 x 20 mL). The combined organic extracts were washed with water (20 mL) and brine (20 mL), dried (Na2SO4), filtered and concentrated in vacuo.Purification by flash chromatography (SiO2, 2 to 10% MeOH in EtOAc) gave 4-(benzyloxy)-2- ((3R,4R,6R)-4-(3,4-difluoro-2-methoxyphenyl)-6-methyl-6-(trifluoromethyl)tetrahydro-2H-pyran-3- yl)-1,6-naphthyridine 6-oxide (192 mg, 73%) as a pale yellow solid.1H NMR (400 MHz, Chloroform-d) δ 8.93 (d, J = 1.8 Hz, 1H), 8.22 (dd, J = 7.3, 2.3 Hz, 1H), 7.69 (d, J = 7.3 Hz, 1H), 7.44 - 7.34 (m, 5H), 6.84 - 6.79 (m, 1H), 6.68 (td, J = 9.2, 7.3 Hz, 1H), 6.55 (s, 1H), 5.14 (ABq, J = 11.7 Hz, 2H), 4.07 - 3.97 (m, 3H), 3.83 (d, J = 2.3 Hz, 3H), 3.45 - 3.37 (m, 1H), 2.07 - 2.00 (m, 1H), 1.82 (dd, J = 13.1, 3.9 Hz, 1H), 1.66 (s, 3H) ppm. ESI-MS m / z calc.560.173, found 561.3 (M+1)+; Retention time: 0.57 minutes using LC / MS method P.

[0436] Step 3:

[0437] POCl3(165 mg, 100 μL, 1.07 mmol) was added to a solution of 4-(benzyloxy)-2- ((3R,4R,6R)-4-(3,4-difluoro-2-methoxyphenyl)-6-methyl-6-(trifluoromethyl)tetrahydro-2H-pyran-3- yl)-1,6-naphthyridine 6-oxide (55 mg, 0.098 mmol) in DCM (1 mL) and the reaction mixture was stirred at ambient temperature for 3 h. Additional POCl3(165 mg, 100 μL, 1.07 mmol) was added and the mixture was heated at 50 °C for 2 h. The reaction was cooled to 0 °C and quenched by addition of ice-cold water (5 mL). The mixture was stirred for 15 min then partitioned between water (10 mL) and DCM (20 mL). The organic phase was separated, washed with water (10 mL) and brine (10 mL), dried (Na2SO4), filtered and concentrated in vacuo. Purification by flash chromatography (SiO2, 0 to 50% EtOAc in heptane) gave 4-(benzyloxy)-5-chloro-2-((3R,4R,6R)-4-(3,4-difluoro-2- methoxyphenyl)-6-methyl-6-(trifluoromethyl)tetrahydro-2H-pyran-3-yl)-1,6-naphthyridine (22 mg, 31%). ESI-MS m / z calc.578.140, found 579.3 (M+1)+; Retention time: 1.0 minutes using LC / MS method P.

[0438] Step 4:

[0439] CataCXium®A Pd G3 (6 mg, 0.008 mmol) was added to a stirring mixture of 4- (benzyloxy)-5-chloro-2-((3R,4R,6R)-4-(3,4-difluoro-2-methoxyphenyl)-6-methyl-6- (trifluoromethyl)tetrahydro-2H-pyran-3-yl)-1,6-naphthyridine (21.3 mg, 0.037 mmol), 1,5-dimethyl- 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-1,2,3-triazole (23 mg, 0.10 mmol), KOSiMe3(12 mg, 0.094 mmol) and B(OMe)3(40 µL, 0.35 mmol) in DME (0.5 mL). Argon gas was bubbled through the reaction mixture for 5 min and the reaction was stirred at 85 °C for 1 h. The mixture was cooled to ambient temperature and concentrated in vacuo. Purification by flash chromatography (12 g SiO2, 0 to 100% EtOAc in hexanes) gave 4-(benzyloxy)-2-((3R,4R,6R)-4-(3,4-difluoro-2- methoxyphenyl)-6-methyl-6-(trifluoromethyl)tetrahydro-2H-pyran-3-yl)-5-(1,5-dimethyl-1H-1,2,3- triazol-4-yl)-1,6-naphthyridine as a clear colourless solid, which was used without further purification in the next step.

[0440] Step 5:

[0441] 4-(Benzyloxy)-2-((3R,4R,6R)-4-(3,4-difluoro-2-methoxyphenyl)-6-methyl-6- (trifluoromethyl)tetrahydro-2H-pyran-3-yl)-5-(1,5-dimethyl-1H-1,2,3-triazol-4-yl)-1,6-naphthyridine was added to a stirred mixture of Pd / C (10 mg, 10 % w / w, 0.009 mmol) in EtOH (4 mL). The mixturewas degassed (vacuum / nitrogen cycles x 3) and the atmosphere was replaced by a hydrogen atmosphere (vacuum / hydrogen cycles x 3). The reaction was stirred under a hydrogen atmosphere for 10 min. The mixture was filtered through a pad of Celite®and the mother liquors were concentrated in vacuo. Purification by reverse phase chromatography (Luna C18column, 1 to 100% ACN in water with 5 mM HCl) gave 2-((3R,4R,6R)-4-(3,4-difluoro-2-methoxyphenyl)-6-methyl-6- (trifluoromethyl)tetrahydro-2H-pyran-3-yl)-5-(1,5-dimethyl-1H-1,2,3-triazol-4-yl)-1,6-naphthyridin- 4(1H)-one hydrochloride (115, 12.5 mg, 55% over 2 steps) as a white solid.1H NMR (400 MHz, Methanol-d4) δ 8.60 (d, J = 6.8 Hz, 1H), 8.00 (d, J = 6.8 Hz, 1H), 7.16 (ddd, J = 8.3, 5.6, 2.1 Hz, 1H), 6.93 (td, J = 9.3, 7.4 Hz, 1H), 6.47 (s, 1H), 4.18 (dd, J = 11.7, 4.5 Hz, 1H), 4.09 (s, 3H), 4.09 - 3.93 (m, 5H), 3.38 (td, J = 11.3, 4.5 Hz, 1H), 2.24 (s, 3H), 2.15 - 2.01 (m, 1H), 1.90 (dd, J = 13.3, 3.9 Hz, 1H), 1.71 (s, 3H) ppm. ESI-MS m / z calc.549.180, found 550.0 (M+1)+; Retention time: 1.83 minutes using LC / MS method Q.

[0442] The following compound was made using methods similar to those described in Example 20, except that, in step 4, 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)picolinonitrile was used as the Suzuki coupling partner in place of 1,5-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)- 1H-1,2,3-triazole to form a nitrile, which underwent a nitrile hydration step as outlined below:

[0443] Nitrile hydration to amide: K2CO3(12 mg, 0.087 mmol) and H2O2(200 µL, 6.53 mmol) were successively added to a stirring solution of 6-(2-((3R,4R,6R)-4-(3,4-difluoro-2-methoxyphenyl)- 6-methyl-6-(trifluoromethyl)tetrahydro-2H-pyran-3-yl)-4-oxo-1,4-dihydro-1,6-naphthyridin-5- yl)picolinonitrile (9.6 mg, 0.017 mmol) in DMSO (1 mL) and the reaction mixture stirred at ambient temperature for 10 min. Purification by high pressure reverse phase chromatography (5 cm x 21.2 mm Luna C18column, 1 to 100% MeCN in water with 5 mM HCl) gave 6-(2-((3R,4R,6R)-4-(3,4-difluoro- 2-methoxyphenyl)-6-methyl-6-(trifluoromethyl)tetrahydro-2H-pyran-3-yl)-4-oxo-1,4-dihydro-1,6- naphthyridin-5-yl)picolinamide (116, 1.6 mg, 16%) as a white solid.1H NMR (400 MHz, Methanol- d4) δ 8.53 (d, J = 5.9 Hz, 1H), 8.13 (d, J = 7.8 Hz, 1H), 7.97 (t, J = 7.7 Hz, 1H), 7.55 (d, J = 2.7 Hz, 1H), 7.53 (s, 1H), 7.10 (t, J = 7.2 Hz, 1H), 6.91 (q, J = 8.8 Hz, 1H), 6.19 (s, 1H), 4.13 (dd, J = 11.7, 4.5 Hz, 1H), 4.01 (d, J = 11.3 Hz, 1H), 3.96 (d, J = 2.4 Hz, 3H), 3.94 - 3.87 (m, 1H), 3.30 (s, 1H), 2.04 (t, J = 12.9 Hz, 1H), 1.92 - 1.82 (m, 1H), 1.68 (s, 3H) ppm; exchangeable H not observed. ESI- MS m / z calc.574.164, found 575.5 (M+1)+; Retention time: 1.90 minutes using LC / MS method Q.Example 21 2-((3R,4R,6R)-4-(3,4-Difluoro-2-methoxyphenyl)-6-methyl-6-(trifluoromethyl)tetrahydro-2H-pyran- 3-yl)-5-(1,4-dimethyl-1H-imidazol-2-yl)-1,6-naphthyridin-4(1H)-one (117)

[0444] Step 1:

[0445] PdCl2(PPh3)2(16 mg, 0.023 mmol) was added to a stirred mixture of 4-(benzyloxy)-5- chloro-2-((3R,4R,6R)-4-(3,4-difluoro-2-methoxyphenyl)-6-methyl-6-(trifluoromethyl)tetrahydro-2H- pyran-3-yl)-1,6-naphthyridine (20 mg, 0.035 mmol), 1,4-dimethyl-1H-imidazole (18 mg, 0.19 mmol), CuI (1 mg, 0.005 mmol), Cs2CO3(25 mg, 0.077 mmol) and AgOAc (2 mg, 0.012 mmol) in 1,4- dioxane (330 µL) and the reaction was degassed by bubbling argon gas through the mixture for 5 min. The reaction was heated at 100 °C for 18 h. Purification by high pressure reverse phase chromatography (10 cm x 50 mm SunFire C18column, 1 to 100% MeCN in water) gave 2- ((3R,4R,6R)-4-(3,4-difluoro-2-methoxyphenyl)-6-methyl-6-(trifluoromethyl)tetrahydro-2H-pyran-3- yl)-5-(1,4-dimethyl-1H-imidazol-2-yl)-1,6-naphthyridin-4(1H)-one (117, 4.4 mg, 22%) as a white solid.1H NMR (400 MHz, Methanol-d4) δ 8.78 (d, J = 5.9 Hz, 1H), 7.79 (d, J = 5.9 Hz, 1H), 7.35 (s, 1H), 7.13 (td, J = 6.3, 3.1 Hz, 1H), 6.92 (q, J = 8.9 Hz, 1H), 6.33 (s, 1H), 4.14 (dd, J = 11.7, 4.5 Hz, 1H), 4.07 - 3.86 (m, 5H), 3.54 (s, 3H), 3.36 (dd, J = 11.5, 4.6 Hz, 1H), 2.37 (d, J = 1.1 Hz, 3H), 2.14 - 2.01 (m, 1H), 1.89 (dd, J = 13.2, 3.9 Hz, 1H), 1.70 (s, 3H) ppm; exchangeable H not observed. ESI- MS m / z calc.548.185, found 549.0 (M+1)+; Retention time: 1.77 minutes using LC / MS method Q.Example 22 (S)-1-(2-((3R,4R,6R)-4-(3,4-Difluoro-2-methoxyphenyl)-6-methyl-6-(trifluoromethyl)tetrahydro-2H- pyran-3-yl)-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)pyrrolidine-3-carboxamide (118)

[0446] Step 1:

[0447] K2CO3(8 mg, 0.06 mmol) was added to a stirring solution of 4-(benzyloxy)-5-chloro-2- ((3R,4R,6R)-4-(3,4-difluoro-2-methoxyphenyl)-6-methyl-6-(trifluoromethyl)tetrahydro-2H-pyran-3- yl)-1,6-naphthyridine (9 mg, 0.016 mmol) and (S)-pyrrolidine-3-carboxamide (4 mg, 0.035 mmol) in THF (0.5 mL) and the reaction mixture was heated to 65 °C for 3 h. The mixture was cooled to ambient temperature. Purification by high pressure reverse phase chromatography (5 cm x 21.2 mm Luna C18column, 1 to 100% MeCN in water with 5 mM HCl) gave (S)-1-(4-(benzyloxy)-2- ((3R,4R,6R)-4-(3,4-difluoro-2-methoxyphenyl)-6-methyl-6-(trifluoromethyl)tetrahydro-2H-pyran-3- yl)-1,6-naphthyridin-5-yl)pyrrolidine-3-carboxamide, which was used without further purification in the next step.

[0448] Step 2:

[0449] Pd / C (3 mg, 10 % w / w, 0.028 mmol) was added to a stirring solution of (S)-1-(4- (benzyloxy)-2-((3R,4R,6R)-4-(3,4-difluoro-2-methoxyphenyl)-6-methyl-6- (trifluoromethyl)tetrahydro-2H-pyran-3-yl)-1,6-naphthyridin-5-yl)pyrrolidine-3-carboxamide in EtOH (1mL) and the reaction mixture was stirred under a hydrogen atmosphere for 5 min. The mixture was filtered through a pad of Celite®and the filtrate concentrated in vacuo. Purification by reverse phase chromatography (5 cm x 21.2 mm Luna C18column, 1 to 100% MeCN in water with 5 mM HCl) gave (S)-1-(2-((3R,4R,6R)-4-(3,4-difluoro-2-methoxyphenyl)-6-methyl-6-(trifluoromethyl)tetrahydro-2H- pyran-3-yl)-4-oxo-1,4-dihydro-1,6-naphthyridin-5-yl)pyrrolidine-3-carboxamide (118, 2.6 mg, 29% over 2 steps) as a white solid.1H NMR (400 MHz, Methanol-d4) δ 7.73 (d, J = 7.1 Hz, 1H), 7.15 - 7.06 (m, 1H), 6.93 (q, J = 8.9 Hz, 1H), 6.84 (d, J = 7.2 Hz, 1H), 6.33 (s, 1H), 4.11 (dd, J = 11.8, 4.5 Hz, 1H), 3.99 (s, 3H), 3.97 - 3.85 (m, 2H), 3.85 - 3.74 (m, 2H), 3.65 (dd, J = 11.8, 6.3 Hz, 1H), 3.60 - 3.49 (m, 1H), 3.28 - 3.16 (m, 2H), 2.43 - 2.30 (m, 1H), 2.29 - 2.16 (m, 1H), 2.06 (t, J = 12.9 Hz, 1H), 1.88 (dd, J = 13.2, 3.9 Hz, 1H), 1.68 (s, 3H) ppm; exchangeable H not observed. ESI-MS m / z calc. 566.195, found 567.2 (M+1)+; Retention time: 1.43 minutes using LC / MS method Q.

[0450] The following compound was made using methods similar to those described in Example 22, except that 1-methylpiperazine was used as the nucleophile in place of (S)-pyrrolidine-3- carboxamide:Example 23 2-((3R,4R,6R)-4-(5-Fluoro-6-methylpyridin-2-yl)-6-methyl-6-(trifluoromethyl)tetrahydro-2H-pyran- 3-yl)-4-oxo-1,4-dihydro-1,6-naphthyridine-5-carboxamide (120)

[0451] Step 1:

[0452] 1-(4-Aminopyridin-3-yl)ethan-1-one (425 mg, 3.12 mmol), HATU (1.25 g, 3.29 mmol) and DIPEA (1.04 g, 1.4 mL, 8.04 mmol) were successively added to a solution of dia-(3S1,4R1,6R*)-4- (5-fluoro-6-methylpyridin-2-yl)-6-methyl-6-(trifluoromethyl)tetrahydro-2H-pyran-3-carboxylic acid (C - 20t, 810 mg, 2.49 mmol) in DMF (22 mL) and the reaction mixture was stirred at ambient temperature for 3 h. The reaction was partitioned between EtOAc (50 mL) and water (50 mL). The organic layer was separated, washed with water (20 mL), a half saturated brine solution (2 x 20 mL) and water (2 x 20 mL), dried (Na2SO4), filtered and concentrated in vacuo. Purification by flash chromatography (SiO2, 20 to 70% EtOAc in heptane) gave:

[0453] First Eluting Diastereomer: (3R,4S,6R)-N-(3-acetylpyridin-4-yl)-4-(5-fluoro-6- methylpyridin-2-yl)-6-methyl-6-(trifluoromethyl)tetrahydro-2H-pyran-3-carboxamide (180 mg, 16%) as a colourless oil.1H NMR (400 MHz, Methanol-d4) δ 9.05 (br s, 1H), 8.51 - 8.40 (m, 2H), 7.33 - 7.21 (m, 1H), 7.09 (dd, J = 8.3, 3.7 Hz, 1H), 4.19 - 4.05 (m, 2H), 3.58 - 3.47 (m, 1H), 3.25 - 3.14 (m,1H), 2.66 (s, 3H), 2.46 (d, J = 2.9 Hz, 3H), 2.29 - 2.20 (m, 1H), 2.08 - 1.98 (m, 1H), 1.40 (s, 3H) ppm; exchangeable H not observed. ESI-MS m / z calc.439.152, found 440.1 (M+1)+; Retention time: 3.09 minutes using LC / MS method E.

[0454] Second Eluting Diastereomer: (3S,4R,6R)-N-(3-acetylpyridin-4-yl)-4-(5-fluoro-6- methylpyridin-2-yl)-6-methyl-6-(trifluoromethyl)tetrahydro-2H-pyran-3-carboxamide (584 mg, 53%) as a pink solid.1H NMR (400 MHz, Methanol-d4) δ 9.05 (s, 1H), 8.49 - 8.43 (m, 2H), 7.32 - 7.26 (m, 1H), 7.13 (dd, J = 8.4, 3.5 Hz, 1H), 4.19 - 4.11 (m, 1H), 4.05 - 3.96 (m, 1H), 3.56 - 3.48 (m, 1H), 3.18 (td, J = 11.2, 4.8 Hz, 1H), 2.67 (s, 3H), 2.45 (d, J = 2.9 Hz, 3H), 2.16 (t, J = 13.1 Hz, 1H), 1.85 (dd, J = 13.2, 4.2 Hz, 1H), 1.60 (s, 3H) ppm; exchangeable H not observed. ESI-MS m / z calc.439.152, found 440.1 (M+1)+; Retention time: 3.08 minutes using LC / MS method E.

[0455] Step 2:

[0456] In a vial, Et3N (269 mg, 0.37 mL, 2.66 mmol) and TMSOTf (885 mg, 0.725 mL, 3.98 mmol) were successively added to a solution of (3S,4R,6R)-N-(3-acetylpyridin-4-yl)-4-(5-fluoro-6- methylpyridin-2-yl)-6-methyl-6-(trifluoromethyl)tetrahydro-2H-pyran-3-carboxamide (Second Eluting Diastereomer, 584 mg, 1.33 mmol) in toluene (17 mL). The vial was sealed, and the reaction mixture was stirred at 80 °C for 2.5 h. In 2 separate occasions, additional amounts of Et3N (269 mg, 0.37 mL, 2.66 mmol) and TMSOTf (885 mg, 0.725 mL, 3.98 mmol) were added and the reaction was stirred at 90 °C for a further 2.5 h and 6 h respectively. The mixture was stirred at ambient temperature for an additional 12 h. The reaction was quenched by addition of a 1 N aqueous NaOH solution (15 mL) and diluted with water (25 mL). The reaction was extracted with EtOAc (2 x 75 mL). The combined organic layers were dried (Na2SO4), filtered and concentrated in vacuo. Purification by reverse phase chromatography (5 to 60% MeCN in water with 0.1% formic acid) gave 2-((3R,4R,6R)-4-(5-fluoro-6-methylpyridin-2-yl)-6-methyl-6-(trifluoromethyl)tetrahydro-2H-pyran-3- yl)-1,6-naphthyridin-4(1H)-one (239 mg, 41%) as a brown solid.1H NMR (400 MHz, Methanol-d4) δ 9.21 (s, 1H), 8.53 (d, J = 5.9 Hz, 1H), 7.43 (d, J = 5.9 Hz, 1H), 7.29 (t, J = 8.9 Hz, 1H), 7.13 (dd, J = 8.3, 3.7 Hz, 1H), 6.35 (s, 1H), 4.14 - 4.08 (m, 1H), 3.97 (t, J = 11.5 Hz, 1H), 3.68 (td, J = 12.0, 4.0 Hz, 1H), 3.43 (td, J = 11.5, 4.6 Hz, 1H), 2.41 (d, J = 2.9 Hz, 3H), 2.20 (t, J = 12.8 Hz, 1H), 1.94 (dd, J = 13.3, 3.8 Hz, 1H), 1.68 (s, 3H) ppm; exchangeable H not observed. ESI-MS m / z calc.421.141, found 422.2 (M+1)+; Retention time: 2.51 minutes using LC / MS method E.

[0457] Step 3 and 4:

[0458] mCPBA (150 mg, 0.669 mmol) was added to a solution of 2-((3R,4R,6R)-4-(5-fluoro-6- methylpyridin-2-yl)-6-methyl-6-(trifluoromethyl)tetrahydro-2H-pyran-3-yl)-1,6-naphthyridin-4(1H)- one (139 mg, 0.316 mmol) in DCM (5.5 mL) and the reaction mixture was stirred at ambient temperature for 23 h. An additional amount of mCPBA (60 mg, 0.27 mmol) was added and the reaction mixture was stirred at ambient temperature for a further 4 h. Et3N (196 mg, 0.270 mL, 1.94 mmol) and TMSCN (317 mg, 0.4 mL, 3.2 mmol) were successively added and the mixture was stirred at ambient temperature for 18 h. Additional amounts of Et3N (196 mg, 0.27 mL, 1.94 mmol) andTMSCN (317 mg, 0.4 mL, 3.2 mmol) were added and the mixture was stirred at ambient temperature for 3 h. The mixture was concentrated in vacuo. The residue was diluted with EtOAc (25 mL) and washed with an aqueous saturated NaHCO3solution (3 x 10 mL). The organic layer was dried (Na2SO4), filtered and concentrated in vacuo. Purification by reverse phase chromatography (5 to 50% MeCN in water with 0.1% formic acid) gave 6-((2R,4R,5R)-5-(5-cyano-4-oxo-1,4-dihydro-1,6- naphthyridin-2-yl)-2-methyl-2-(trifluoromethyl)tetrahydro-2H-pyran-4-yl)-3-fluoro-2-methylpyridine 1-oxide (82 mg, 56%) as a pale yellow solid.1H NMR (400 MHz, Chloroform-d) δ 12.61 - 12.49 (m, 1H), 8.66 (d, J = 5.9 Hz, 1H), 7.61 (d, J = 5.6 Hz, 1H), 7.40 - 7.29 (m, 2H), 6.22 (s, 1H), 4.78 - 4.62 (m, 1H), 4.15 (dd, J = 12.0, 4.9 Hz, 1H), 3.86 (t, J = 11.7 Hz, 1H), 3.31 - 3.21 (m, 1H), 2.56 (d, J = 2.9 Hz, 3H), 2.25 (t, J = 12.6 Hz, 1H), 1.96 (dd, J = 13.0, 3.7 Hz, 1H), 1.61 (s, 3H) ppm. ESI-MS m / z calc.462.132, found 463.1 (M+1)+; Retention time: 1.84 minutes using LC / MS method S.

[0459] Step 5:

[0460] In a vial, iron (35 mg, 0.63 mmol) was added to a solution of 6-((2R,4R,5R)-5-(5-cyano- 4-oxo-1,4-dihydro-1,6-naphthyridin-2-yl)-2-methyl-2-(trifluoromethyl)tetrahydro-2H-pyran-4-yl)-3- fluoro-2-methylpyridine 1-oxide (82 mg, 0.18 mmol) in acetic acid (1.5 mL) under nitrogen. The vial was sealed, and the reaction mixture was stirred at 70 °C for 16 h. The mixture was cooled at ambient temperature, diluted with EtOAc (15 mL), and washed with an aqueous saturated NaHCO3solution (2 x 10 mL). The combined aqueous layers were extracted with EtOAc (20 mL). The combined organic layers were washed with brine (10 mL), dried (Na2SO4), filtered and concentrated in vacuo to give 2- ((3R,4R,6R)-4-(5-fluoro-6-methylpyridin-2-yl)-6-methyl-6-(trifluoromethyl)tetrahydro-2H-pyran-3- yl)-4-oxo-1,4-dihydro-1,6-naphthyridine-5-carbonitrile (71 mg, 76%) as a grey solid, which was used without further purification in the next step.1H NMR (400 MHz, Methanol-d4) δ 8.62 (d, J = 5.9 Hz, 1H), 7.61 (d, J = 5.6 Hz, 1H), 7.33 - 7.26 (m, 1H), 7.14 (dd, J = 8.3, 3.7 Hz, 1H), 6.38 (s, 1H), 4.15 - 4.07 (m, 1H, overlapped with EtOAc), 3.95 (t, J = 11.5 Hz, 1H), 3.68 (td, J = 12.1, 3.9 Hz, 1H), 3.42 (td, J = 11.6, 4.3 Hz, 1H), 2.40 (d, J = 2.9 Hz, 3H), 2.18 (t, J = 12.7 Hz, 1H), 1.94 (dd, J = 13.2, 3.9 Hz, 1H), 1.67 (s, 3H) ppm; exchangeable H not observed. ESI-MS m / z calc.446.137, found 447.1 (M+1)+; Retention time: 1.99 minutes using LC / MS method S.

[0461] Step 6:

[0462] A solution of 2-((3R,4R,6R)-4-(5-fluoro-6-methylpyridin-2-yl)-6-methyl-6- (trifluoromethyl)tetrahydro-2H-pyran-3-yl)-4-oxo-1,4-dihydro-1,6-naphthyridine-5-carbonitrile (70 mg, 0.13 mmol) and TFA (740 mg, 0.5 mL, 6.5 mmol) in a mixture of toluene (0.6 mL) and water (20 μL) was stirred at 75 °C for 18 h. The reaction mixture was concentrated in vacuo. The residue was solubilized in EtOAc (15 mL) and washed with a 20% aqueous K2CO3solution (3 x 10 mL). The organic layer was dried (Na2SO4), filtered and concentrated in vacuo. Purification by reverse phase chromatography (5 to 50% MeCN in water with 0.1% formic acid) gave 2-((3R,4R,6R)-4-(5-fluoro-6- methylpyridin-2-yl)-6-methyl-6-(trifluoromethyl)tetrahydro-2H-pyran-3-yl)-4-oxo-1,4-dihydro-1,6- naphthyridine-5-carboxamide (120, 34 mg, 55%) as a white solid.1H NMR (400 MHz, DMSO-d6) δ11.84 - 11.57 (m, 1H), 8.40 (d, J = 5.9 Hz, 1H), 7.47 (t, J = 9.2 Hz, 1H), 7.43 - 7.35 (m, 1H), 7.33 (br d, J = 6.1 Hz, 1H), 7.26 - 7.14 (m, 2H), 6.28 (s, 1H), 4.03 (dd, J = 11.6, 4.3 Hz, 1H), 3.88 - 3.75 (m, 2H), 3.37 - 3.24 (m, 1H, overlapped with water), 2.37 (d, J = 2.7 Hz, 3H), 2.05 - 1.95 (m, 1H), 1.92 - 1.82 (m, 1H), 1.64 (s, 3H) ppm. ESI-MS m / z calc.464.147, found 465.2 (M+1)+; Retention time: 2.42 minutes using LC / MS method E.

[0463] The following compounds were made using methods similar to those described in Example 23, except that, in step 1, different acids were used as the amide coupling partner in pla...

Claims

CLAIMS What is claimed is:

1. A compound of formula (I-A):or a pharmaceutically acceptable salt thereof, wherein: X1is C-R1or N; X2is C-R2, N, or N+-O-; X3is C-R3, N, or N+-O-; X5is C-R5, N, or N+-O-; p, Xa, and Xbare defined as follows: (i) p is 1, Xais C-R11R12, and Xbis O; (ii) p is 1, Xais O, and Xbis C-R13R14; or (iii) p is 0 and Xbis O; Xsis C-Rsor N; Xtis C-Rtor N; R1is H, OH, halo, CN, C1-C6alkyl, C1-C6haloalkyl, C1-C6alkoxy, C1-C6haloalkoxy, –(CH2)mOn(CH2)oOCH3, –(CH2)mRa, –C(O)(CH2)mRa, –C(O)ORb, –C(O)Rb, –C(O)NRbRc, –NRbRc, –CRdReRf, –CRbRcNRgC(O)CRhRiRj, –NRbC(O)CRcRgRj, C3-C6cycloalkyl, 5-6 membered heteroaryl, or 4-10 membered heterocyclyl, wherein said C3-C6cycloalkyl, 5-6 membered heteroaryl, or 4-10 membered heterocyclyl may be unsubstituted or may be substituted with 1-4 substituents independently selected from halo, C1-C6alkyl, C1-C6haloalkyl, C1-C6alkoxy, and C1-C6haloalkoxy; R2, R3, R4, and R5are each independently H, OH, CN, halo, C1-C6alkyl, C1-C6alkoxy, C1-C6haloalkyl, –NHS(O)2(C1-C6alkyl), –C(O)ORb, –C(O)NRbRc, –(CH2)mO(CH2)oCH3, 5-6 membered heteroaryl, or 5-6 membered heterocyclyl, wherein said 5-6 membered heteroaryl or 5-6 membered heterocyclyl may be unsubstituted or may be substituted with 1-4 substituents independently selected from C1-C6alkyl and –C(O)NRbRc; R6, R7, R8, and R9are defined as follows: (i) R6and R7are each independently H, OH, C1-C6alkyl, C1-C6haloalkyl, C3-C6cycloalkyl, or C1-C6alkoxy; andR8and R9are each independently H, OH, C1-C6alkyl, C1-C6haloalkyl, C3-C6cycloalkyl, or C1-C6alkoxy; or (ii) R6and R7are each independently H, OH, C1-C6alkyl, C1-C6haloalkyl, C3-C6cycloalkyl, or C1-C6alkoxy; and R8and R9, together with the carbon atom to which they are attached, form a C3-C6cycloalkyl; or (iii) R6, R7, R8, and R9, together with the carbon atom to which they are attached, form a fused C6-C10aryl optionally substituted with 1-3 Ry; R10is H or CH3; R11and R12are each independently H, OH, C1-C6alkyl, C1-C6haloalkyl, C3-C6cycloalkyl, or C1-C6alkoxy; R13and R14are each independently H, OH, C1-C6alkyl, C1-C6haloalkyl, C3-C6cycloalkyl, or C1-C6alkoxy; Rsand Rtare each independently H, OH, halo, C1-C6alkyl, C1-C6alkoxy, C1-C6haloalkyl, C1-C6haloalkoxy, C3-C6cycloalkyl, –O-C3-C6cycloalkyl, –NRbRc, –NO2, –SO3H, –(CH2)mORb, or –O(CH2)mOCH3, or Rsand Rt, together with the carbon atoms to which they are attached, form a ring of formula:Y is O or CH2; Ru, Rv, and Rware each independently H, OH, halo, C1-C6alkyl, C1-C6alkoxy, C1-C6haloalkyl, C1-C6haloalkoxy, –NRbRc, –NO2, –SO3H, –(CH2)mORb, or –O(CH2)mOCH3; each Rxis independently H, halo, C1-C6alkyl, or C1-C6haloalkyl; each Ryis independently H, OH, C1-C6alkyl, C1-C6haloalkyl, C3-C6cycloalkyl, or C1-C6alkoxy; Rais OH, halo, C1-C6alkoxy, or –NRbRc; Rb, Rc, Rg, Rh, and Riare each independently H or C1-C6alkyl, or Rband Rc, together with the nitrogen atom to which they are attached, form a 3-6 membered heterocyclyl; Rd, Re, and Rfare each independently H, OH, halo, C1-C6alkyl, or C1-C6alkoxy; Rjis H, C1-C6alkyl, –NRbRc, or –N(CH3)3+; m and o are each independently 0, 1, 2, or 3; and n is 0 or 1.

2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein: Xais CH2;Xbis O; R6and R7are each independently H, OH, C1-C6alkyl, C1-C6haloalkyl, C3-C6cycloalkyl, or C1-C6alkoxy; R8and R9are each independently H, OH, C1-C6alkyl, C1-C6haloalkyl, C3-C6cycloalkyl, or C1-C6alkoxy; or R8and R9, together with the carbon atom to which they are attached, form a C3-C6cycloalkyl; Rsand Rtare each independently H, OH, halo, C1-C6alkyl, C1-C6alkoxy, C1-C6haloalkyl, C1-C6haloalkoxy, –NRbRc, –NO2, –SO3H, –(CH2)mORb, or –O(CH2)mOCH3, or Rsand Rt, together with the carbon atoms to which they are attached, form a ring of formula:p is 0 or 1.

3. The compound of any one of claims 1 to 2, or a pharmaceutically acceptable salt thereof, wherein p is 0.

4. The compound of any one of claims 1 to 2, or a pharmaceutically acceptable salt thereof, wherein p is 1, optionally wherein: (i) p is 1, Xais CR11R12, and Xbis O; or (ii) p is 1, Xais O, and Xbis CR13R14.

5. The compound of any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein the compound has a formula (I-A-1):.

6. The compound of any one of claims 1 to 5, or a pharmaceutically acceptable salt thereof, wherein X1is C-R1, and R1is H, CN, C1-C6alkyl, C1-C6alkoxy, or –C(O)ORb, optionally wherein R1is H, CN, –CH3, –OCH3, –C(O)OCH3, or –C(O)OCH2CH3.

7. The compound of any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof, wherein X2is C-R2, and R2is H, OH, CN, halo, C1-C6alkyl, C1-C6alkoxy, –NHS(O)2(C1-C6alkyl), –C(O)ORb, –C(O)NRbRc, 5-6 membered heteroaryl, or 5-6 membered heterocyclyl, wherein said 5-6 membered heteroaryl or 5-6 membered heterocyclyl may be unsubstituted or may be substituted with 1-4 substituents independently selected from C1-C6alkyl and –C(O)NRbRc, optionally wherein R2is H, Cl, F, OH, CN, –CH3, –OCH3, –C(O)OH, –C(O)NH2, –C(O)N(H)CH3, –N(H)S(O)2(CH3),8. The compound of any one of claim 1 to 7, or a pharmaceutically acceptable salt thereof, wherein X3is N.

9. The compound of any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, wherein X3is C-R3, and R3is H, CN, halo, C1-C6alkoxy, –C(O)ORb, or –C(O)NRbRc, optionally wherein R3is H, Cl, F, CN, –OCH3, –C(O)OCH3or –C(O)N(CH3)2.

10. The compound of any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, wherein R4is H, halo, C1-C6alkyl, –C(O)ORb, or –C(O)NRbRc, optionally wherein R4is H, Cl, F, – CH3, –C(O)OCH2CH3or –C(O)NH2.

11. The compound of any one of claims 1 to 10, or a pharmaceutically acceptable salt thereof, wherein X5is CR5, and R5is H, halo, or –C(O)NRbRc, optionally wherein R5is H, F, or –C(O)NH2.

12. The compound of any one of claims 1 to 11, or a pharmaceutically acceptable salt thereof, wherein R7is H, OH, C1-C6alkyl, C3-C6cycloalkyl, or C1-C6alkoxy, optionally wherein R7is H, OH, –OCH3, –CH3, or cyclopropyl.

13. The compound of any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof, wherein R8and R9are each independently H, C1-C6alkyl, C1-C6haloalkyl, or C3-C6cycloalkyl, or R8and R9, together with the carbon atom to which they are attached, form a C3-C6cycloalkyl, optionally wherein: (i) R8is H or C1-C6alkyl, optionally wherein R8is H, –CH3, or –CH2CH3; (ii) R9is H, C1-C6alkyl, or C1-C6haloalkyl, optionally wherein R9is H, –CH3, or –CF3; or (iii) R8and R9, together with the carbon atom to which they are attached, form a C3-C6cycloalkyl, optionally wherein R8and R9, together with the carbon atom to which they are attached, form a cyclobutane.

14. The compound of any one of claims 1 to 13, or a pharmaceutically acceptable salt thereof, wherein R10is H.

15. The compound of any one of claims 1 to 13, or a pharmaceutically acceptable salt thereof, wherein R10is CH3.

16. The compound of any one of claims 1 to 15, or a pharmaceutically acceptable salt thereof, wherein Xsis C-Rs, and Rsis H, OH, halo, C1-C6alkyl, C1-C6alkoxy, C3-C6cycloalkyl, –O-C3-C6cycloalkyl, –(CH2)mORb, or –O(CH2)mOCH3, optionally wherein Xsis C-Rs, and Rsis H, F, Cl, OH, – CH3, –CH2OH, –CH2OCH3, –OCH3, cyclopropyl, –O-cyclopropyl, –OCH(CH3)2, or – OCH2CH2OCH3.

17. The compound of any one of claims 1 to 16, or a pharmaceutically acceptable salt thereof, wherein Xtis C-Rt, and Rtis H, halo, C1-C6alkyl, C1-C6alkoxy, or C3-C6cycloalkyl, optionally wherein Xtis C-Rt, and Rtis H, Cl, F, –CH3, –OCH3, or cyclopropyl.

18. The compound of any one of claim 1 to 15, or a pharmaceutically acceptable salt thereof, wherein Rsand Rt, together with the carbon atoms to which they are attached, form a ring of formula:, optionally wherein Rsand Rt, together with the carbon atoms to which they are attached, form a ring of formula:.

19. The compound of any of claims 1 to 18, or a pharmaceutically acceptable salt thereof, wherein Ruis H, halo, C1-C6alkyl, C1-C6alkoxy, C1-C6haloalkyl, optionally wherein Ruis H, F, or – CH3.

20. The compound of any of claims 1 to 19, or a pharmaceutically acceptable salt thereof, wherein Rvis H, halo, or C1-C6alkyl, optionally wherein Rvis H, F, or –CH3.

21. The compound of any of claims 1 to 20, or a pharmaceutically acceptable salt thereof, wherein Rwis H.

22. The compound of any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein the compound has a formula (I-A-2):.

23. The compound of any one of claims 1 to 4 and 22, or a pharmaceutically acceptable salt thereof, wherein R7is H, C1-C6alkyl, or C1-C6alkoxy, optionally wherein R7is H, –CH3, or –OCH3.

24. The compound of any one of claims 1 to 4 and 22 to 23, or a pharmaceutically acceptable salt thereof, wherein Rsis H, halo, C1-C6alkyl, C1-C6alkoxy, C3-C6cycloalkyl, or –(CH2)mORb, optionally wherein Rsis H, F, Cl, –CH3, –OCH3, cyclopropyl, or –CH2OCH3.

25. The compound of any one of claims 1 to 4 and 22 to 24, or a pharmaceutically acceptable salt thereof, wherein Rtis H, halo, C1-C6alkyl, or C3-C6cycloalkyl, optionally wherein Rtis H, F, Cl, – CH3, or cycloproyl.

26. A compound selected from Table A, optionally wherein the compound is selected from Table B, or a pharmaceutically acceptable salt thereof.

27. A compound selected from Table C, or a pharmaceutically acceptable salt thereof.

28. A compound selected from Table D, or a pharmaceutically acceptable salt thereof.

29. A compound selected from Table E, or a pharmaceutically acceptable salt thereof.

30. The compound of any one of claims 1 to 29 in non-salt form.

31. A pharmaceutical composition comprising the compound of any one of claims 1 to 29, or a pharmaceutically acceptable salt thereof, or the compound of claim 30, and one or more pharmaceutically acceptable carriers or vehicles.

32. A method of inhibiting a voltage-gated sodium channel in a subject comprising administering to the subject the compound of any one of claims 1 to 29, or a pharmaceutically acceptable saltthereof, tire compound of claim 30, or the pharmaceutical composition of claim 31, optionally wherein tire voltage-gated sodium channel is Nav1.8.

33. A method of treating or lessening the severity in a subject of chronic pain, gut pain, neuropathic pain, musculoskeletal pain, acute pain, inflammatory pain, cancer pain, idiopathic pain, postsurgical pain, visceral pain, multiple sclerosis, Charcot-Marie-Tooth syndrome, incontinence, pathological cough, or cardiac arrhythmia comprising administering to the subject an effective amount of the compound of any one of claims 1 to 29, or a pharmaceutically acceptable salt thereof, the compound of claim 30, or the pharmaceutical composition of claim 31, optionally wherein:(i) the method comprises treating or lessening the severity in the subject of neuropathic pain, optionally wherein the neuropathic pain comprises post-herpetic neuralgia, small-fiber neuropathy, idiopathic small-fiber neuropathy, diabetic neuropathy, or diabetic peripheral neuropathy; or(ii) the method comprises treating or lessening the severity in the subject of musculoskeletal pain, optionally wherein the musculoskeletal pain comprises osteoarthritis pain; or(iii) the method comprises treating or lessening the severity in the subject of acute pain, optionally wherein tire acute pain comprises acute post-operative pain; or(iv) the method comprises treating or lessening the severity in the subject of postsurgical pain, optionally wherein the postsurgical pain comprises bunionectomy pain, abdominoplasty pain, or herniorrhaphy pain; or(v) the method comprises treating or lessening the severity in the subject of visceral pain.

34. The method of any one of claims 32 to 33, wherein said subject is treated with one or more additional therapeutic agents administered concurrently with, prior to, or subsequent to treatment with the compound, pharmaceutically acceptable salt, or pharmaceutical composition.

35. Use of the compound of any one of claims 1 to 29, or a pharmaceutically acceptable salt thereof, the compound of claim 30, or the pharmaceutical composition of claim 31, as a medicament.

Images